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1 Introduction 
Ischemia is defined by the arrest of blood flow in the organ cutting thus oxygen and 
metabolite supply indispensable for its survival and function. Reperfusion occurs when 
blood flow is restored and it is associated with tissue injuries. Ischemia reperfusion 
injury (IRI) remains one of the major problems in liver surgery and transplantation; it 
determines the viability of hepatic tissue after resection and the recovery of the grafted 
organ.  
Therapeutic strategies against IRI have been developed during the last 60 years and 
great advances into the mechanisms responsible of injuries have been achieved. 
However, efficient therapy against IRI is still lacking and few clinical studies in phase 
III have proven their effectiveness. This could be due, in part, to the complexity of the 
mechanisms responsible of IRI and to the specific drugs activity and their potential 
adverse effects.  
Polyethylene glycols (PEG) are water soluble and nontoxic polymers. PEG is non 
immunogenic, shows little toxicity and is eliminated from the body intact by either the 
kidneys (for PEGs < 30 kDa) or in the faeces (for PEGs > 20 kDa) [1].  Also, PEG has 
been associated with the majority of events occurring during IRI. Indeed, it has been 
shown that PEG reduces reactive oxygen species, prevent cell death, maintain 
mitochondrial integrity and reduce inflammation and endoplasmic reticulum stress [2-
6]. From this perspective, it is reasonable to expect that PEG administration may be an 
effective therapeutic strategy against IRI. 
The aim of this thesis is to investigate the beneficial effects of PEG 35 in different 
models of IRI that mimic clinical situation of liver surgery. In the first study, we 
investigated the impact of the intravenous administration of PEG 35 before liver warm 
IRI. In the second one, we investigated whether PEG 35 administrated intravenously 
could protect against cold IRI in steatotic rat livers. Finally, we developed a new 
washout solution containing PEG 35 to prevent reperfusion injury after prolonged cold 
preservation. 
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2 The Liver 
The liver is located in the right upper quadrant, between the fifth intercostal space in the 
midclavicular line and the right costal margin. It weighs approximately 1800 grams in 
men and 1400 grams in women. The surfaces of the liver are smooth and convex in the 
superior, anterior and right lateral regions. It is separated incompletely into lobes, 
covered on their external surfaces by a thin connective tissue capsule. The main hepatic 
function is the uptake of substrates from the intestine in order to be stored, metabolized 
and distributed to the peripheral circulation for being used by other tissues. 
Furthermore, it is the main detoxifying organ of the body, which removes wastes and 
xenobiotics by metabolic conversion and biliary excretion.                                                                                               
2.1  Organization of the liver 
The liver is structurally and functionally complex and has been considered second only 
to brain in its complexity. Awareness of the complexities and heterogeneity of the liver 
will add greater understanding of disorder that lead to toxicity, cancer, and other 
diseases. 
2.1.1 Liver anatomy and vasculature 
Anatomically human liver is divided into right and left lobes by the falciform ligament, 
which connects the liver to the anterior abdominal wall and the diaphragm. The right 
lobe is further subdivided into two smaller lobes, the caudate and the quadrate lobes. 
The left part of the liver can also be divided into medial and lateral sections by the 
tissue named as ligamentum teres. Furthermore, the right lobe is firmly attached to the 
gall bladder, a pear-shaped pocket that stores and evacuates bile. The liver can also be 
divided into eight segments, where each one has its own vascular and biliary supply [7] 
(Figure 1A).  
The liver contains blood equivalent to approximately 25% of the cardiac output [8]. The 
portal vein and the hepatic artery are the two main vascular systems that supply blood to 
the liver. The portal vein supplies about 70% of the blood flow and 40% of the oxygen 
while the hepatic artery supplies 30% of the flow and 60% of the oxygen [8]. The portal 
blood drains from the mesenteric, gastric, splenic, and pancreatic veins and travels to 
the liver where it branches into the right and left sides of the liver. 
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The conducting portal vessels deliver blood to the parenchymal vessels called 
preterminal and terminal portal venules, respectively. Blood from the terminal portal 
venules enters the sinusoids [9]. The hepatic artery generally accompanies the portal 
veins in the portal triads and its smaller branches feed the sinusoids at varying levels 
and biliary tracts (which most often subsequently drains into sinusoids; a so-called 
portal-portal flow). The sinusoidal blood flow is carefully regulated and collects into 
terminal hepatic venules (also called central veins) prior to emptying into larger hepatic 
veins and eventually to the vena cava [10]. 
The portal triad is defined by the portal vein, bile duct, and hepatic artery, however the 
portal area contains on average about 6 profiles (range is 2–35) with an average of 1–2 
arteries, 1 portal vein, 1–2 bile ducts, lymphatics, nerves in a connective tissue matrix 
comprised mainly by type 1 collagen [10]. 
 
 
 
 
 
 
 
2.1.2 Hepatic Functional units 
The lobule, proposed by Matsumoto in 1979, has been gaining acceptance as the 
functional unit of the liver over other conceptual views because it’s based on vessel 
architecture [10]. Hepatic lobule is a small division of the liver defined at the 
histological scale. The classic hepatic lobule is a polygonal structure where the hepatic 
venule forms its central axis and in its periphery boundaries are regularly distributed the 
Figure 1: Liver anatomy (A) and vasculature (B) 
B A 
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portal triads, containing a bile duct and a terminal branch of the hepatic artery and portal 
vein (Figure 2).  
 
 
 
 
 
 
 
 
 
2.2 Liver cells 
Hepatocytes are the most numerous and comprise 60% of the total cells and 80% of the 
volume of liver. Sinusoidal endothelial cells (SECs), Kupffer cells, hepatic stellate cells 
(HSC) and biliary epithelium make up a significant number (3–20% each) of the 
remaining biologically important cells [7, 10] (Figure 3). 
2.2.1 Hepatocytes      
Hepatocytes are arranged in plates or laminae of cords of 1 cell thick (called muralium) 
that branch and anastomose in a continuous labyrinth with limiting plates being at the 
capsule and portal regions. The 6 or more surfaces of the hepatocyte either are adjacent 
parenchymal cells, border bile canaliculi, or are exposed to the peri-sinusoidal space 
(this surface being covered by microvilli) [10]. Being the workhorses of the liver, 
hepatocytes contain the machinery necessary to carry out the thousands of vital 
functions. Normally, about 15% of the cell volume is composed of smooth and rough 
Figure 2: Schematic representation of the lobule 
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endoplasmic reticulum and there are about 30 lysosomes and 500 peroxisomes 
(microbodies) per cell. The mitochondria number about 1,000 per hepatocyte and there 
are numerous free ribosomes, Golgi complex, cytoskeleton elements (such as 
microfilaments, intermediate filaments, and microtubules), and varying levels of 
cytoplasmic lipid and glycogen. One of the main hepatocyte functions is the production 
of bile, which averages about 15 ml/kg/day in humans. With age, the number of 
hepatocytes decreases and hypertrophy, polyploidy, lysosomes, and smooth 
endoplasmic reticulum increases. The mitochondria and microbodies remain unchanged 
with age and the microsomal drug-metabolizing capabilities decrease [10-12].                                                                                   
2.2.2 Hepatic sinusoid cells 
The walls of hepatic sinusoid are lined by three different cell types: sinusoidal 
endothelial cells (SEC), Kupffer cells (KC), and hepatic stellate cells (HSC, formerly 
known as fat-storing cells, Ito cells, lipocytes, perisinusoidal cells, or vitamin A-rich 
cells). Additionally, intrahepatic lymphocytes, including pit cells, i.e., liver-specific 
natural killer cells, are often present in the sinusoidal lumen [13]. 
i) Sinusoidal endothelial cells 
SECs are a layer of cells between the hepatocytes and the blood flowing in sinusoids. 
SEC contains numerous fenestrae (pores) which are clustered together in groups known 
as “sieve plates” and allow the exchange between the blood and the surrounding tissue.  
The endothelial fenestrae are dynamic structures whose diameters are affected by 
luminal blood pressure, vasoactive substances, drugs and toxins.  
SECs represent an important blood clearance system, as all transport between the lumen 
and the hepatocytes has to pass through this filter. Furthermore, it permits rapid access 
to substances in the blood. SECs play an important role in immunity and inflammation, 
as secrete pro-inflammatory mediators such as interleukin-1 (IL-1), interleukin-6 (IL-6), 
interferons and eicosanoids. They facilitate also adhesion of leucocytes and 
lymphocytes by secreting chemokines and expressing molecules, such as intracellular 
adhesion molecule (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1).  Thus, 
along with the Kupffer cells, the endothelium participates in host defense mechanisms. 
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Furthermore, they contribute to the formation of new blood vessels and regulate 
sinusoidal blood flow by releasing vasoconstrictor and vasodilator factors. 
ii) Kupffer cells 
Kupffer cells represent 15% of the liver cells (30% of sinusoidal cells) and are derived 
from circulating monocytes. They can proliferate locally, are phagocytic, are the major 
producers of cytokines as mediators of inflammation and provide “cross-talk” with 
other cells. Kupffer cells remove through endocytosis toxicants and bacteria from the 
circulation, as well as toxic and infective substances of intestine origin. Kupffer cells 
also produce both beneficial and toxic substances that contribute to host defense and 
liver injury respectively [10].  
iii) Stellate cells 
Stellate cells are located in the space of Disse, between hepatocytes and sinusoidal 
endothelial cells. In this way, they are able to interact with the surrounding cell types. 
Stellate cells contain fat droplets and constitute the most important storage site of 
retinoids, including vitamin A. In healthy liver, they are quiescent. However, when 
activated, they synthesize collagen and thus contribute to the development of cirrhosis 
[14].  
 
Figure 3 Liver cells organization [15] 
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3 Hepatic ischemia reperfusion injury: insight into the 
mechanism 
3.1 Ischemic injury 
Two major types of ischemic injury that are attributable to IRI can be distinguished: 
The ‘warm’ IRI which is developed in situ during liver surgery or during various forms 
of shock or trauma, and might lead to liver or even multiorgan failure. The ‘cold’ IRI, 
which occurs during ex vivo preservation in storage solution during liver transplantation 
surgery [16]. Hepatic cells response to the two kind of ischemia is different, hepatocytes 
are very susceptible to warm ischemia; however, SEC damage occurs predominantly 
during cold ischemia [17]. 
The mechanisms involved in both type of ischemia are multifactorial and share the most 
common signalization pathway. Understanding these mechanisms is of great interest 
because it permits the development of new effective strategies against IRI. 
3.1.1 ATP depletion 
The liver, a well-differentiated tissue, requires large amounts of oxygen to support its 
various specialized functions. These functions are maintained by energy derived from 
aerobic metabolism. As cells become anoxic, oxidative phosphorylation ceases and 
adenosine triphosphate (ATP) reserves are consumed rapidly. Lack of ATP leads to 
impairment of all energy-dependent functions, thus, ATP depletion could be considered 
as the initial common pathway of cell injury, responsible for cellular edema, 
cytoskeleton disorganization, proteasome activation and cell death [18-21]. ATP can be 
saved by cooling the organ, which reduces the tissue’s metabolic demands for nutrients 
and oxygen (cold ischemia) [22-24]. However, intracellular homeostatic functions are 
decelerated equally which induces cellular edema.  
3.1.2 Cellular edema  
Disturbance of the electrolyte balance is a major consequence of slowing the 
metabolism by hypothermia. Normally, the cells are bathed in an interstitial fluid high 
in sodium (Na
+1
) and calcium (Ca
2+
) and low in potassium (K
+
), compared with the 
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intracellular electrolyte concentrations (44). The intracellular concentrations of Na
+
 and 
K
+
 are maintained by an energy dependent cation transport system in the cell membrane 
[25]. This enzyme system uses ATP to make Na
+
 impermeable outside the cell, 
counteracting the colloidal osmotic pressure derived from the intracellular proteins and 
other impermeable anions, and causes K
+
 to accumulate in the cell. Hypothermic 
preservation suppresses the activity of this Na
+
 pump and decreases the membrane 
potential of the plasma membrane. Consequently, chloride (C1
-
) enters the cell down a 
concentration gradient with water and cause cell edema [26-28].  
3.1.3 Acidosis 
During hepatic ischemia, ATP-dependent cellular metabolic activities are gradually 
stopped, intracellular ATP is rapidly depleted and the redox process of the hepatocytes 
is blocked and as a consequence the metabolic pattern is shifted from aerobic to 
anaerobic. The enhanced anaerobic glycolysis leads to the accumulation of acidic 
metabolites, such as lactic acid and ketone bodies. This is accompanied by hypofunction 
of mitochondrial oxidative phosphorylation, resulting in the decrease of pH values 
between tissues and cells, known as metabolic acidosis [29]. This metabolic naturally 
occurring acidosis actually protects against the onset of necrotic cell death in 
hepatocytes. Conversely, restoration of a normal pH during reperfusion of ischemic 
cells enhance ATP-dependent enzyme such as proteases and phospholipases and 
accelerates cell killing, a phenomenon called the « pH paradox » [30]. 
3.1.4 Proteasome activation 
Ubiquitin proteasome system (UPS) is the principal non-lysosomal proteolytic pathway 
responsible for the degradation of misfolded, aged and damaged proteins [31, 32]. In 
addition, UPS is an energy dependent system that modulates many regulatory proteins 
involved in a wide range of cellular processes which include inflammatory process, cell 
cycle, metabolism, growth, and differentiation [32, 33]. Majetschak et al. provided 
evidences that the 26S proteasome is under direct control of the cellular energy status 
and that a subset of 26S proteasomes is a cell-destructive protease, which is activated as 
the tissue ATP level declines [18]. Thus, UPS inhibition is protective against IRI in 
different organs [34-39].  
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3.2 Reperfusion injury 
Efforts to restore blood flow in hypoxic tissue can paradoxically result in more 
destructive than beneficial effects, depending on the length of the ischemic period. 
Previous research indicates that the main damaging effects in IRI involve reactions 
following restoration of blood flow to the tissue rather than the ischemia itself [40]. 
3.2.1 Oxidative stress 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are one of the 
earliest and most important components of tissue injury after reperfusion of ischemic 
organs. The major ROS include the superoxide radical, hydroxyl, and hydrogen 
peroxide. The prime sources of ROS production in ischemic livers include cytosolic 
xanthine oxidase (XO), Kupffer cells, and adherent PMN [41, 42]. ROS-induced injury 
targets proteins, enzymes, nucleic acids, cytoskeleton, cell membranes, and lipid 
peroxides, resulting in decreased mitochondrial function, and lipid peroxidation [43]. 
The endothelial cells damage caused by ROS leads to the loss of microvascular integrity 
and decreased blood flow. Endogenous antioxidant compounds, such as superoxide 
dismutase, catalase, glutathione, and beta-carotene, may limit the effects of ROS but 
these systems can become overwhelmed by large quantities of ROS [44]. 
 
Figure 4 The formation of ROS and RNS during IRI (modified from [40]) 
(XO, xabthine oxidase; SOD, superoxide dismutase; ETC, electron transport chain; 
NOX, NADPH oxidase; MPO, myeloperoxidase; KC, kupffer cells) 
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3.2.2 Inflammation 
The activation of inflammatory cells is a key event in the development of liver injury 
during ischemia and reperfusion. Kupffer cells are activated during reperfusion which 
generate ROS, RNS and pro-inflammatory cytokines, such as Tumor necrosis Factor α 
(TNFα), interferon-γ (INF-γ), interleukin-12 (IL-12) and Interleukin-1 (IL-1). These 
chemokines promote the expression of adhesion molecules, such as the intercellular 
adhesion molecule (ICAM), potentiating thus the activation, recruitment, and adhesion 
of neutrophils to the EC. Adhered neutrophils trigger cell death by releasing various 
proteases (elastases, proteinases, and collagenases), which degrade components of the 
extracellular matrix, attack cells, and inactivate various proteins such as 
immunoglobulins and proteins of complement. Furthermore, neutrophils generate ROS, 
like hydrogen peroxide, through activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase. In addition, the produced cytokines, ROS and the 
increased translocation of P-selectin (endothelial adhesion molecule) to the surface of 
endothelial cells and platelets promote the adherence of leukocytes to the microvascular 
endothelium. The inflammatory cascade induces significant organ infiltration and injury 
[45-47].  
3.3 Cellular consequences of IRI 
3.3.1 Mitochondrial dysfunction 
The mitochondria are the location where oxidative phosphorylation mainly takes place, 
and the mitochondria participate in multiple pathophysiological processes of IRI. A 
large number of ROS and RNS are generated in the mitochondria during the state of 
ischemia. Hypoxia impair the process of oxidative phosphorylation in cells and 
obstructs the production of ATP, causing disorders of the cytoplasmic ions such as Ca2+, 
Na+, and H+ in the mitochondria, and leads to the opening of high-conductance pores in 
the mitochondrial inner membrane. These pores conduct both positively and negatively 
charged solutes of up to 1,500 Da. Pore opening induces mitochondrial permeability 
transition (MPT) responsible for membrane depolarization, swelling, and uncoupling of 
oxidative phosphorylation [29, 48]. MPT was implicated in lethal cell injury associated 
with anoxia, reperfusion, and oxidative stress to heart and liver cells [40, 48]. 
Treatments that ameliorate mitochondria recovery have been associated with less graft 
damage and better recovery [48-51]. 
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3.3.2 Apoptosis and necrosis 
Hepatocytes and SECs are the two main cell types that are injured in IRI. Hepatocytes 
are more sensitive to warm ischemic injury, while SECs are more sensitive to cold 
ischemia. Physiologically, exclusive injury of one cell type is not found and there is 
evidence that both cell types have been injured directly in both cold and warm IRI. 
There has been debate about what the primary mode of cell death is in liver IRI: 
apoptosis or necrosis. Apoptosis is an energy dependent process, so in theory when 
there is greater depletion of ATP, necrosis should dominate. Also, necrosis takes longer 
to become apparent, normally more than 3h. This is challenging to show experimentally 
in vivo, as tissue ATP before and after reperfusion would need to be measured as well as 
the change in metabolic state of the cell. Many of the same initiators and pathways are 
involved for both types of cell death, so there is much overlap, referred as necroptosis 
[19, 52]. 
3.3.3 Autophagy 
Autophagy is a tightly regulated pathway implicated in many physiological and 
pathological processes. Autophagy is essential for normal development and 
embryogenesis, as contributes to the clearance of apoptotic cells. Autophagic 
degradation of cellular constituents can efﬁciently recycle essential nutrients so that 
basic biological processes can be sustained [53]. The process of autophagy can be 
divided into four basic steps:  induction, formation of autophagosome, autophagosome 
fusion with the lysosome, and degradation, where more than 30 autophagy-related 
proteins participate. The first step, the induction of autophagy, requires the beclin-1–
class III PI3K (phosphoinositide 3-kinase) complex.  After induction, the isolation 
membrane is elongated in order to sequester the cytosolic components and form the 
double membrane autophagosome. This step is primarily mediated by LC3II. LC3, the 
full length precursor protein, is converted to LC3-I which then is conjugated with 
phosphatidylethanolamine and thus is converted into LC3-II.  LC3-II is inserted into the 
autophagosomal membrane, a process that play an essential role in the expansion of the 
autophagosomes [54]. Next, the outer membrane of autophagosomes fuse with 
lysosomes to generate the autophagolysosome and finally the contents of the 
autophagolysosome are degradated onto the lysosome [55].  
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The role of autophagy during warm and/or cold liver IRI remains 
discordant.  Depending on the context, induction or impairment of autophagy during 
warm and/or cold liver IRI can be protective or detrimental for liver cells. Stimulation 
of impaired autophagy following warm and/or cold IRI may promote hepatocyte 
survival by degradation of intracellular contents to maintain ATP production and 
removal of damaged organelles and protein aggregates [56, 57]. Excessive and long-
term upregulation of autophagy, as it occurs during severe ischemic insult of the liver, 
may lead to destruction of essential proteins and organelles resulting in hepatocellular 
apoptosis and necrosis [57].  
3.3.4 Endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is a membrane system that forms a series of flattened 
sacs within the cytoplasm of eukaryotic cells and serves multiple functions, being 
important particularly in the synthesis, folding, modification, and transport of proteins.  
It is well known that ischemia reperfusion leads to altered Ca
2+
 homeostasis [58]. 
Knowing that ER is the site where Ca
2+
 is stored and released, perturbation of Ca
2+
 
homeostasis induces ER stress. Consequently, newly synthesized unfolded proteins 
accumulate in the organelle. To cope with accumulated unfolded proteins, mammalian 
cells trigger a specific adaptive response called the unfolded protein response (UPR). 
The UPR has three branches: inositol-requiring enzyme 1 (IRE1), PKR-like ER kinase 
(PERK) and activating transcription factor (ATF6). These proteins are normally held in 
inactive states in ER membranes by binding to intra-ER chaperones, particularly the 78-
kD glucose-regulated/binding immunoglobulin protein (GRP78). In response to stimuli 
that divert ER chaperones to misfolded proteins, IRE1, PERK and ATF6 initiate signal 
transduction processes in order to promote the expression of genes required to fold 
newly synthesized proteins and to degrade the unfolded proteins [59]. However, when 
injury is excessive, the same ER stress signal transduction pathways induce cell death 
[60]. 
Accumulating evidence has suggested that perturbations at the ER are involved in the 
promotion of cell death during IRI [61]. In line with this, activation of ER stress 
markers has been observed in tissue biopsies from human allograft after reperfusion 
[62]. Prevention of ER stress by rapamicine, tauroursodeoxycholic acid, N-
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acetylcyteine, trimetazidine or ischemic preconditioning (IP) has been shown to be 
effective in reducing IRI [63-67]. Also, the use of IGL-1 preservation solution resulted 
in less injury through ER stress inhibition when compared to UW solution in rat 
orthotopic liver transplantation [68].  
3.3.5 Cytoskeleton disorganization 
The cytoskeleton is the inner structural elements of a cell, composed of microtubules, 
microfilaments, and larger filaments that spread out through the cytoplasm. The 
cytoskeleton regulates cell motility, the intracellular distribution of organelles, and 
trans-endothelial permeability. Since cellular microfilaments and microtubules are in an 
energy-requiring dynamic state of continuous formation and disassembly, ATP 
deficiency during ischemia is responsible, in part, of cytoskeleton disturbance.  
During cold ischemia, rounding and cytosolic retraction of SEC occurs and cells detach 
from their underlying attachments as a consequence of disruption of the cytoskeleton. 
Also, it has been reported that chemical hypoxia caused marked cytoskeletal disruption 
characterized by degradation of actin microfilaments, disappearance of focal adhesions, 
retraction of the cytoplasm, and the appearance of gaps between the cells [69]. These 
structural alterations are reported to cause organ dysfunction observed at the moment of 
reperfusion [70, 71]. 
The subcellular distribution of filamentous actin (F-actin), being an important 
component of the cytoskeleton, as well as the balance between F-actin and monomeric 
G-actin seem to largely determine the functional outcome [72]. In liver cells, F-actin 
forms microfilaments involved in intracellular transport processes, exo- and 
endocytosis, maintenance of cell shape, and canalicular motility responsible for bile 
flow [72]. They are located particularly around the bile canaliculi exhibiting regulatory 
functions on bile secretion, but also in the apical membrane region of hepatocytes 
ensuring stability and mobility [73]. In hepatocytes, a decrease in F-actin content 
determines inhibition of store-operated calcium channels (SOCs), disruption of the 
organization of the endoplasmic reticulum, and functional disturbances of tight 
junctions [74]. It has been reported that after warm ischemia, F-actin is reduced in rabbit 
livers resulting in the loss of cell-integrity and cytoplasmic transport in the liver causing 
damage to organelles and changes in cell morphology [75]. Little work has been done to 
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investigate protective strategies against cytoskeleton disruption. Killer et al. have shown 
that atrial natriuretic peptide (ANP) preserved F-actin content through a mechanism 
dependent in p38 MAPK activation [76] during liver IRI.  
3.3.6 Glycocalix disruption 
It is now well recognized that the luminal surface of the ECs that line our vasculature is 
coated with a glycocalyx (GCX) of membrane-bound macromolecules comprised of 
sulfated proteoglycans, hyaluronan, glycoproteins, and plasma proteins that adhere to 
this surface matrix [77]. The glycocalyx play a central role in modulating the oncotic 
forces that regulate the exchange of water in microvessels, in transducing fluid shear 
stress into the intracellular cytoskeleton of endothelial cells, in the initiation of 
intracellular signaling, and in the inflammatory response cascade [78, 79]. During liver 
IRI, ROS/RNS-mediated degradation of the GCX, induces vasoconstriction, facilitates 
leukocyte adherence, and directly activates innate immune cells. Preliminary 
experiments revealed that hepatic sinusoids contain a functional GCX that is damaged 
during murine hepatic ischemia reperfusion and major liver surgery in patients [40, 80]. 
However, the underlying mechanisms remains poorly defined. 
 
Figure 5 The glycocalyx under normophysiological (A) and ischemia/reperfusion-
induced pathophysiological circumstances (B) [40] (SECs, sinusoidal endothelial cells; 
ecSOD, extracellular superoxide dismutase; SD, space of Disse; TFPI, tissue factor 
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pathway inhibitor; AT, antithrombin; vWF, von Willebrand factor; ICAM-1, 
intracellular adhesion molecule 1; RBC, red blood cell; MC, monocyte; SCs, stellate 
cells; HC, hepatocyte 
3.4 Cellular mediators involved in IRI 
3.4.1 Adenosin monophosphate activated protein kinase  
AMPK is a serine–threonine kinase that functions as a fuel gauge and maintains energy 
homeostasis during cellular stress. AMPK is a heterotrimeric complex of α, β, and γ 
subunits. AMP and ADP binding to the γ subunit allosterically activates AMPK and 
facilitates the phosphorylation of the activating Thr172 site in the α subunit by upstream 
kinases including liver kinase B 1 (LKB1) and calcium–calmodulin-dependent kinase 
kinase 2 (CaMKK2), and possibly transforming growth factor-β-activated protein 
kinase-1 (TAK1) [81]. When ATP consumption exceeds production, there is an ensuing 
increase in cellular ADP content. Conversion of two ADPs to AMP (and ATP) by 
adenylate kinase also increases the cytosolic concentration of AMP. The increase in 
both AMP and ADP activates AMPK by binding to the regulatory nucleotide-binding 
domains of the AMPK gamma subunit. Desactivation of AMPK is mediated in part by 
protein phosphatase 2A and 2C, which dephosphorylate the Thr172 site. AMPK is also 
negatively regulated by acetylation and oxidation of cysteine residues in the AMPK α 
subunits [81].  
AMPK activation during ischemia activates downstream targets in order to decrease 
cellular process that consume energy and induce cellular signaling pathway in order to 
provide necessary metabolite to the cell. In liver, AMPK activation has been shown to 
protect ischemic liver through endoplasmic reticulum stress (ERS) inhibition [65], 
autophagy induction [82], hypoxic inducible factor 1 alpha (HIF-1α) stabilization [83] 
and mitochondria protection. Indeed, melatonin has been shown to improve 
mitochondrial function after cold ischemia [84] through AMPK activation [85]. 
3.4.2 Hypoxic Inducible Factor 1 
HIF-1 is a heterodimer formed by α and β subunits which are constitutively expressed. 
The β subunit is independent of O2, whereas the protein stability of the α subunit 
depends on the cellular levels of O2. Under normoxic conditions, the α subunit is 
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degraded by a complex process involving the prolylhydroxylases, the Von Hippel 
Landau protein and the 26 S proteasomes [86]. In ischemic conditions, hypoxia HIF-1α 
regulates the adaptive response of the organ to the changes in oxygenation [87]. Indeed, 
HIF-1α confers protection against IRI by activating others genes such as heme 
oxygenase-1 (HO-1) and downstream proteins including Erythropoetin (Epo), Vascular 
endothelia growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) [83, 88].  
3.4.3 Nitric oxide 
Nitric oxide (NO) is a gaseous molecule with an unpaired electron in its valence shell. 
This structural configuration results in NO being highly reactive, with a consequent 
half-life in the order of 5–10 s. Numerous clinical and non-clinical benefits of NO are 
described in various organ systems. The effects of NO on liver ischemia reperfusion 
may prove to be harmful, beneficial or a combination of both. The determining factors 
are the length of the ischemic insult and the enzymatic source of NO. In fact, NO 
generated by the eNOS isoform protects against liver I/R injury, whereas inducible NOS 
(iNOS)-derived NO may have either a protective or a deleterious effect during the early 
phase of IRI, depending on the length of ischemia, length of reperfusion and 
experimental model. The protective effects of NO are presented in figure 6.  
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Figure 6: Mechanism of protection of nitric oxide in liver IRI. ATP, adenosine 
triphosphate; NO, nitric oxide; pO2, partial oxygen pressure (modified from [89]) 
3.4.4 Mitogen Activated Protein Kinases 
Mitogen activated protein kinases (MAPKs) play an important role in intracellular 
signal transduction in response to extracellular stimuli and dual phosphorylation of their 
threonine and tyrosine residues is necessary for their activation. Once activated, these 
kinases are translocated to the nucleus, where they phosphorylate and activate different 
transcription factors and thus the transcription of various genes. MAPKs are classified 
as: (1) Extracellular signal regulated kinases, ERK ½, (2) JunNH2-terminal kinases 1/2 
(JNK 1/2) and (3) p38 MAPK. ERK 1/2 is usually activated by mitogenic and 
proliferative stimuli, like growth hormone receptors, whereas JNKs and p38s are 
stimulated by various cellular stresses like ROS, heat shock, inflammatory cytokines, 
and ischemia and for this reason are also referred as stress-activated protein kinases [90] 
[91]. p38 kinase regulates cell proliferation and differentiation and can modulate either 
pro-proliferative or pro-apoptotic signals [92]. Besides this, p38 activation has been 
mainly associated with the production and activation of inﬂammatory mediators [93]. 
The hepato-protective effects of preconditioning (PC) have been associated with 
activation of JNK-1 and p-p38 and subsequent entry of hepatocytes into the cell cycle, 
thus favoring hepatocyte survival against IRI [94]. However, more recent studies in 
steatotic livers revealed that PC, through PPAR-α activation, reduced p38 and JNK 
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expression. This was also associated with reduced adiponectin levels and oxidative 
stress [95]. Furthermore, the pro-apoptotic ERK has been shown to be activated during 
cardiac PC [96].  
3.4.5 Metalloproteinases 
Metalloproteinase 9 (MMP-9) is a zinc dependent secreted gelatinase which catalysis 
degradation of type IV collagen and gelatin. It has been shown that liver IRI is reduced 
by up to 80% in MMP-9-/- knockouts. In normal animals, increased expression of 
MMP-9 on macrophages and neutrophils during reperfusion was associated with pro-
inflammatory cascades which increases neutrophil transmigration in liver sinusoids and 
increases TNF-α and interferon γ secretion and CD4+ T cell activation [97, 98]. The 
mechanisms by which MMP-9 expression is increased in liver during ischemia 
reperfusion were not investigated in these knockout studies, but a possible pathway 
involves induction of MMP-9 by ROS and tumor necrosis factor α (TNF-α) [98]. 
3.4.6 Heme oxygenase-1 
Heme oxygenase (HO) is the rate-limiting enzyme in the catabolism of heme, followed 
by production of CO, biliverdin, and free iron. The HO system is believed to confer 
cytoprotection by inhibiting inflammation, oxidation, and apoptosis, and maintaining 
microcirculation. HO-1, an inducible form of HO, serves a vital metabolic function as 
the rate-limiting steps in the heme degradation pathway, and affords protection in 
models of hepatic IRI [99-101]. The cytoprotection often seen in the transplanted organ 
following local HO-1 overexpression may include several factors, such as: a) 
antioxidant function, b) maintenance of microcirculation, c) anti-apoptotic function, and 
d) anti-inflammatory function [99, 100]. 
3.4.7 Heat shock proteins 
Heat-shock proteins (HSPs), or stress proteins, are ubiquitous highly conserved proteins 
produced by cells in response to exposure to stressful conditions. HSPs constitute a 
large family of proteins that are often classified based on their molecular weight: hsp10, 
hsp40, hsp60, hsp70, hsp90, etc. They play crucial roles in folding/unfolding of 
proteins, assembly of multiprotein complexes, transport/sorting of proteins into correct 
subcellular compartments, cell-cycle control and signaling, and protection of cells 
  Introduction 
   
21 
 
against stress/apoptosis. In addition, extracellular HSPs can stimulate antigen-
presenting cells of the immune system, such as macrophages and dendritic cells [102]. 
HSPs are induced during exposure to a wide variety of stresses, including ischemia-
reperfusion in order to protect cells from damage. They have been associated with anti-
apoptotic effect, decreases pro-inflammatory mediators, such as NF-kB and enhances 
the anti-oxidant capacity of the cell [101, 103, 104]. Various studies have evidenced that 
the induction of HSP72 and HO-1 expression during IP contributed to the acquisition of 
improved hepatic function and increased tolerance against IRI [105, 106].  
3.4.8 Sirtuins 
Sirtuins are highly conserved class III histone deacetylases with homology to the yeast 
silent information regulator 2 (Sir2). To date, seven sirtuins have been described in 
mammals (SIRT1 through SIRT7). Sirtuin 1 (SIRT1) is a histone deacetylase that either 
activates or suppresses the transcription activities of various non-histone proteins, 
through its NAD
+
-dependent activity. SIRT1 has been associated with the 
pathophysiology of IRI in several organs [107]. In fact, SIRT1 is involved in a wide 
variety of cellular processes, including oxidative stress, DNA damage, apoptosis, 
cellular stress and autophagy [108-113]. It has been reported that SIRT1 deacetylates 
p53 thus reducing its transcriptional activity and its ability to induce apoptosis [114]. 
Also, Forkhead box-containing protein O 1 (FoxO1) is a target for SIRT1 and its 
deacetylation has been involved in detoxification of ROS and promotion of autophagy 
[115]. Furthermore, we have recently shown that SIRT1 activation contributes, in part, 
to the protective effects of liver IP against IRI [116].  
4 Clinical situations associated with liver ischemia reperfusion 
injury 
IRI is an inevitable problem in many clinical situation of liver surgery such as liver 
transplantation, trauma and liver resection.  
4.1 Liver Transplantation 
Liver transplantation (LT) is the only lifesaving therapy for the end-stage liver diseases. 
In LT, IRI is principally caused by blood flow disturbances which starts with the brain 
death and is due to severe hemodynamic disturbances in the cadaveric donors. The 
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clamping of hepatic artery causes a short, but severe liver ischemia during the 
harvesting operation. In addition, the cold ischemia during allograft liver storage may 
also cause a further ischemic damage. The allograft liver transplantation from living 
related donors is also subjected to warm ischemia, but in such condition disturbances 
related to brain death are not present and cold ischemia is also shorter. Indeed, IRI is 
less frequent and less severe in transplantation from living donors. The final and 
biologically more severe stage of the injury occurs during the reperfusion as a 
consequence of the blood flow restoration. IRI is the major cause of early allograft 
dysfunction (EAD), associated with worst graft and recipient survival rates. Depending 
on the criteria used, the reported incidence of EAD has varied in different series and 
ranged from 2% to 23%. Among the 23.2% of recipients with EAD, 18.8% died [117, 
118].  
Dr Thomas Starlz is acknowledged as the first person to successfully performed 
deceased LT in the 1960s. In the 1970s, developments in surgical technique helped to 
advance the field, but rejection of the organ was a limiting factor in survival. A vital 
discovery in the advancement of the field was the development of cyclosporine in 1976 
by Sir Roy Calne. Cyclosporine allowed longer graft and patient survival. Since, 
surgical techniques have been refined, medical therapies are more sophisticated, and 
awareness for transplantation is more widespread.  
Liver transplant activity started in Spain in 1984. Drs. Margarit & Jaurrieta carried out 
the first liver transplant at Bellvitge Hospital (Barcelona). Since 2003, more than 1000 
liver transplants are performed annually (1,108 in 2008). As a consequence of this, the 
liver transplant rate in 2007 was 24.6 per million population (pmp), one of the largest 
ever reached in the world. According to the World Transplant Registry – developed by 
the Spanish Transplant Organization in collaboration with the World Health 
Organization – around 20,000 liver transplants are performed annually all over the 
world [119]. In the period between 1984 and 2013, 85.4 % of patients who underwent 
transplant were residents in Catalonia, 13.6% (569) were resident in the rest of Spain 
and 0.7% (31) were from abroad. This information was not available for 12 patients 
[120]. 
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4.1.1 Indications 
LT is indicated in the cases of fulminant hepatic failure, liver-based metabolic defect or, 
more commonly, cirrhosis with complications such as hepatic encephalopathy, ascites, 
hepatocellular carcinoma, hepatorenal syndrome, or bleeding caused by portal 
hypertension (Table 1). While the complications of cirrhosis can often be managed 
relatively effectively, they indicate a change in the natural history of the disease that 
should lead to consideration of liver transplantation [121]. Referral for transplantation 
should also be considered for the rare diseases state in which the liver is not failing but 
causing other systemic disease (e.g., amyloidosis or oxaluria). In Catalonia, the most 
frequent indication is cirrhosis (48.9%), followed by hepatocellular carcinoma (30.0%), 
although there are differences according to recipient age. In pediatric patients, the most 
frequent indications are congenital biliary diseases [120].  
The benefit of transplantation must be weighed against the considerable potential 
morbidity and mortality of undergoing a major surgical procedure. Therefore, 
transplantation is generally reserved to those who are felt to have poor quality of life 
and high mortality without LT. Patients should be projected to have a longer life with 
transplant than in its absence, referred to as transplant survival benefit. 
Table 1. General Indications for Liver Transplantation [121] 
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4.1.2 Complications of a liver transplant 
Currently, the main limitation of liver transplantation is the poor number of donors. 
Although Spain has the greater number of graft donor in the world, the number of 
patients in waiting list exceeds the number of liver donor. Despite all the efforts made to 
increase organ donation in recent years, the rate of organ donation remains relatively 
stagnant comparing to the increased patients in waiting list [119]. 
To counter the lack of available organs for transplantation, various strategies have been 
developed to optimize the use of available organs. These strategies include the re-
evaluation of the variables of acceptance of an organ to be transplanted such as marginal 
liver grafts and grafts with rare metabolic disorders (domino transplant), and the 
development of various transplantation techniques alternatives to conventional such as 
split technique and living donor liver transplantation. 
 
4.1.3 Marginal liver grafts 
Limited pool of donor organs for liver transplantation has led to the acceptance of 
marginal livers such as steatotic ones, despite their higher risk of EAD and non-
function. In fact, steatotic liver grafts are associated with an EAD rate of 60% compared 
with less than 5% for nonsteatotic grafts [122-124]. This is due to their poor tolerance to 
IRI [117], evidenced by the exacerbated oxidative stress, mitochondrial damage, and 
microcirculatory alterations [58, 123]. For these reasons, there is an urgent need for the 
development of strategies in order to minimize the detrimental effects of IRI in case of 
steatotic livers or to eliminate the fat content. 
4.2 Trauma  
The liver is the most commonly injured organ in blunt abdominal trauma and the second 
most commonly injured organ in penetrating abdominal trauma. Most hepatic injuries 
are relatively minor and heal spontaneously with nonoperative management which 
consists of observation, and possibly arteriography and embolization. Operative 
intervention to manage the liver injury is needed in about 14 % of patients including 
those with hemodynamic instability or those who fail nonoperative management [125]. 
As far as surgical approaches are concerned, IRI contributed significantly to mortality 
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and morbidity. The modification of existing clamping techniques and the ischemic 
preconditioning are the most promising techniques till recently to prevent liver IRI 
[126]. Hence, clinicians should be familiar with the concept of hepatic IRI  and respond 
appropriately and timely [127].  
4.3  Hepatic resection 
Liver resection requires occlusion of the blood supply to the liver in order to reduce 
bleeding from the cut liver surface. This temporary interruption of blood causes 
significant IRI.  
 
5 Therapeutic strategies against liver ischemia reperfusion 
injury 
Protective strategies against liver IRI include surgical interventions known as ischemic 
conditioning, the use of pharmacologic agents, the application of organ preservation 
techniques and the use of wash out solutions.  
5.1 Ischemic conditioning 
Ischemic conditioning is a form of endogenous protection induced by transient 
subcritical ischemia in order to diminish IRI in various organs including liver, heart and 
brain [128-130]. In this regard, we can distinguish three types of ischemic conditioning: 
1) ischemic preconditioning (IPC), ischemic postconditioning (IPost) and remote 
ischemic conditioning (RIC). 
5.1.1 Ischemic preconditioning 
IPC is based on the application of short periods of ischemia (5-10 minutes), separated 
by short reperfusions (10-15 minutes) prior to a sustained episode of ischemia. In this 
way, hepatocytes are prepared to respond favorably against the sequential prolonged 
ischemic insult. IPC process involves multiple extracellular signals, and intracellular 
second messengers [131-133], such as diminution of ROS production, apoptosis and 
inflammation. IPC has been applied successfully in patients with steatotic livers 
undergoing major resection [126]. 
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5.1.2 Ischemic postconditioning 
IPost was developed to overcome the clinical difficulties related to the application of IC 
before ischemia. It involves the same surgical procedure of brief episode of ischemia 
but it is applied at the beginning of the reperfusion phase. IPost has been evaluated in 
transplantation studies of the liver, heart, brain, and kidney [134] and ameliorated organ 
function. Several extracellular factors produced endogenously are known to play an 
essential role in IPost (adenosine, bradykinin, opioid peptides, and ROS [129, 130, 
134].  
5.1.3 Remote ischemic conditioning 
There are now results showing that, in animals, transient ischemia of a wide range of 
tissues induces a systemic multi-organ protection against subsequent extended IRI in a 
remote organ. This was first observed in the coronary arteries of the heart and has also 
been noted in remote organs such as the kidneys, small intestine and liver [134, 135]. 
5.2 Pharmacologic conditioning 
Pharmacologic research for the protection against IRI is based on its pathophysiological 
mechanisms. In this sense, all the parameters implicated in ROS-mediated damage, 
inflammation, cellular death or cytoskeleton disruption represent potential targets of 
pharmacologic PC.  
Although the advance in defining the molecular mechanisms behind the IRI and the 
various therapeutic strategies proposed, few clinical studies at phase III achieved to 
provide encouraging results that ameliorate the clinical outcome. 
5.3 Graft preservation 
The main goal in organ preservation is to maintain function of the organ and tissue 
during storage so that the graft will be viable at reperfusion (See appendix: Emerging 
concepts in liver graft preservation). 
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5.3.1 Static cold storage (SCS) 
To date, the predominant organ preservation method used by most centers is SCS. The 
principles of SCS are based on the diminution of metabolism by hypothermia. The 
appropriate preservation solution is infused into the organ (the cooling phase) and then 
stored statically [136].   
Cooling 
SCS is the most widely used method for preserving organs for transplantation. Cooling 
is necessary to reduce cellular metabolism and the oxygen requirements in order to 
prevent tissue injury [137].  
In order to obtain viable organs after long-term preservation, various methods have been 
proposed, ranging from organ freezing and vitrification [138, 139] to “supercooling” 
(subzero non-freezing at 0 ºC to -5 ºC) [140-143]. In general, long-term survival rates 
after transplantation are disappointing.   
However, in a recent study by Berendsen et al, the combination of “supercooling” (cold 
preservation at -6 ºC) with other parameters achieved effective preservation of liver 
grafts for 4 days [23]. This promising new technique comprises three steps: first, 
“supercooling” of the organ at -6°C to reduce the cellular metabolism; second, 
subnormothermic machine perfusion at 21°C (see the dynamic preservation section 
below), which reinitiates the metabolism and replenishes ATP levels, and third, the use 
of two preservatives, 3-O-methyl-d-glucose (3-OMG) and polyethylene-glycol 35. Each 
of these conditions is necessary to achieve successful liver transplantation [22]. With 
this in mind, supercooling techniques may be a potentially useful tool for suboptimal 
livers which are currently discarded for transplantation purposes, and may have great 
impact on global organ sharing. 
Preservation solutions 
Although cold is a fundamental requirement for tissue preservation, it has harmful 
repercussions due to the induction of cell swelling [144] and cytoskeletal alteration 
[145]. This was, in part, the reason for the development of commercial organ 
preservation solutions able to prevent many of the cellular alterations associated with 
hypothermia and to mitigate the harmful effects of cooling.   
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EuroCollins (EC) solution was developed in the 1970s as a high potassium-sodium 
solution (intracellular composition) which does not contain oncotic agents but does 
contain glucose. Given that glucose is impermeable to renal cells, this preservation 
solution was suitable for kidney preservation when relatively short times were needed 
or DCD organs were used. However, the permeability of the liver and pancreatic cells to 
glucose leads to the loss of the osmotic effect, and also causes the subsequent anaerobic 
metabolization of glucose, inducing intracellular acidosis and thus limiting cell 
preservation. This is why glucose was later substituted by other larger sugar molecules 
such as lactobionate and raffinose in University of Wisconsin (UW) solution, which 
remains in the extracellular space and preserves its beneficial effect. The use of the UW 
preservation solution improved organ preservation time from 6 to 16 hours [26].  
The efficacy of UW solution is based on the prevention of edema by impermeants 
(raffinose, lactobionate), and the addition of an ATP precursor (adenosine) and anti-
oxidant components (allopurinol, reduced glutathione). Drawbacks include the presence 
of hydroxyethyl starch (HES) as oncotic support, which has been associated with high 
blood viscosity and consequent tissue saturation with the preservation solution. As a 
result, washout of blood from the graft and blood flow during reperfusion may be 
reduced [146, 147]. In addition, the high K+ concentration is associated with cellular 
depolarization and activation of voltage-dependent channels [148]. The problems 
caused by HES and K+ led to the development of other preservation solutions without 
oncotic agents such as Celsior and HTK (Custodiol) and others with polyethylene 
glycol (PEG) as oncotic agent, such as Institute George Lopez solution (IGL-1) and 
Tissue and Organ Conservation Solution (SCOT). 
Celsior was developed initially in the 1990s as a cardiac preservation solution with a 
low potassium and high sodium composition. Due to its extracellular composition, 
Celsior was also adopted for the preservation of abdominal organs as an alternative to 
UW. Other solutions without oncotic agents such as histidine-tryptophan-ketoglutarate 
solution (HTK) were also developed. HTK presents low viscosity and for this reason 
provides more rapid cooling and better washout of blood elements during organ 
procurement than UW. Celsior and HTK solutions have been extensively used for liver 
transplantation [149-151].  However, some limitations for HTK use have recently been 
reported.  Stewart et al reported that HTK is associated with reduced graft survival in 
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case of additional risk factors such as DCD, cold ischemia time over 8 hours, and 
donors over 70 years when compared  to UW solution [152]. 
In IGL-1 preservation solution, HES was substituted by a PEG with a molecular weight 
of 35 KDa (PEG 35), and the high K
+
/ low Na
+
 ratio was reversed. Both experimental 
[68, 153] and clinical [154-156] studies of liver and kidney transplantation have shown 
the beneficial effects of IGL-1 against apoptosis, endoplasmic reticulum stress, 
microcirculation dysfunction and immune response. Moreover, in previous studies of 
cold preservation and ex vivo perfusion, we have reported that IGL-1 contributes to a 
more efficient preservation of both non-steatotic and steatotic rat liver grafts compared 
to UW [83, 157, 158], The beneficial effects of IGL-1 include prevention of hepatic 
damage, oxidative stress and mitochondrial injury, and are mediated through nitric 
oxide (NO) production. So, IGL-1 is the first solution reported to be advantageous in 
SCS of suboptimal livers. Also, SCOT preservation solution which contain PEG 20 and 
low K
+
/high Na
+
 concentrations was reported to show a higher renal protection against 
the immune response, mainly due to the “immunocamouflage” process provided by 
PEG20 [159].  
5.3.2 Dynamic preservation: Machine perfusion technique 
For standard liver grafts, SCS with different preservation solutions remains highly 
successful. However, with the increasing need for organs in recent years, the use of 
novel techniques for optimizing suboptimal graft preservation is arousing interest.  
Machine perfusion (MP) consists of creating a controlled recirculating flow of 
preservation solution through the organ using a pump. This continuous perfusion 
permits better penetration of the preservation solution, a thorough washout of blood and 
equilibration of the interstitium with the perfusate medium, delivery of oxygen and 
nutrients (if the perfusate is oxygenated), and removal of toxic metabolites (when the 
perfusate is renewed or filtered). In addition, it allows real-time monitoring of the 
functional and biochemical performance of the graft and the provision of metabolic 
support during preservation [160].    
Unlike the kidney, the MP protocol for the liver is determined mainly by the 
temperature of preservation: hypothermic (HMP) at 4ºC, normothermic (NMP) at 37ºC 
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and subnormothermic (SNMP) at 20ºC-25ºC. Also, several flows and pressures 
(pulsatile or not), single or dual perfusion (hepatic artery and portal vein), oxygenation 
or non-oxygenation, and different MP solution compositions have been tested in various 
liver graft experimental models [161]. 
Hypothermic Machine Perfusion (HMP) 
HMP is a dynamic cold preservation method at 4ºC which ensures homogeneous and 
continuous supply of metabolic substrates to the graft during the ex vivo period [162]. 
This procedure is designed to overcome or reverse the injuries due to the non-controlled 
warm ischemic period or the hypothermia itself. During HMP, aerobic metabolism 
decreases but does not stop completely and the provision of metabolic substrates allows 
the reduction of the cellular insults seen during reperfusion.  
HMP offers several advantages over SCS. Guarrera et al. were the first to compare 
HMP to SCS in human liver transplantation, and showed that HMP improves graft 
function and attenuates classical biochemical markers of liver preservation injury [163]. 
Given the fact that ROS accumulation during ischemia can lead to significant 
hepatocyte toxicity, HMP has been shown to protect the rodent liver from ROS by a 
reduction in glutathione depletion and superoxide anion release when compared with 
SCS [164]. And in the case of suboptimal livers, Bessems et al. showed that HMP 
improved both hepatocellular and endothelial function while reducing damage in a diet-
induced rat fatty liver model [165].  
In contrast to the kidney, in which successful HMP does not necessarily depend upon 
oxygenation, oxygenated HMP (HOPE) has been developed as a means of improving 
the quality of liver preservation in normal or ECD livers [166]. Oxygenated 
preservation enables grafts to restore tissue homeostasis and to maintain the functional 
integrity of hepatocytes during ischemia. In a recent study, Schlegel et al. also described 
a protective effect on the rodent biliary system using HMP in DCD grafts that 
underwent transplantation [167]. As expected, perfusion with the HOPE system 
decreased the parameters of hepatocellular injury and lowered immunogenic 
upregulation.  
Subnormothermic machine perfusion (SNMP) 
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Recently it has been suggested that the use of SNMP systems may be suitable for ex 
vivo preservation and recovery of human liver for transplantation. SNMP is an 
intermediate status for graft conservation, using sub-thermic conditions (20–25 °C), 
taking advantage of the lower metabolic demand in sub-physiological temperature 
conditions, while still maintaining sufficient metabolism for viability testing and 
improvement of graft function. SNMP has already proven advantageous in reducing 
markers of biliary injury during preservation and in restoring normal biliary physiology 
[168]. A recent study by Bruinsma et al. is the first demonstration of the capacity of 
SNMP to sustain human livers. This group showed that SNMP effectively supports the 
human liver ex vivo with minimal injury, and normalizes physiological disturbances 
post-ischemia [169]. 
Normothermic Machine Perfusion (NMP) 
The principle of normothermic perfusion is the maintenance of normal cellular 
metabolism in a physiological environment throughout the preservation period by 
maintaining normal temperature (37ºC) and providing oxygen and essential substrates 
[170]. This ensures large-scale metabolic activity and the maintenance of energy 
reserves such as ATP content. NMP has the advantage of allowing viability assessment 
prior to transplantation. As the liver metabolism is maintained during preservation, 
markers including bile production and liver enzymes can be measured.  
NMP is an emerging technology whose potential in liver preservation has been 
described in several animal studies, which have shown its superiority over SCS in the 
preservation of liver grafts [170-172]. Interestingly, porcine and murine models of DCD 
livers are significantly improved by NMP compared to organs preserved by SCS [173, 
174].  
Recently, Kavikumar et al. reported the first clinical trial of transplanted livers with 
NMP [175]. Their study included 10 transplanted patients with relatively low risk 
donors and recipients, and showed that NMP is safe and feasible in human applications. 
This study opens up new avenues for research into liver graft preservation with NMP. 
Recently, NMP has emerged as a novel tool for decreasing steatosis in a process named 
“defatting”. In a preliminary study using porcine livers, ex vivo normothermic perfusion 
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for 48 h led to a 50% reduction in lipid droplet size in perivenous hepatocytes, reaching 
the size found in control lean livers [176]. Moreover, NMP of steatotic livers from 
Zucker Ob rats using a “defatting cocktail” decreased the intracellular lipid content by 
50% over 3 h of perfusion [177]. Decreasing steatosis prior to transplantation by short 
term NMP would allow the transplantation of severely steatotic livers and thus alleviate 
the donor liver shortage. 
5.4 Graft wash out 
After cold storage, preserved liver grafts need to be washed out before reperfusion to 
remove preservation solution and metabolic waste in order to ameliorate transplant 
revascularization and viability after transplantation. The washout step seems to be 
neglected in experimental research and washout solutions were not investigated as well 
as preservation solution. In clinical practice, surgeons usually use Ringer lactate 
solution (RLS) or albumin based solution (5% human albumin). Although RLS has a 
simple composition and was not designed to reduce reperfusion injury, it has been 
shown to be effective in liver transplantation [178]. Adam et al uses albumin rinse 
solution at Paul Brusse Hospital; in a prospective randomized study, they have shown 
that serum albumin flush solution preserved better liver grafts than RLS [179].  
Since 1991, Gao et al. developed Carolina rinse solution which has been designed to 
prevent reperfusion injury in liver transplantation. Carolina rinse solution contains 
extracellular inorganic ions similar to RLS, adenosine, a calcium channel blocker, 
antioxidant and radical scavengers (allopurinol, gluthatione and desferrioxamine). 
Carolina rinse solution also contains fructose and mildly acidotic pH to reduce hypoxic 
cell death. Adenosine and mildly acidotic pH were identified as key components.  It has 
been shown that the simple use of Carolina rinse solution enhance survival significantly 
after rat liver transplantation when compared to RLS. Carolina rinse diminished 
postoperative sinusoidal endothelial cell damage and reduced Kupffer cells activation 
significantly. Also, Carolina rinse solution diminished graft swelling, improved hepatic 
microcirculation and reduced postoperative elevation in serum enzyme 2 to 3 folds 
[180-182].  
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6 Polyethylene glycol in ischemia reperfusion injury  
6.1 Structure 
PEG are water-soluble polymer formed by a process of linking repeating units of 
ethylene glycol to form polymers with linear or branched shapes of different molecular 
weight (Figure 4  ) [183]. The FDA has approved the use of PEG as a vehicle or a base 
in foods, cosmetic and pharmaceuticals, including injectable, topical, rectal and nasal 
formulations [184]. PEG is non immunogenic, shows little toxicity and is eliminated 
from the body intact by either the kidneys (for PEGs < 30 kDa) or in the faeces (for 
PEGs > 20 kDa) [1]. Because of the high flexibility, hydrophilicity, and large number of 
water molecules integrated into its chains, PEG presents a hydrodynamic volume 
greater than would be expected from its molecular weight and has high protein-rejecting 
properties [184, 185]. PEG has an apparent molecular weight 5–10 times higher than 
corresponding soluble protein of similar molecular mass, as shown by gel permeation 
chromatography [184].  
 
6.2 The effects of PEG 
In general, PEGs prevent the generation of reactive oxygen species (ROS) [186, 187], 
enhance cell survival pathways in hypoxia/reoxygenation conditions [6], protected 
injured mitochondria [2] and repair endothelial cell damage during post-ischemic 
reperfusion [6, 188]. PEG exerts its cytoprotective role through the restoration of 
membrane integrity [6, 145, 186, 189] or by entering the cell through the disrupted 
Figure 7 Structural formulae of polyethylene glycol [184] 
(m-PEG, monomethoxy-PEG) 
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membranes and interacting with cellular organelles [3]. In hypothermic hepatocyte 
preservation, PEG8 (8kDa) prevented cell swelling through a mechanism that was 
independent of its osmotic properties [144]. Also, PEG used as cryoprotectant in 
supercooling technique was necessary to achieve successful liver transplantation [24]. 
Moreover, PEG suppressed hypothermic-induced cell swelling in hepatocyte 
preservation [187] and protected primary hepatocyte during supercooling preservation 
[190].  As a colloid, PEG changes the way proteins interact with each other and with 
water in the glycocalyx and it has been reported that PEG-lipids mimic the inhibiting 
effect of the cell glycocalyx on adhesion [191]. 
6.2.1 PEG as additive to preservation solution 
PEG has been added to preservation solutions as a colloid agent to prevent cell swelling. 
However, it seems that PEG benefits are mediated by others mechanisms in addition to 
its oncotic properties. IGL-1 solution, which contain PEG 35 at 1g/L has been shown to 
be superior to UW solution in many experimental studies and was proposed as an 
effective alternative in steatotic liver preservation [158]. The beneficial effects of IGL-1 
include prevention of hepatic damage, ERS, oxidative stress, mitochondrial injury, 
microcirculation dysfunction and immune response [192]. Knowing that the main 
difference between IGL-1 and UW preservation solution is the substitution of the 
colloid HES by PEG 35, we can speculate that all these protective effects are the result 
of PEG 35 supplementation.  
Moreover, a PEG of smaller size (PEG20), is the basic component SCOT preservation 
solution which have been shown to be effective in kidney preservation and provides a 
higher renal protection against the immune response, mainly through 
“immunocamouflage” process provided by PEG20 [159]. Moreover, PEG20 at 15 g/L 
in SCOT solution has been found to reduce alloantigen recognition after liver 
reperfusion in comparison to UW solution [193].  
Even so, the use of PEG 35 as oncotic agent has been shown to be more effective than 
PEG20 for liver graft preservation [194]. However, in kidney model of transplantation 
in pigs, it has been shown that PEG of 20 kDa was more effective than PEG 35 in 
ameliorating glomerular function and preventing histological injuries [195]. The authors 
conclude that PEG 35 act by a concentration dependent manner and high concentration 
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of PEG 35 of 15 or 30 g/L induces cellular damage [195]. This could be explained by 
the high viscosity and the lower clearance of PEG 35 in these storage solutions.  
6.2.2 PEG as additive to machine perfusion liquid 
PEG has been also used in MP solutions. Bessems y al have shown that substitution of 
HES in Polysol perfusion solution by PEG resulted in equal or better function and less 
damage in rat liver after 24h of HMP . Moreover, Polysol-PEG solution was more 
efficient than UW-Gluconate perfusion solution [196]. More recently, it has been shown 
that PEG 35 addition to SNMP at 5g/L in supercooling technique was necessary to 
achieve successful transplantation after 6 days preservation [190]. On the other hand, in 
a model of kidney auto transplantation in pigs after 60 min of warm ischemia and 24h 
of HMP, it has been shown that the use of SCOT solution which contain PEG20 at 
15g/L result in more damage when compared to the two reference perfusion solutions 
for kidney: UW-M and KPS [195]. 
6.2.3 PEG as preconditioning agent  
PEG is not absorbed by gastrointestinal tract, so its use was limited to its addition to 
preservation or perfusion solutions. Recently, it has been shown that intravenous 
delivery of 10% PEG 15–20 prior to reperfusion following 60 minutes of ischemia by 
left anterior descending artery (LAD) occlusion in rats, resulted in significant recovery 
of left ventricular ejection fraction, markedly less myocardial apoptosis and inhibition 
of ventricular fibrosis and adverse remodeling. PEG treatment led to the upregulation of 
myocardial prosurvival signaling pathways such as Akt, ERK1/2, GSK-3β, and eNOS 
[197]. PEG use as a method of pharmacological preconditioning may be a very 
promising strategy in clinical situation of IRI. 
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Hepatic IRI is an inevitable clinical problem for liver surgery. PEGs are water soluble 
nontoxic polymers that have been extensively used in biomedical applications and 
proved their effectiveness in preventing tissue injuries.  
 
In this sense, the main objective of this thesis was to study the potential contribution of 
PEG to liver graft protection against IRI. 
 
For that purpose, we established the following specific objectives: 
 
1- To investigate whether the intravenous administration of a high molecular 
weight PEG of 35 kDa (PEG 35) could be an effective strategy for assessing rat 
liver preconditioning against warm IRI. 
 
2- To evaluate the potential protective effects of intravenous administration of PEG 
35 in steatotic livers subjected to cold ischemia reperfusion. 
 
3- To determine whether a new rinse solution containing PEG 35 could prevent 
reperfusion injury in liver grafts. 
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Abstract 
Hepatic ischemia reperfusion injury (IRI) is an inevitable clinical problem for liver 
surgery. Polyethylene glycols (PEGs) are water soluble nontoxic polymers that have 
proven their effectiveness in various in-vivo and in-vitro models of tissue injury. The 
present study aims to investigate whether the intravenous administration of a high 
molecular weight PEG of 35 kDa (PEG35) could be an effective strategy for rat liver 
preconditioning against IRI. PEG35 was intravenously administered at 2 and 10 mg/kg 
to male Sprague Dawley rats. Then, rats were subjected to one hour of partial ischemia 
(70%) followed by two hours of reperfusion. The results demonstrated that PEG35 
injected intravenously at 10 mg/kg protected efficiently rat liver against the deleterious 
effects of IRI. This was evidenced by the significant decrease in transaminases levels 
and the better preservation of mitochondrial membrane polarisation. Also, PEG35 
preserved hepatocyte morphology as reflected by an increased F-/G-actin ratio and 
confocal microscopy findings. In addition, PEG35 protective mechanisms were 
correlated with the activation of the pro-survival kinase Akt and the cytoprotective 
factor AMPK and the inhibition of apoptosis. Thus, PEG may become a suitable agent 
to attempt pharmacological preconditioning against hepatic IRI. 
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Introduction 
Ischemia reperfusion injury (IRI) is inherent to surgical procedures such as liver 
resection and liver transplantation. The deleterious effects caused by IRI are the main 
cause of graft primary non-function and dysfunction [1]. Many strategies have been 
developed to protect against IRI such as ischemic preconditioning (IPC) and the use of 
different drugs. However, these strategies didn’t prove their effectiveness in clinical 
setting and efficient treatments are still lacking.  
Polyethylene glycols (PEGs) are water soluble non-toxic polymers with different 
molecular weights and properties that have been extensively used in numerous 
applications (cosmetic, foods, pharmacy and biomedicine) [2]. Also, PEGs have been 
found to exert beneficial effects in various in-vivo and in-vitro models of tissue injury 
[3-8]. Recently, it has been demonstrated that intravenous administration of high 
molecular weight PEG of 20 and 35 kDa protected rat heart against reperfusion injury 
and steatotic livers against cold IRI, respectively [9, 10]. The protective effects were 
associated with decreased vascular permeability, decreased oxidative stress and 
inhibition of cell death [8, 11]. 
The aim of the present study is to examine the potential benefits of prophylactic 
intravenous administration of PEG35 in order to prevent warm IRI in rat liver, as well 
as to investigate the underlying mechanisms. 
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Meterials and Methods 
Animals 
Male Sprague-Dawley rats (250-300 g) were purchased from Charles River (France) 
and housed in a temperature and humidity controlled room under a constant 12-hour 
light/dark cycle. Animals had free access to water ad libitum and rat chow (standard 
laboratory pelleted formula A04, Panlab, Barcelona, Spain). This study was performed 
in accordance with European Union directive 2010/63/EU for animal experiments and 
approved by the Ethics Committees for Animal Experimentation of the University of 
Barcelona (No. 696/14). 
 
Surgical Procedure 
All the procedure was performed under isofluorane inhalation (induction dose of 5 % 
and maintenance dose of 1.5-2 %). Also, analgesia was applied before surgery by 
subcutaneous injection of buprenorphine at the dose of 0.05 mg/kg. After laparotomy, 
ischemia was induced by occlusion of the hepatic artery and portal vein of the left and 
median lobes using an atraumatic micro vascular clip (70% ischemia). After one hour of 
ischemia, liver reperfusion was established by removal of the clamp and the abdomen 
was sutured. Then, rats were kept in clean cages with free access to water and standard 
rodent chow. After 2h of reperfusion, animals were sacrificed by cervical dislocation 
under isoflurane anaesthesia for blood and tissue collection. Sham operated rats 
underwent the same procedure without vascular clamping. 
 
Drug Treatment:  
PEG 35 was kindly provided by Institute Georges Lopez (IGL). PEG 35 was dissolved 
in phosphate buffer saline (PBS) and administrated 10 min before liver ischemia by 
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intravenous bolus via the penile vein at the concentration of 2 mg/kg or 10 mg/kg using 
PEG 35 solution of 1g/L and 5g/L, respectively. For intravital microscopy study, PEG 
35 was fused with fluorescein (PEG-FITC) as previously described by Mero at al [12].  
Experimental Groups: 
Rats were randomly distributed into four groups as follows:   
Group 1: (Control: Ctr, n=6): Midline incision was performed and hepatic pedicle was 
dissected. Then, 500µL of PBS was injected intravenously via the penile vein and 
abdomen was sutured. After 2h, rats were sacrificed for blood and sample collection.  
Group 2: (IR 2h, n=6): Rats were pre-treated with 500µL of PBS intravenously and then 
subjected to one hour of ischemia followed by 2h of reperfusion. Then, animals were 
sacrificed and plasma and liver samples were collected. 
Group 3: (PEG 2mg/kg, n=6): Same as group 2 but rats were pre-treated with 
intravenous administration of PEG35 at the dose of 2 mg per kg body weight. 
Group 4: (PEG 10mg/kg, n=6): Same as group 2 but rats were pre-treated with 
intravenous administration of PEG35 at the dose of 10 mg per kg body. 
 
Biochemical determinations: 
Hepatic injury 
Plasma levels of alanine aminotransferase (AST) and aspartate amino transferase (ALT) 
were measured using a commercial kit from RAL (Barcelona, Spain) according to 
manufacturer’s protocol.  
Glutamate dehydrogenase activity 
GLDH activity was determined using a commercial kit (GLDH, Randox laboratories 
Ltd., Crumlin, UK) by quantifying the decrease in absorbance at 340 nm according to 
the manufacturer’s protocol.   
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Determination of Nitrites and Nitrates  
Nitric oxide levels were measured as nitrate plus nitrite (NOx) in tissue samples using a 
commercial colorimetric assay kit (Cayman Chemical Co., Ann Arbor, MI, USA).  
 
Western blot analysis:  
Liver tissue was homogenized in HEPES buffer and 50µg of protein were separated on 
6-10% SDS-PAGE gels and transferred to PVDF membranes. Membranes were then 
incubated overnight at 4°C using the following antibodies: anti-eNOS (BD 
Transduction Laboratories, Lexington, KY, USA), anti-phosphorylated Akt, anti-total 
and anti-phosphorylated AMPK (Cell Signaling Technology Inc., Beverly, MA, USA), 
and anti-β-actin (Sigma Chemical, St. Louis, MO, USA). The corresponding secondary 
antibody was then added for 1 hour at room temperature and membranes were 
developed using the enhanced chemiluminescence reagents from Avision (Advansta, 
Menlo Park, CA, USA). Signals were quantified by scanning densitometry using the 
Quantity One software for images analysis. Results were expressed as densitometric 
ratio between the protein of interest and the correspondent control (β-actin, total 
AMPK, total Akt).  
 
Histology: 
Formalin-fixed paraffin-embedded liver tissues were cut in 5µm sections and stained 
with hematoxylin and eosin according to standard procedures. Images were analysed by 
an independent investigator in blind manner.  
 
F/G-actin ratio measurements: 
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To analyse the levels of F-actin and G-actin, liver samples were homogenized with 
PHEM buffer (60 mM Pipes, 20 mM HEPES, 10 mM EGTA, 2 mM MgCl2, 1% Triton-
X100, pH 7.0) and ultra-centrifuged (48.000 rcf) at 4°C for 5min to separate both 
fractions. Supernatant, containing G-actin, was collected; the F-actin pellet was washed 
twice with cold PHEM buffer and then dissolved in 1x SDS sample buffer. Equivalent 
amounts of proteins were separated by 10% SDS-PAGE, and F-actin and G-actin were 
determined by western blot and quantified by scanning densitometry. The F/G-actin 
ratio was calculated.   
 
Intravital microscopy  
Rats were anesthetized with isofluorane inhalation, laparotomized and putted in a prone 
position over a cover slip mounted on the stage of a Leica TCS SP5 resonant scan 
multiphoton confocal microscope (Leica Microsystems Heidelberg GmbH) equipped 
with an incubation system with temperature control, a HCX IR APO L 25× water 
immersion objective (Numerical Aperture  0.95), resonant scanner at 8000 lines/s and a 
near infrared Titanium:Saphire laser (MaiTai, SpectraPhysics) for two photon excitation 
running at 800 nm. 
The following vital dyes were injected intravenously as indicated: Hoechst 33342 
trihydrochloride (12mg/Kg, Invitrogen, H3570) for DNA-Nuclei staining; Rhodamine 
123 (0.11mg/Kg, Sigma, R8004) for mitochondrial membrane potential dye, Evans 
Blue (20 mg/Kg, Sigma, E2129-10), a bulk fluid-phase albumin marker that enhances 
contrast of plasma and PEG35 conjugated with fluorescein isothiocyanate (PEG-FITC).  
Images were acquired with resonant scan at 8000 lines/second. 
 
Confocal fluorescence microscopy: 
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Liver was fixed, cryoprotected with sucrose, embedded in OCT and frozen on a cooper 
plate on dry ice. Ten-micrometer cryosections were cut in a cryostat and post fixed in 
4% buffered paraformaldehyde for 10 min and then permeabilized with PBS containing 
0.1% Triton X-100 and 1% BSA for 30 min. For actin visualization, the slides were 
incubated with TRITC-phalloidin (dilution 2 µM, Sigma) in PBS with 1% BSA and 
0.2% Triton X-100 for 30 min. Slides were washed three times for 15 min with PBS. 
The last PBS wash included Hoechst 33342 (dilution 1 mM, Invitrogen). Finally, 
cryosections were mounted using Mowiol (Calbiochem). Confocal images were 
acquired with a Leica TCS SP5 laser scanning microscope. Hoechst-33342 and 
Phalloidin-A555 images were acquired sequentially using 405 and 561 nm laser lines. 
The confocal pinhole was set at 1 airy unit and when 3D reconstruction was required 
stacks of images every 0.3mm were acquired. The hepatocytes size (in µm2) and 
circularity as (4π×Area)/Perimeter2 (based on Phalloidin staining) were quantified on 
ImageJ. The red channel (phalloidin-A555 staining) was processed to segment 
hepatocytes. Hepatocytes were selected and size and circularity was measured (in 1.5 
mm2 of each sample). A value of 1.0 indicated a perfect circle; as the value approached 
0.0, indicated a more polyhedral shape. 
 
Statistical analysis: 
Data are expressed as means ± standard error and were compared statistically by the 
one-way analysis of variance, followed by the Tukey test (Graph Pad Prism 
software). P < 0.05 was considered significant. 
 
Results 
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In order to evaluate the effect of PEG35 in liver IRI, we firstly determined the liver 
damage through transaminases levels and hepatic histology after 1 hour of ischemia 
followed by 2 hours of reperfusion. As shown in Figure 1A and B, IR group led to 
significant increases in transaminases levels compared to control group, which was 
prevented when rats were pretreated with intravenous injection of PEG35 at 10 mg/kg. 
By contrast, no significant differences were observed when PEG35 at 2 mg/kg was 
administered. Histological findings shown in Figure 1C were in accordance with liver 
injury parameters. Animals subjected to IR showed extensive areas of coagulative 
hepatic necrosis with disruption of hepatic cords and haemorrhage randomly distributed 
throughout the hepatic parenchyma. PEG at 10mg/kg reduced the extent and the number 
of necrotic areas. 
It is well known that hepatic damage after reperfusion is associated with mitochondrial 
alterations. For this reason, we measured GLDH activity to assess mitochondrial injury 
after two hours of reperfusion. As indicated in Figure 2A, the increase in GLDH levels 
observed in ischemic group was prevented in PEG 10 mg/kg group. No changes were 
observed in PEG 10 mg/kg versus control. By contrast, pretreatment with PEG35 at 2 
mg/kg was not sufficient to protect mitochondria against IRI. Also, we performed 
intravital multiphoton microscopy in living rats at one hour of reperfusion to evaluate 
mitochondrial polarization status using Rh123 (Figure 2B). In the livers of control rats, 
bright punctate Rh123 fluorescence was observed representing cells with polarized 
mitochondria. However, livers from ischemic rats showed a dimmer diffuse cytosolic 
fluorescence indicating mitochondrial depolarization. Importantly, when rats were 
pretreated with PEG35 at 10 mg/kg, mitochondrial depolarization was lessened after 
ischemia and totally reverted after reperfusion.  
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Next, we investigated the potential signalling mechanisms involved in the beneficial 
effects of PEG35 pretreatment. In this sense, it has been reported that protein kinase B 
(Akt) is a pro-survival protein that decreases apoptosis in models of IRI [13]. Also, it is 
well known that AMPK is a cellular metabolic sensor that switches the cell to an energy 
conserving status under ischemic conditions [14]. Our results show that PEG35 
administration at the dose of 10 mg/kg induced a significant activation of both Akt and 
AMPK (Figure 3A and 3B, respectively).  
Both AMPK and Akt have been shown to activate endothelial nitric oxide synthase 
(eNOS) [15]. However, no changes in eNOS activation were found when PEG was used 
(Figure 3C) although a significant increase in nitrites/nitrates levels in liver tissue were 
observed (Figure 3D).  
Given the central role played by apoptosis in liver IRI, we evaluated the effects of 
PEG35 on hepatic apoptosis by measuring caspases 3 and 9. As shown in Figure 3, PEG 
10mg/kg promoted a significant reduction of cleaved caspases 3 and 9. No significant 
differences were found regarding pretreatment with PEG35 at 2mg/kg although a 
tendency towards a decrease was observed when compared to IR group (Figure 4).   
In addition, we studied the potential PEG effects on cytoskeleton. Confocal microscopy 
images of F-actin stained with phalloidin showed that, in PEG35 pre-treated livers, 
filamentous actin associated to the membrane micro-filamentous network and the peri-
canalicular band are kept preserved (Figure 5A). Also, morphology of hepatocytes in 
ischemic livers was compromised after ischemia reperfusion as shown in quantification 
of hepatocytes size and circularity (Figures 5B and 5C). Increase in size and circularity 
indicates that hepatocytes have swollen and lost their shape which was less evident in 
case of PEG treated livers. Moreover, IRI induced an important decrease of F/G-actin 
ratio, which was significantly prevented when PEG 10mg/kg was administered, as it is 
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indicated in Figure 4D. Also, it has been reported that activation of p38 leads to 
cytoskeletal changes by increasing the hepatocyte F-actin content after IRI [16]. For this 
reason, we investigated whether the cytoskeleton preservation observed with PEG pre-
treatment was correlated with changes in p38 phosphorylation status. Indeed, our results 
showed that PEG preconditioning increased p38 activation (Figure 5E). 
Finally, we performed intravital microscopy using PEG-FITC in order to study its 
localization in liver tissue. We observed that PEG was still present in liver vascular bed 
after one hour of ischemia and one hour of reperfusion, which is showed in the 
additional movie file [see Additional file 1]. 
 
Discussion 
IRI is an important cause of liver damage occurring during surgical procedures 
including hepatic resection and liver transplantation, and represents the main cause of 
graft dysfunction and primary non function after transplantation [17]. PEGs are water 
soluble non-toxic polymers that are known to play an important role in the 
cytoprotection against ischemic damage. Recent studies have shown that PEG exerts 
anti-inflammatory, anti-apoptotic, immunosuppressive and membrane stabilization 
effects [4, 5, 8, 18-20]. From this perspective, it is reasonable to expect that PEG 
administration may be an effective therapeutic strategy against IRI. In this study, we 
demonstrate, for the first time, that PEG35 preconditioning protects rat liver against 
warm IRI. 
 We have focused our study on PEG with molecular weight of 35kDa because it has 
been previously demonstrated that PEG35 was effective to prevent cold IRI in liver 
when it was added to organ preservation solutions [21-23]. Moreover, PEG35 has been 
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shown to protect renal cells against cold ischemia [24]. Also, we recently evidenced that 
PEG35 addition to washout solution protected cold stored livers against reperfusion 
injury [25]. However, PEGs with different molecular weights such as PEG8 [11] or 
PEG20 [26] might also be useful for conferring protection against IRI.  
In order to achieve an efficient hepato-protection, the most suitable concentration of 
PEG35 was 10 mg/kg. This concentration was well tolerated as control rats injected 
with PEG35 at 10 mg/kg did not present any liver damage (data not shown). 
The beneficial effects induced by PEG35 are mainly associated with the preservation of 
the mitochondrial status, as revealed by decreases in GLDH levels and intravital 
microscopy findings. Since mitochondria are sensitive targets for damage during IRI 
[23, 24], the lessened hepatic injury observed when PEG35 was administered at 
10mg/kg coincided with increased mitochondrial preservation.     
We next determined whether PEG35 beneficial effect could be related to the activation 
of protective cell signalling pathways. Our results showed that PEG35 at 10 mg/kg 
contributes to AMPK and AKT activation.  These facts are in line with previous reports 
showing that PEG20 protects against heart ischemia through AKT activation [7, 8] and 
PEG35 protects rat liver against reperfusion injury, in part, through AMPK activation 
[9]. These observations suggest that PEG protective effects are not only related to its 
known role as an oncotic support but also to its pharmacological properties. 
Akt and AMPK activation has been related to apoptosis inhibition in many models of 
IRI [15, 27, 28]. As it was expected, PEG 35 at 10 mg/kg prevented caspase 3 and 
caspase 9 activation. These observations are in line with results observed by Malhotra et 
al. who demonstrated that PEG15-20 protected cardiac myocytes from hypoxia and re-
oxygenation induced apoptosis [8]. Moreover, we have previously reported that PEG35 
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addition to preservation solutions acts as an oncotic agent ameliorating organ graft 
preservation by reducing apoptosis in rat liver transplantation [29]. 
Nitric oxide (NO) is a gaseous vasodilator implicated in the regulation of hepatic 
microcirculation, which is impaired upon IRI [25]. In this sense, we found that PEG35 
at 10 mg/kg significantly increased NOx levels and this was not correlated with eNOS 
activation. This observation is concomitant with a previous published report showing 
that PEG induced arteriolar dilatation which was not correlated to eNOS activation [26].  
However, we have recently evidenced that the benefits of PEG in IRI were associated 
with closely e-NOS activation [8, 9]. Thus, more investigations are needed to elucidate 
the precise mechanisms of NO generation mediated by PEG. 
Structural alterations of the cytoskeleton following ischemia reperfusion have been 
reported to cause disturbances of intracellular transport processes, cell motility and 
microcirculation leading to organ dysfunction [30-33]. In liver cells, F-actin is a 
relevant component of liver cytoskeleton which forms microfilaments involved in 
intracellular transport processes, such as exocytosis and endocytosis, maintenance of 
cell shape, and canalicular motility responsible for bile flow [25, 32, 34, 35]. In this 
context, we have explored whether PEG35 pretreatment could maintain the cytoskeleton 
structure and preserve the morphological characteristics of hepatocytes. Indeed, our 
present data confirmed that F-actin/G-actin ratio is increased as a consequence of PEG 
administration at 10 mg/kg. Furthermore, confocal microscopy findings confirmed that 
PEG contributes to the regulation of endothelial cell barrier by rearranging the actin 
cytoskeleton. Hepatocytes presented a more normal hexagonal morphology in livers 
pretreated with PEG35 compared with livers submitted to IRI. All of these observations 
are consistent with a recent study in lung endothelial cells evidencing that PEG15-20 
preserves the architecture of the endothelial cytoskeleton [36]. Moreover, it has been 
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demonstrated that PEG induced membrane stabilization through sarcolemmal lipid-raft 
architecture preservation [8]. These published data suggested that PEG interaction with 
cell membrane (adhesion or intercalation) preserved the cytoskeleton. In our study we 
further evidenced that PEG-induced-p38 MAPK activation may also be responsible for 
cytoskeleton preservation. However, the precise mechanisms of how PEG could affect 
cytoskeleton remain to be elucidated. 
Currently, the proposed strategies against IRI rely on surgical procedures such as IPC, 
or on the use of pharmacological agents (pharmacologic preconditioning) [37]. IPC is a 
well-established technique that consists on the application of brief episodes of ischemia 
and reperfusion which cause protection against the subsequent prolonged ischemic 
insult [38]. However, this manipulation is not tolerated in most operation rooms. 
Pharmacologic preconditioning consist on the administration of drugs that block 
injurious pathways directly, or trigger endogenous protective mechanisms [37]. 
Although most of these drugs were effective in reducing IRI in many experimental 
models, studies that evaluate their efficacy in the clinical settings are still lacking. 
Moreover, their benefits are limited to the specific drug activity and their potential 
adverse effects. Compared to IPC and pharmacologic preconditioning, PEG present the 
advantageous of being safe and multi-target drug. Indeed, PEG effects are associated 
with the majority of the events occurring during IRI such as oxidative stress, 
mitochondrial preservation, cytoskeleton protection and the induction of prosurvival 
and cytoprotective signaling pathways. 
Conclusions: 
In conclusion, the present work evidences that intravenous administration of PEG35 is a 
useful tool for liver preconditioning against the deleterious effects of IRI. Based on 
these findings, PEG35 could be useful in clinical settings. 
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FIGURES LEGEND 
 Figure 1: Hepatic injury after ischemia-reperfusion. PEG35 at 10 mg/kg decreases 
AST (A) and ALT (B) levels and the number of necrotic areas as shown by histological 
findings (eosin/hematoxylin staining) (C). Data represent mean ± SEM. *p<0.05 vs Ctr, 
#p<0.05 vs IR 2h, +p<0.05 vs PEG 2mg/kg 
Figure 2: Mitochondrial damage after liver ischemia reperfusion. PEG35 at 10 
mg/kg decreases glutamate dehydrogenase (GLDH) levels (A) and preserve 
mitochondrial polarization status (B) (mitochondrial membrane potential dye 
Rhodamine123 (green color), the nuclei dye Hoechst (blue color) and the plasma 
albumin dye Envans blue (red color)). Data represent mean ± SEM. *p<0.05 vs Ctr, 
#p<0.05 vs IR 2h. 
Figure 3: Effect of PEG35 on Akt, AMPK, eNOS activation and NO generation. 
PEG 35 preconditioning at 10 mg/kg enhances AMPK and Akt activation and increase 
nitrite/nitrate levels without any effect in eNOS. Western blot and densitometric 
analysis of phosphorylated Akt / b-actin (A) phosphorylated AMPK / total AMPK (B) 
eNOS / b-actin (C) and biochemical determination of Nitrite+Nitrate levels in liver 
tissue (D). Data represent mean ± SEM. *p<0.05 vs Ctr, #p<0.05 vs IR 2h. 
Figure 4:  Effect of PEG35 on liver apoptosis after ischemia reperfusion. PEG35 at 
10 mg/kg reduced the levels of apoptotic proteins Caspase 3 and 9. Western blot and 
densitometric analysis of Cleaved Caspase 3 / pro-caspase 3 (A) and Cleaved Caspase 9 
/ pro-caspase 9 (B). Data represent mean ± SEM. #p<0.05 vs IR 2h, +p<0.05 vs PEG 
2mg/kg 
Figure 5: PEG35 preconditioning contribution on cytoskeleton preservation. 
Images of confocal microscopy show that, in PEG 35 pretreated livers, filamentous 
actins (red) and hepatocytes morphology were better preserved when compared with 
 67 
 
non-treated ones. Also, PEG 35 pretreatment at 10 mg/kg enhance significantly F/G-
actin ratio and phospo-p38 protein levels. Confocal microscopy for F-actin (A), 
determination of hepatocyte size (B) and hepatocyte circularity (C) and western blot and 
densitometric analysis of F-actin/G-actin (D) and phosphorylated p38 (E). Data 
represent mean ± SEM. *p<0.05 vs Ctr, #p<0.05 vs IR 2h, +p<0.05 vs PEG 2mg/kg.   
 
Additional File 1: Rats were treated intravenously with fluorescent PEG35 (PEG-
FITC) and then submitted to 1 hour of hepatic ischemia followed by 1 hour of 
reperfusion. The confocal microscopy findings after reperfusion confirmed the presence 
of PEG in the liver vascular system.   
  
 68 
 
 
 
 
 
 
  
  
 69 
 
  
 70 
 
 
Research Article
Protective Effect of Intravenous High Molecular Weight
Polyethylene Glycol on Fatty Liver Preservation
Mohamed Bejaoui,1 Eirini Pantazi,1 Emma Folch-Puy,1
Arnau Panisello,1 María Calvo,2 Gianfranco Pasut,3 Antoni Rimola,4,5 Miquel Navasa,4,5
René Adam,6 and Joan Roselló-Catafau1,5
1Experimental Pathology Department, Institute of Biomedical Research of Barcelona (IIBB-CSIC), 08036 Barcelona, Catalonia, Spain
2Serveis Cientifico-Te`cnics, Universitat de Barcelona, 08036 Barcelona, Catalonia, Spain
3Pharmaceutical and Pharmacological Sciences Department, University of Padova, 35122 Padova, Italy
4Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, Catalonia, Spain
5Centro de Investigacio´n Biome´dica en Red de Enfermedades Hepa´ticas y Digestivas (CIBEREHD), Barcelona, Catalonia, Spain
6Centre Hepato-Biliaire, AP-P-HP Hoˆpital Paul Brousse, Inserm U776, Universite´ Paris Sud, Villejuif, 75008 Paris, France
Correspondence should be addressed to Joan Rosello´-Catafau; jrcbam@iibb.csic.es
Received 29 May 2015;Revised 8 August 2015;Accepted 12 August 2015
Academic Editor: Hartmut Jaeschke
Copyright © 2015Mohamed Bejaoui et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Ischemia reperfusion injury (IRI) leads to significant tissue damage in liver surgery. Polyethylene glycols (PEGs) are water
soluble nontoxic polymers that have proved their effectiveness against IRI. The objective of our study was to investigate the
potential protective effects of intravenous administration of a high molecular weight PEG of 35kDa (PEG 35) in steatotic livers
subjected to cold ischemia reperfusion. In this study, we used isolated perfused rat liver model to assess the effects of PEG 35
intravenous administration after prolonged cold ischemia (24 h, 4∘C) and after reperfusion (2 h, 37∘C). Liver injury was measured
by transaminases levels and mitochondrial damage was determined by confocal microscopy assessing mitochondrial polarization
(after cold storage) and by measuring glutamate dehydrogenase activity (after reperfusion). Also, cell signaling pathways involved
in the physiopathology of IRI were assessed by western blot technique. Our results show that intravenous administration of PEG
35 at 10mg/kg ameliorated liver injury and protected the mitochondria. Moreover, PEG 35 administration induced a significant
phosphorylation of prosurvival protein kinase B (Akt) and activation of cytoprotective factors e-NOS and AMPK. In conclusion,
intravenous PEG 35 efficiently protects steatotic livers exposed to cold IRI.
1. Introduction
Organ preservation is a fundamental requirement in organ
transplantation; it preserves the viability of the organ during
its transport from the donor to the recipient so that the graft
can maintain its function after transplantation [1]. Besides
advances in organ preservation, the presence of steatosis
remains a limiting factor for the suitable preservation of
liver grafts, as steatotic livers are particularly vulnerable to
hepatic ischemia reperfusion injury (IRI) [2]. Their use is
accompanied by increased risk of primary failure and lowered
success of liver transplantation [3]. Currently, the increasing
needs of transplantation as well as the scarce of donors pool
have obliged the physicians to take advantage of suboptimal
liver grafts, as steatotic ones [4]. For this reason, there is an
urgent need to explore new strategies that provide a more
efficient preservation of steatotic liver grafts. Minimizing
the deleterious effects of hypothermia could decrease the
reperfusion injury and, consequently, assure an increased rate
of graft survival after transplantation.
Polyethylene glycols (PEGs) are water soluble nontoxic
polymers that have been employed in many biomedical
applications such as gastrointestinal disorders and drugs
pegylation [5, 6]. Besides their usefulness as oncotic agents
in preservation solutions [7, 8], it has been shown that
PEGs molecules protect against cold injury and ischemic
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damage. Indeed, PEG used as cryoprotectant in supercooling
techniquewas necessary to achieve successful liver transplan-
tation [9]. Moreover, PEG suppressed hypothermic-induced
cell swelling in hepatocyte preservation [10] and protected
primary hepatocyte during supercooling preservation [11].
Also, PEG protected cardiac myocytes from hypoxia and
reoxygenation-induced cell death [12], decreased oxidative
stress [13], and protected injured mitochondria [14].
With this in mind, we hypothesized whether intravenous
administration of PEG in the rat prior to organ procure-
ment could protect fatty liver graft against hypothermic
and hypoxic damage occurring during preservation and the
subsequent reperfusion injury. Our results demonstrated that
PEG 35 prevented the deleterious effects of cold IRI when
administered intravenously in obese rats.
2. Materials and Methods
2.1. Animals. Male homozygous obese Zucker rats, aged 9 to
10 weeks, were purchased from Charles River (France) and
housed at 22∘C with free access to water and standard chow.
All experiments were approved by the Ethics Committees for
Animal Experimentation (CEEA, Directive 697/14), Univer-
sity of Barcelona, and were conducted according to European
Union regulations for animal experiments (Directive 86/609
CEE).
2.2. Liver Procurement and Ex Vivo Perfusion. All procedures
were performed under isoflurane anesthesia inhalation.After
laparotomy, the common bile duct was cannulated and livers
were flushed with 40mL of chilled UWpreservation solution
(4∘C) by the mean of catheter insertion into the aorta. After
cooling, a second catheter was inserted into the portal vein
to complete liver rinsing with further 10mL of UW solution.
The whole liver was then excised and preserved at 4∘C for
24 h in the same solution. This procedure implicates the
death of the animal under isoflurane anesthesia, and thus
the application of analgesia or euthanasia was unnecessary.
After 24 h of cold preservation, steatotic livers were removed
from preserved solution and flushed at room temperature
with 20mL of Ringer Lactate solution to eliminate the
metabolite waste accumulated during liver storage. Then,
livers were perfused at 37∘C via the portal vein in a closed
and controlled pressure circuit. Time point 0 was considered
when the portal catheter was satisfactorily connected to
the circuit. During the first 15minutes of perfusion (initial
equilibration period), the flowwas progressively increased in
order to stabilize the portal pressure at 12mmHg (Pression
Monitor BP-1;Pression Instruments, Sarasota, FL).The flow
was controlled by a peristaltic pump (Minipuls 3; Gilson,
France). The reperfusion liquid (150mL for each perfusion)
consisted of a cell culture medium (William’s medium E;
BioWhittaker, Barcelona, Spain) with a Krebs-Henseleit-like
electrolyte composition enriched with 5% albumin as oncotic
supply. The medium was continuously gassed with 95% O
2
and 5% CO2 gas mixture and subsequently passed through
a heat exchanger (37∘C) and a bubble trap prior to entering
the liver. After 120 minutes of normothermic reperfusion,
the effluent perfusion fluid was collected for biochemical
determinations and hepatic tissues were sampled and stored
at −80∘C for further analysis.
2.3. Drug Treatment. PEG 35 was kindly provided by IGL-1
Company. PEG 35 was dissolved in physiological saline
(5 g/L) and administrated 10min before liver procurement by
intravenous bolus through the penile vein at the concentra-
tion of 10mg/kg.
For confocal microscopy study with PEG-FITC, PEG 35
was fused with fluorescein as previously described byMero et
al. [15].
2.4. Experimental Groups. All animals were randomly dis-
tributed into different experimental groups, as indicated
below (Scheme 1).
Protocol 1: Effect of PEG 35 in Fatty Livers after Cold Storage.
In order to study the effects of PEG 35 administration in cold
preservation, rats were randomly divided into the following
groups:
(1)Group 1: Control 1 (Ctr 1) (𝑛 = 4): control livers
were flushed via the portal vein with Ringer’s lactate
solution immediately after laparotomy. Then liver
samples were collected for posterior analysis.
(2) Group 2 (𝑛 = 6): UW: steatotic livers were preserved
for 24 hours in UW solution at 4∘C.Then, livers were
flushed with Ringer’s solution and the effluent liquid
was collected for further biochemical determinations.
Liver tissue was stored at −80∘C.
(3) Group 3 (𝑛 = 6): PEG 35: livers were pretreated with
PEG 35 intravenously at 10mg/kg 10min before liver
procurement and then preserved for 24 hours in UW
solution as in group 2.
Protocol 2: Effect of PEG 35 in Fatty Livers after 24 h of Cold
Storage and 2 h of Normothermic Reperfusion. To examine the
effect of PEG 35 in liver injury after normothermic perfusion,
fatty livers were randomized in the following groups:
(1) Control group (Ctr 2) (𝑛 = 4): after procurement,
steatotic livers were ex vivo perfused for 2 h at 37∘C
as described above, without prior cold storage.
(2) UW group (𝑛 = 6): fatty livers were preserved in UW
preservation solution for 24 hours at 4∘C and then
subjected to 2 h of normothermic reperfusion at 37∘C.
(3) PEG 35 group (𝑛 = 6): Zucker Ob rats were pretreat-
ed with intravenous administration of PEG 35 at
10mg/kg, 10min before liver procurement. Then,
livers were preserved for 24 h in UW solution and
finally ex vivo perfused for 2 hours at 37∘C.
2.5. Liver Injury: Transaminases Assay. Hepatic injury was
assessed in terms of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels with commercial
kits from RAL (Barcelona, Spain). Briefly, 100 𝜇L of effluent
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Protocol 1:
Protocol 2:
Control 1 group (n = 4)
UW group (n = 6)
10min
Control 2 group (n = 4)
UW group (n = 6)
10min
Anesthesia and laparotomy
24h cold ischemia
24h cold ischemia
24h cold ischemia
24h cold ischemiaPEG 35 group (n = 6)
PEG 35 group (n = 6)
PEG 35 i.v. (10mg/kg)
Ex vivo perfusion (2 hours)
Ex vivo perfusion (2 hours)
Ex vivo perfusion (2 hours)
PEG 35 i.v. (10mg/kg)
Scheme 1:Experimental designs to investigate PEG 35 effects on steatotic livers after cold ischemia at 4∘C (Protocol 1) and after cold storage
followed by normothermic ex vivo reperfusion (Protocol 2).
washout liquid or perfusatewas added to 1mLof the substrate
provided by the commercial kit and then transaminases
activity was measured at 340 nm with a UV spectrometer
and calculated following the supplier’s instructions. Results
were normalized using a commercial calibrator (Biocal, RAL,
Barcelona, Spain).
2.6. Mitochondrial Damage
2.6.1. Glutamate Dehydrogenase Activity. Glutamate dehy-
drogenase (GLDH) is a mitochondrial enzyme present pre-
dominantly in liver and contributes to the oxidative deami-
nation of glutamate. Measurable increases in serum levels are
indicative of mitochondrial damage. Serum concentrations
of GLDH were determined using a commercial kit (GLDH,
Randox laboratories Ltd., Crumlin, UK) by quantifying the
decrease in absorbance at 340 nm according to the manufac-
turer’s protocol.
2.6.2. ConfocalMicroscopy. After 24 h of hypothermic preser-
vation, fatty livers pretreated with PEG conjugated to FITC
(PEG-FITC) or saline were washed out via the portal vein
with 20mL of Ringer lactate solution containing fluorescent
dyes.The fluorescent dyes were diluted in the washout liquid
and injected to the preserved fatty liver at the following final
concentrations: Hoechst 33342 trihydrochloride (12mg/kg
body weight, Invitrogen, H3570) for DNA-nuclei staining
and rhodamine 123 (0.11mg/kg body weight, Sigma, R8004)
for mitochondrial membrane potential staining. Fatty livers
were then carefully sectioned (0.5 cm3 fragments) and the
internal side of the liver was exposed on the glass coverslip
mounted on the stage of a Leica TCS SP5 resonant scan
multiphoton confocal microscope (Leica Microsystems Hei-
delberg GmbH) equipped with a HCX IR APO L 25x water
immersion objective (Numerical Aperture 0.95), scanner
at 400 lines/s, and a near infrared Titanium:Saphire laser
(MaiTai, SpectraPhysics) for two-photon excitation running
at 800 nm. Images were acquired with resonant scan at
8000 lines/second. Two-photon excitation was performed
at 800 nm and emission of the different fluorescent dyes
was captured at the following wavelength ranges: PEG-
FITC (400–550 nm), Hoechst 33342 (400–470 nm), and rho-
damine 123 (500–550 nm).
2.7. Vascular Resistance. Vascular resistance was defined as
the ratio of portal venous pressure which was maintained at
12mmHg during the reperfusion to flow rate and expressed
in mmHg/min per gram of liver/mL. Perfusion flow rate was
assessed continuously throughout the reperfusion period and
expressed as mL/min per gram of liver.
2.8. Western Blotting Technique. Liver tissue was homog-
enized in HEPES buffer and proteins were separated by
SDS-PAGE and transferred to PVDF membranes. Then,
membranes were immunoblotted over night at 4∘C using
the following antibodies: anti-p-AMPK𝛼 (Thr172, #2535),
anti-AMPK𝛼 (#2603), anti-p-SAPK/JNK (Thr183/Tyr185),
anti-p-p38 MAP kinase (Thr180/Tyr182, #9211),and anti-p-
p44/42 MAPK (Erk1/2, Thr202/Tyr204, #9101); the above
antibodies were all purchased from Cell Signaling (Danvers,
MA); anti-eNOS (610296) was purshased form Transduction
Laboratories (Lexington KY) and anti-b-actin (A5316) was
purshased from Sigma Chemical (St. Louis, MO, USA).After
washing, bound antibody was detected after incubation for
1h at room temperature with the corresponding secondary
antibody linked to horseradish peroxidase. Bound complexes
were detected and quantified by scanning densitometry.
2.9. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism version 4.02 for Windows (GraphPad
Software). Quantitative data are reported as mean ± SEM
and statistical comparison was performed with analysis of
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Figur e 1:Hepatic andmitochondrial injuries after cold ischemia. PEG 35 administration decreases aspartate aminotransferase (AST) (a) and
alanine aminotransferase (ALT) levels (b) after 24 h of cold storage. Confocal microscopy of mitochondrial membrane potential stained with
rhodamine 123 (green) after cold storage: mitochondrial depolarization occurs after preservation (c); however, in rats pretreated with PEG 35
conjugated to FITC, we observed bright punctate fluorescence showing polarized mitochondria (d). No PEG fluorescence has been detected
in liver sinusoids, neither in hepatocytes nor bound to cell membrane (d). Ctr 1: anaesthesia and laparotomy; UW: livers preserved in UW
preservation solution for 24 hours at 4∘C; PEG 35: Zucker obese rats treated intravenously with PEG 35 at 10mg/kg and steatotic livers were
then subjected to 24 h cold ischemia. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 1; #𝑝 < 0.05 versus UW.
variance, followed by Tukey tests. An associated probability
of 𝑝 < 0.05 was considered to be significant.
3. Results
3.1. Effect of Intravenous PEG 35 on Cold Storage of Steatotic
Rat Livers. To investigate the protective effect of intra-
venous PEG 35 treatment on liver preservation, we measured
transaminases levels in the effluent of washout liquid after
24 h of cold storage. As shown in Figures 1(a) and 1(b), liver
preservation resulted in increased AST/ALT levels versus
control group and the intravenous administration of PEG
35 at 10mg/kg decreased significantly transaminases release
indicating substantially less hepatocellular damage. Also, we
exploredmitochondrial polarization after fatty liver preserva-
tion using rhodamine 123 vital dye. In livers pretreated with
PEG 35, we observed bright punctate fluorescence standing
for the cells with polarized mitochondria. By contrast, in
nontreated livers, we observed a cloudy diffuse cytosolic
fluorescence standing for cells with depolarized mitochon-
dria (Figures 1(c) and 1(d)). Moreover, our result shows that
when obese rats were treated with PEG-FITC, no significant
PEG fluorescence was detected in liver sinusoids neither into
hepatocytes or other liver cells nor bound to cell membrane
(Figure 1(d)).
3.2. Effect of Intravenous PEG 35 Administration on Fatty
Liver Injury after Ischemia Reperfusion. In the following, we
evaluated the reperfusion injury after 2 hours of ex vivo
perfusion at 37∘C (Protocol 2). We observed a significant
decrease in transaminases levels in the perfusate from rats
pretreated with PEG 35 when compared to the untreated
ones (Figures 2(a) and 2(b)). Moreover, the evaluation of
mitochondrial damage, measured by GLDH activity, showed
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Figur e 2: Hepatic and mitochondrial injuries after cold ischemia and reperfusion. PEG 35 administration decreases aspartate aminotrans-
ferase (AST) (a), alanine aminotransferase (ALT) (b), and glutamate dehydrogenase (GLDH) levels after 2 hours of ex vivo perfusion. Ctr
2: liver procurement and ex vivo perfusion; UW: livers preserved in UW preservation solution for 24 h at 4∘C and then subjected to 2 h of
normothermic ex vivo perfusion; PEG 35: rats treated intravenously with PEG 35 (10mg/kg) and then subjected to 24 h cold ischemia followed
by 2h of normothermic ex vivo perfusion. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 2; #𝑝 < 0.05 versus UW.
significant decreases when rats were pretreated with PEG 35
(Figure 2(c)).
Steatotic livers present fat accumulation in the cytoplasm
of the hepatocytes which causes disturbance of the sinusoidal
flow during reperfusion [2, 16]. Given that, we explored
vascular resistance and endothelial nitric oxide synthase
(eNOS) activation after reperfusion. Figure 3(a) shows that
eNOS protein expression decreased after 2 h of ex vivo
perfusion in UW compared to control group. In contrast,
pretreatment with PEG 35 clearly induced eNOS expression
which was concomitant with decreased vascular resistance
(Figure 3(b)).
Next, we explored whether the hepatoprotective effect of
PEG 35 could be attributed to well-known cell signaling path-
ways associated with IRI such as adenosine monophosphate
activated protein kinase (AMPK) and protein kinase B (Akt).
As shown in Figure 4(a), liver preservation followed by 2
hours of ex vivo perfusion promoted Akt phosphorylation,
which was further enhanced when rats were pretreated with
PEG 35. Regarding AMPK, PEG 35 administration prior to
liver procurement induced a significant activation in AMPK
in comparison to non-PEG 35-treated rats (Figure 4(b)).
It is well known that mitogen activated protein kinase
(MAPK) signaling pathway regulates inflammation and cell
survival during IRI [17, 18].We therefore assessed the possible
involvement of MAPK regulation in the protective effect of
PEG 35. As indicated in Figure 5, all MAP kinases (p-p38,
p-JNK, and p-Erk) levels were increased at 2 h reperfusion.
A significant reduction in p-p38 activation was evident after
PEG 35 treatment (Figure 5(a)). On the contrary, no changes
for JNK and Erk activity were found (Figures 5(b) and 5(c),
resp.).
4. Discussion
The beneficial effects of PEG in tissue injury are well doc-
umented [5, 12–14, 19]. However, because PEG molecules
are not absorbed in the gastrointestinal tracts, their use
against ischemic damage was limited to their addition to
preservation solutions as oncotic agents. The present study
was thus designed to investigate if the intravenous PEG 35
administration by a unique and nontoxic dose of 10mg/kg
could protect steatotic liver grafts against the deleterious
75
BioMed Research International
eNOS
140
160
120
100
80
60
40
20
0
∗
∗
#
Ctr 2 UW PEG 35
𝛽-actin
eN
O
S/
𝛽
-a
ct
in
 (a
.u
.)
(a)
∗9
8
7
6
5
4
3
2
1
0
Ctr 2 UW PEG 35
Va
sc
ul
ar
 re
sis
ta
nc
e (
m
m
H
g·
m
i
n
·g
/m
L)
(b)
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effects of cold storage and the subsequent reperfusion. Our
data demonstrated that pretreatment of rats with PEG 35
lessened liver injury associated with ischemia reperfusion.
In our study, we have used the isolated perfused rat
liver (IPRL) model, a widely used and appreciated method
to assess cellular injury and liver function in an isolated
setting. In comparison to other in vitro models, the IPRL-
model does have considerable advantages, such as the use
of the entire intact organ instead of only single cells or
several layers of cells (i.e., isolated hepatocytes or the liver
slice model) and an intact cellular architecture. Furthermore,
the use of an acellular perfusion solution (Krebs solution)
prevents alloreactivity and permits a conclusive focus on
IRI effects. Regarding liver transplantation, IPRL model
presents the advantages of minimizing the use of laboratory
animals as well as the suppression of the immunological
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by 2h of normothermic ex vivo perfusion. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 2; #𝑝 < 0.05 versus UW.
reactions and the influences of other organs occurring during
transplantation. The disadvantage of the IPRL-model is the
duration of reperfusion, which is limited to 90–120 minutes
and the fact that it remains an in vitro tool that merely
simulates the initial phase after liver transplantation. In this
sense IPRL model could be considered as a pre-screening
model before liver transplantation especially in ischemia
reperfusion research [20, 21].
In contrast to the current pharmacological strategies used
against IRI, PEG administration presents the advantages of
being amultitarget strategy. In fact, IRI is amultifactorial dis-
ease including oxidative stress, inflammation, proteasome
activation, endoplasmic reticulum stress, mitochondrial
damage, and cytoskeleton alterations which lead to cell death
and organ dysfunction [22–24]. PEG has been associated
with the majority of these events as it has been shown that
PEG reduces reactive oxygen species, prevents cell death,
maintainsmitochondrial integrity, and reduces inflammation
and endoplasmic reticulum stress [12, 14, 19, 25, 26].
The half-life and biodistribution of the polymer and
consequently its activity mainly depend on its molecular
weight. Based on our experience in organ preservation, we
used PEGwith amolecular weight of 35kDa. Indeed, we have
previously demonstrated that PEG 35 addition to washout
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solution protected the liver against reperfusion injuries [27].
Moreover, PEG 35 addition to IGL-1 preservation solution
protects kidney and liver grafts against ischemic damage
[7, 8, 28, 29]. PEG with a molecular weight of 20 kDa has
also been used as an additive to HTK and SCOT preservation
solutions and was associated with protective effects against
IRI in pancreas [30], kidney [8], intestine [26], and liver grafts
[31]. In addition, PEG20 has been shown to protect against
cardiomyocyte apoptosis induced by hypoxia [12]. However,
PEG 35was more effective than PEG20 in protecting porcine
proximal tubular epithelial cell line against cold storage at the
same doses used [32].
Mitochondrial protection is essential for graft survival
after transplantation [33]. Thus, we further explored mito-
chondrial depolarization after cold preservation and we evi-
denced that PEG 35 prevented fatty liver mitochondria depo-
larization after prolonged cold ischemia. Also, mitochondrial
injury was lessened after liver reperfusion as indicated by
the decrease in GLDH release. These results are in accor-
dance with previous published data showing that PEG 2kDa
improved mitochondrial function in vitro and in vivo after
acute spinal cord injury [25]. Moreover, PEG of 4 kDa inhib-
ited mitochondrial pore transition (MPT) and cytochrome
C release in rat liver mitochondria [34]. Also, PEG (1.5and
2 kDa) was able to cross the cytoplasmic membrane and
directly interact with neuronal mitochondria to preserve its
structure and restore function [14]. Interestingly, PEG with
higher molecular weight (4 kDa) failed to exert significant
improvement in neuronal injured mitochondria indicating
that PEG-mediated mitochondrial protection is dependent
on the size of PEG [14]. In our study, we did not detect any
PEG fluorescence after cold storage in liver sinusoids, neither
in hepatocytes nor bound to cell membrane. In this sense,
the mechanism by which PEG 35 decreases mitochondrial
damage and exerts its protective effects needs more profound
investigation.
Our results show that PEG35activated eNOS, the enzyme
responsible for nitric oxide (NO) generation, and conse-
quently decreased vascular resistance.This could also explain
the protective mechanism of PEG toward mitochondria as it
has been showed that NO protects rat hepatocytes against
reperfusion injury through the inhibition of MPT [35].
Previous study from Bertuglia et al. has shown that PEG
15–20 kDa reduced vasoconstriction and the altered capillary
perfusion after ischemia reperfusion [36]. However, in that
case, the decreased vascular resistance of PEG were not
mediated by eNOS activation [36].
In order to explore whether the beneficial effects of
PEG 35 are associated with other well-known cell signaling
pathways involved in IRI, we further evaluated the acti-
vation of AMPK and Akt and the regulation of MAPKs.
AMPK is a metabolic fuel gauge and energy regulator
activated during ischemia in order to induce an energy-
saving state preventing thus the lactate accumulation and
cell death [37–39]. Here, we showed that PEG 35 enhanced
AMPK levels after reperfusion, which could contribute to
assuring energy levels sufficient to cell survival. Another
cytoprotective marker is Akt, a serine-threonine protein
kinase that is linked to cell survival during reperfusion
[40–42]. Data reported here revealed that PEG 35 increased
Akt levels, as similarly observed with PEG 20 in cardiac
myocyte submitted to IRI [12]. Regarding MAPKs signalling,
we observed that PEG 35 was capable of preventing p38
activation, while no changes were found on JNK and ERK
pathways. The data reported here are consistent with pre-
viously reported works showing that the inhibition of p38
prevented preservation-induced graft injury and improved
the outcome of liver transplantation [43–45]. Other studies
as well reported that PEG 35 decreased p38 activation while
it activated JNK in cold stored porcine proximal tubular cell
line [32].
The rationale of PEG 35 intravenous administration was
to induce a pharmacological preconditioning against the
subsequent cold storage and reperfusion injury. PEG presents
the advantages of being safe andmultifactorial agent andmay
constitute a novel strategy to increase liver graft preservation.
This could be relevant in clinical situation of brain-dead
donors or steatotic livers, both being risk factors in liver
transplantation. Until now, PEG has been used clinically
for ischemia reperfusion purpose as additive to preservation
solution due to its oncotic properties. In this study, we
used UW solution which contains hydroxyethyl starch as an
oncotic support in order to demonstrate that the protective
mechanisms of PEG are not only related to its oncotic effect,
but also to other properties such as the preservation of
mitochondria and the induction of protective cell signaling
pathway (eNOS, Akt, and AMPK). In a previous study we
have shown that PEG addition to rinse solution protected
preserved liver against the subsequent reperfusion injury
(PEG postconditioning). Interestingly, when liver grafts were
preserved in IGL-1 solution which contains PEG 35, the
rinse solution does not show any additional protective effect
[46]. In this sense, PEG pre- and postconditioning would be
considered as a safe and protective strategy applicable to all
preservation solutions.
5. Conclusions
PEG 35 represents a potential pharmacological agent for pre-
venting the deleterious effects of cold IRI and may constitute
a novel clinical strategy to increase liver graft preservation,
especially for “marginal” organs.
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Abstract
AIM: To test whether a new rinse solution containing 
polyethylene glycol 35 (PEG-35) could prevent isch-
emia-reperfusion injury (IRI) in liver grafts. 
METHODS: Sprague-Dawley rat livers were stored in 
University of Wisconsin preservation solution and then 
washed with different rinse solutions before ex vivo  
perfusion with Ringer’s lactate solution and a new rinse 
solution enriched with PEG-35 at either 1 or 5 g/L. 
We assessed the following: liver injury (transaminase 
levels), mitochondrial damage (glutamate dehydroge-
nase), liver function (bile output and vascular resis-
tance), oxidative stress (malondialdehyde), nitric oxide, 
liver autophagy (Beclin-1 and LCB3) and cytoskeleton 
integrity (filament and globular actin fraction); as well 
as levels of metalloproteinases (MMP2 and MMP9), 
adenosine monophosphate-activated protein kinase 
(AMPK), heat shock protein 70 (HSP70) and heme oxy-
genase 1 (HO-1). 
RESULTS: When we used the PEG-35 rinse solution, 
reduced hepatic injury and improved liver function were 
noted after reperfusion. The PEG-35 rinse solution 
prevented oxidative stress, mitochondrial damage, and 
liver autophagy. Further, it increased the expression 
of cytoprotective heat shock proteins such as HO-1, 
HSP70, and AMPK, and contributed to the restoration 
of cytoskeleton integrity after IRI. 
CONCLUSION: Using the rinse solution containing 
PEG-35 was effective for decreasing liver graft vulner-
ability to IRI. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Liver washout; Liver transplantation; Rinse 
solution; Ischemia-reperfusion injury; Polyethylene 
glycol 35; Nitric oxide; Adenosine monophosphate-ac-
tivated protein kinase; Heme oxygenase 1; Heat shock 
protein 70; Metalloproteinases
Core tip: Research into optimal rinse solutions for 
graft washout is limited, and their clinical application 
is dependent on surgeon preference. We present a 
new rinse solution containing polyethylene glycol 35 
(PEG-35) that is not only suitable for washing liver 
grafts after cold preservation, but also provided good 
graft protection against reperfusion injury. Using 
PEG-35 in the rinse solution resulted in less hepatic in-
jury, a significant induction of cytoprotective proteins, 
and the preservation of cytoskeletal integrity. Thus, 
PEG-35 supplemented rinse solutions may contribute 
to liver graft protection against ischemia-reperfusion 
injury.
Zaouali MA, Bejaoui M, Calvo M, Folch-Puy E, Pantazi E, 
Pasut G, Rimola A, Abdennebi HB, Adam R, Roselló-Catafau 
J. Polyethylene glycol rinse solution: An effective way to pre-
vent ischemia-reperfusion injury. World J Gastroenterol 2014; 
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INTRODUCTION
Liver transplantation (LT) has had a profound impact on 
patient outcomes in end-stage liver disease, representing 
the most effective treatment for many patients with acute 
or chronic liver failure[1]. Ischemia-reperfusion injury (IRI) 
is an inherent risk of  LT, and is often responsible for 
early graft failure within the first week of  surgery[2-4]. IRI 
is initiated when the liver is recovered from the donor 
and placed in cold storage; it continues when the graft is 
re-warmed prior to LT, and persists at graft revasculariza-
tion after LT[3,4]. Research has identified several strategies 
to reduce the impact of  these multifactorial processes on 
graft function.
Maintaining organ viability during cold storage (i.e., 
preservation) is an important prerequisite for a successful 
outcome after LT[1,5]. For this reason, the composition 
of  organ preservation solutions is crucial; during cold 
storage, the solution must prevent cell swelling, impaired 
energy metabolism, acidosis, and the accumulation of  
precursors of  reactive oxygen intermediates[1,5]. Currently, 
the University of  Wisconsin (UW) solution is the one 
most commonly used for LT[6,7]. However, several studies 
have reported that its composition is limited by: (1) the 
high concentration of  K+ ions in preserved grafts that 
could cause cardiac arrest in the recipient at reperfusion[8]; 
(2) the oncotic agent, hydroxyl-ethyl starch (HES), which 
confers high viscosity with incomplete distribution of  
the UW solution in the liver graft, particularly between 
the intravascular space and liver parenchyma; and (3) the 
hyper-aggregating effects of  HES on erythrocytes, which 
may hamper liver graft reperfusion[9-11]. These limitations 
have led physicians to rinse grafts before revascularization 
to remove the K+ ions, HES, and toxins that accumulate 
during preservation, and to ensure optimal conditions for 
graft revascularization and viability. 
Current studies on rinse solutions for organ washout 
are limited, particularly for the liver. Ringer’s lactate so-
lution (RLS) was initially used, before a more effective 
alternative was proposed by Adam et al[12] who used a 
macromolecular albumin solution to restrict reperfu-
sion damage. Later, the Carolina rinse (CR) solution was 
shown to prevent IRI[13-15], but it has a complex compo-
sition and contains HES, which induced red blood cell 
aggregation and incomplete washout[11]. Despite some re-
ductions in liver injury, the optimal washout solution has 
yet to be established and current practice depends mostly 
on physician preference.
In previous studies, we have used polyethylene glycol 
(PEG) 35 as an oncotic agent in Institut Georges Lopez 
(IGL-1) preservation solutions for liver graft conserva-
tion[16-18]. PEG-35 is a non-toxic, water-soluble polymer 
that prevents red blood cell aggregation when compared 
to HES[1,11]. PEG has shown protective effects in diffe-
rent organs and can reduce oxidative stress through the 
preservation or restoration of  membrane integrity[19]. 
Moreover, several studies have demonstrated the efficien-
cy of  PEG in kidney[20], heart[21], liver[22], pancreas[23], and 
small bowel[24] preservation in experimental models and 
clinical studies. 
In the present study, we investigated the efficacy of  
liver washout with a new PEG-35 rinse solution after 
graft cold preservation in UW solution. 
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (250 g body weight) were anes-
thetized under isoflurane inhalation anesthesia according 
to European Union regulations (Directive 86/609 EEC), 
and surgery was performed as previously reported[25]. An-
imals were randomly distributed into groups as described 
below.
Liver washout
After 24 h cold storage in UW solution, the liver grafts 
were subjected to normothermic washout with different 
rinsing solutions (Table 1 and Table 2) and then re-per-
fused for 2 h at 37 ℃. The experimental groups were as 
follows: Group 1, Ringer’s lactate solution (RLS) (n = 8) 
as shown in Table 1; the liver grafts were flushed with 
RLS (15 min; room temperature) and then re-perfused 
for 2 h at 37 ℃. Group 2, Base solution (BS) (n = 8); 
same as Group 1, but flushed with the BS, as indicated in 
Table 2. Group 3, (BS + PEG1) (n = 8); same as Group 1, 
but flushed with BS supplemented with PEG-35 at 1 g/L 
(Table 2). Group 4, (BS + PEG5) (n = 8); same as Group 
1, but flushed with the BS supplemented with PEG-35 at 
5 g/L (Table 2).
Model of isolated perfused rat liver
After cold storage in UW solution, the liver grafts were 
rinsed at room temperature for 15 min using one of  the 
rinse solutions indicated above. Then livers were con-
nected via the portal vein to a recirculating perfusion 
Zaouali MA et al . New rinse solution for preventing IRI
82 November 21, 2014|Volume 20|Issue 43|WJG|www.wjgnet.com
system for 2 h at 37 ℃. Time zero was the point at which 
the portal catheter was satisfactorily connected to the 
circuit. As previously reported, during the first 15 min 
of  perfusion (initial equilibration period), the flow was 
steadily increased until we achieved stabilization of  the 
portal pressure at 12 mm Hg (Pressure Monitor BP-1; 
World Precision Instruments, Sarasota, Florida). The flow 
was controlled by a peristaltic pump (Minipuls 3; Gilson, 
France)[26,27]. The reperfusion liquid consisted of  a cell 
culture medium (William’s medium E; BioWhittaker, 
Barcelona, Spain) with a Krebs-Heinseleit-like electrolyte 
composition enriched with 5% albumin for oncotic pres-
sure[28]. Before entering the liver, the buffer was exposed 
to a mixture of  95% O2 and 5% CO2, a heat exchanger 
(37 ℃), and a bubble trap[27,28]. During normothermic re-
perfusion lasting 120 min, the effluent was collected at 30 
min intervals to measure the liver aminotransferase levels 
and the liver function (bile, vascular resistance). Biochem-
ical parameters were measured 2 h after reperfusion.
Biochemical determinations
Transaminase assay: Hepatic injury was assessed by 
measuring transaminase levels using commercial kits 
from RAL (Barcelona, Spain). Briefly, 200 µL of  effluent 
perfusate was added to the substrate provided by the 
commercial kit and the levels of  aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) were 
determined at 365 nm with an ultraviolet spectrometer 
and calculated according to the manufacturer’s instruc-
tions[27,29].
Bile Output: Liver function was assessed by measuring 
bile production. Bile was collected through a cannulated 
bile duct and output was reported as microliter per gram 
of  liver (µL/g liver)[26].
Vascular resistance: Liver circulation was assessed by 
measuring perfusion flow rate and vascular resistance. 
The perfusion flow rate was assessed continuously dur-
ing reperfusion (expressed as mL/min/g liver). Vascu-
lar resistance was defined as the ratio of  portal venous 
pressure to flow rate (expressed as mmHg/min/g liver/
mL)[26].
Glutamate dehydrogenase activity: The mitochondrial 
enzyme glutamate dehydrogenase (GLDH) was used as 
an indirect measure of  mitochondrial damage as previ-
ously reported[28]. 
Lipid peroxidation assay: Lipid peroxidation in the 
liver was used as an indirect measure of  the oxidative in-
jury induced by ROS. Lipid peroxidation was determined 
by measuring the formation of  malondialdehyde (MDA) 
with the thiobarbiturate reaction[28].
Determination of  nitrites and nitrates: Nitric oxide 
(NO) production by the liver was determined by measur-
ing tissue accumulation of  nitrites and nitrates, as previ-
ously reported[28].
Western blot analysis 
Liver tissue was homogenized as previously described[28]. 
Total protein was loaded in Laemmli buffer onto a 
SDS-polyacrylamide gel in a Mini Cell (Bio-Rad). The 
proteins were transferred to polyvinylidene difluoride 
membranes and blocked in 1 × phosphate buffered sa-
line (PBS)/0.05% Tween 20/5% non-fat dry milk. Mem-
branes were immunoblotted with antibodies directed 
against phospho-AMPK (adenosine monophosphate-
activated protein kinase) (Thr172), total AMPK, Beclin-1, 
and LCB3 (Cell Signaling Technology Inc, Beverly, Mas-
sachusetts); anti-endothelial NO synthase (eNOS) and 
heat shock protein (HSP) 70 (BD Transduction Labo-
ratories, Lexington, Kentucky); and β-Actin, actin, and 
heme oxygenase-1 (HO-1; Sigma Chemical, St. Louis, 
Missouri). The secondary antibody was added for 1 h and 
the membranes were developed using enhanced chemilu-
minescence reagents from Bio-Rad (Hercules, California) 
and quantified by scanning densitometry. 
Zymography
Frozen tissue samples were homogenized with a lysis 
buffer and centrifuged as described elsewhere[30]. Super-
natants were used for extraction of  gelatinolytic activ-
ity with Gelatin-Sepharose 4B (Amersham Biosciences, 
Uppsala, Sweden). Extracted liver samples were used to 
perform gelatin zymography using gelatinase zymogra-
phy standards. The gels were stained in 0.1% amido black 
in a 1:3:6 ratio of  acetic acid:methanol:water for 30 min 
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Table 1  Composition of Ringer’s lactate solution
Ringer lactate solution
Composition Concentration (mg/100 mL)
NaCl 600
KCl   40
CaCl2.2H2O   27
NaC3H5O3 312
Osmolarity (mOsm/L) 277
pH 5.0-7
Table 2  Composition of the different rinse solutions: BS, 
BS+PEG35 at 1g/L (BS+PEG1) and BS+PEG35 at 5g/L 
(PEG+PEG5)
Composition BS BS + PEG1 BS + PEG5
CaCl2.2H2O (mmol/L)       1.3        1.3    1.3
KH2PO4 (mmol/L)     5     5 5
NaH2PO4 (mmol/L)   20   20   20
MgSO4.7H2O (mmol/L)     5     5     5
Lactobionic acid (mmol/L) 100 100 100
Raffinose (mmol/L)   30   30   30
PEG 35 (g/L) -     1     5
pH        7.4        7.4       7.4
Osmolarity (mOsm/L) 320 320 320
BS: Base solution; BS + PEG1: BS with PEG-35 at 1 g/L; BS + PEG5: BS 
with PEG-35 at 5 g/L.
compared statistically by variance analysis, followed by 
the Student-Newman-Keuls test (Graph Pad Prism soft-
ware). P < 0.05 was considered significant.
RESULTS
Liver injury
Effluent fluid was collected to determine ALT and AST 
levels after 2 h of  reperfusion as a predictor of  organ 
damage after cold IRI. Figure 1 shows the AST and ALT 
profiles of  the liver grafts subjected to washout with RLS, 
BS, and BS+PEG-35 solutions (Table 2). Use of  the BS 
solution supplemented with PEG-35 prevented AST and 
ALT release after 2 h of  reperfusion when compared 
to both the RLS and BS solutions. No differences were 
found when BS + PEG1 (1 g/L) and BS + PEG5 (5 g/L) 
solutions were compared. 
Liver function 
Liver function was assessed by measuring bile produc-
tion and vascular resistance. As indicated in Figure 2A, 
a significant increase was observed in bile production 
after 2 h of  reperfusion in liver grafts flushed with BS + 
PEG1 and BS + PEG5 rinse solutions when compared 
to RLS and BS alone. These results were consistent with 
a reduced vascular resistance after 2 h of  reperfusion, as 
shown by the profiling studies reported in Figure 2B. 
Oxidative stress and mitochondrial injury in the liver 
To evaluate the effect of  PEG-35 rinse solutions in oxi-
dative stress and mitochondrial damage, we measured 
levels of  MDA, a lipoperoxidation marker. We observed 
a significant MDA reduction with the PEG-35 rinse solu-
tions when compared to BS alone (Figure 3A). This pre-
ventive effect was more marked when compared to RLS. 
These results were consistent with liver mitochondrial 
damage measured by GLDH activity in liver perfusate at 
the end of  the 2-h reperfusion period. Livers rinsed with 
RLS showed the highest GLDH activity when compared 
to those rinsed with BS alone (Figure 3B). PEG-35 (ei-
ther 1 g/L or 5 g/L) added to BS significantly reduced 
and destained in the solvent, followed by a final wash in 
distilled water. Gelatinolytic enzymes were detected as 
transparent bands on the gel[30].
Confocal fluorescence microscopy
The liver was fixed, cryoprotected with sucrose, embed-
ded in optimal cutting temperature (OCT) media, and 
frozen on a copper plate on dry ice. Cryosections (5 
µm) were cut in a cryostat and post fixed in 4% buffered 
paraformaldehyde for 10 min, and then permeabilized 
with PBS containing 0.1% Triton X-100 and 1% bovine 
serum albumin (BSA) for 30 min. For actin visualization, 
the slides were incubated with tetramethylrhodamine-
phalloidin (TRITC-phalloidin, Sigma; dilution 2 µmol/L) 
in PBS with 1% BSA and 0.2% Triton X-100 for 30 min. 
Slides were washed 3 times for 15 min with PBS. The last 
PBS wash included Hoechst 33342 (Invitrogen; dilution 
1 µmol/L). Finally, cryosections were mounted using 
Mowiol (Calbiochem). 
Confocal images were acquired with a Leica TCS 
SP5 laser scanning microscope (Leica Microsystems, 
Germany) equipped with a 63x NA1.4 oil-immersion 
objective. Hoechst-33342 and Phalloidin-A555 images 
were acquired sequentially using an acousto-optical beam 
splitter with 405 and 561 nm laser lines and emission de-
tection ranges of  415-450 and 570-650 nm respectively. 
The confocal pinhole was set at 1 Airy unit and when 
3-dimensional reconstruction was required, stacks of  im-
ages every 0.3 mm were acquired. The sinusoid circularity 
of  livers (based on Phalloidin staining) was quantified on 
ImageJ (Wayne Rasband, National Institute of  Health, 
United States) as 4π × [(Area)]/[(Perimeter)2]. Briefly, the 
red channel (phalloidin-A555 staining) was mean filtered 
(radius 1), before thresholding, conversion to a binary im-
age, and inversion. Sinusoids were selected and circularity 
was measured (in 16 mm2 of  each sample). A value of  1.0 
indicated a perfect circle; as the value approached 0.0, an 
increasingly elongated shape was more likely.
Statistical analysis
Data were expressed as mean ± standard error, and were 
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Figure 1  Alanine aminotransferase (A) and aspartate aminotransferase (B) levels in the perfusate of livers rinsed with different washout solutions (RLS, 
BS, BS + PEG1, and BS + PEG5) and subjected to 2 h of normothermic reperfusion. aP < 0.05 vs RLS; cP < 0.05 vs BS. Please see BS composition in Scheme 1. 
PEG: Polyethylene glycol; RLS: Ringer’s lactate solution; BS: Base solution; BS + PEG1: BS with PEG-35 at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
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GLDH levels when compared to RLS and BS alone. No 
differences were observed between the PEG-35 groups.
Cell signaling pathways implicated in liver protection
We evaluated the cytoprotective cell signaling pathways 
involved in liver grafts by assessing the effect of  PEG-35 
rinse solutions on AMPK phosphorylation. We found 
a significant increase in phosphorylated AMPK levels 
in liver grafts rinsed with PEG-35 containing solutions 
when compared to RLS and BS (Figure 4A). This was 
concomitant with increases in nitrite/nitrate levels and 
eNOS activation (Figures 4B and C). 
In addition, we examined the effect of  PEG-35 rinse 
solutions on the induction of  heme oxygenase-1 (HO-1) 
and HSP70 (known cytoprotective proteins involved in 
the reduction of  liver damage after IRI). The highest 
HO-1 protein levels were observed in livers rinsed with 
PEG-35 solution when compared to RLS and BS alone. 
Major differences were observed between the 5 g/L 
and 1 g/L concentrations of  PEG-35 (Figure 5A). The 
HSP70 protein expression pattern was similar to that de-
scribed for HO-1 expression (Figure 5B).
Liver cytoskeleton alteration
Next, we evaluated the impact of  PEG-35 rinse solutions 
on liver cytoskeleton distribution by assessing changes in 
filamentous actin (F-actin) and globular actin (G-actin). 
Our results demonstrated that the greatest G-actin frac-
tion was observed in livers rinsed with the RLS when 
compared to BS and PEG-35 solutions (Figure 6). Con-
versely, the F-actin fraction was higher in the PEG-35 so-
lution than in either RLS or BS alone (Figure 6). This was 
consistent with the metalloproteinase (MMP) activation 
shown in Figure 7. In fact, we observed a significant re-
duction in MMP9 activity in livers flushed with PEG-35 
solutions when compared to those flushed only with RLS 
or BS. No differences were found between the PEG-35 
solutions. In addition, we observed an increased MMP2 
activity only when BS was used. However, no differences 
were found between the PEG-35 solutions and RLS (Fig-
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Figure 2  Bile production and vascular resistance (A), in livers rinsed with different washout solutions (RLS, BS, BS + PEG1, and BS + PEG5) and sub-
jected to 2 h of normothermic reperfusion (B). aP < 0.05 vs RLS; cP < 0.05 vs BS. PEG: Polyethylene glycol; RLS: Ringer’s lactate solution; BS: Base solution; BS 
+ PEG1: BS with PEG-35 at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
Figure 3  Hepatic malondialdehyde (A) and glutamate dehydrogenase (B) in livers rinsed with different washout solutions (RLS, BS, BS + PEG1, and BS + 
PEG5) and subjected to 2 h of normothermic reperfusion. aP < 0.05 vs RLS; cP < 0.05 vs BS. PEG: Polyethylene glycol; RLS: Ringer’s lactate solution; BS: Base 
solution; BS + PEG1: BS with PEG-35 at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
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ure 7B). The alterations in the actin cytoskeleton resulted 
in changes in cell shape and adhesiveness: we observed 
sinusoidal shape changes in livers rinsed with RLS as op-
posed to a normal hexagonal morphology in livers rinsed 
with the PEG-35 solutions (Figure 8).
Liver autophagy
In liver grafts subjected to 24 h of  UW cold preservation 
and 2 h of  reperfusion, we evaluated the incidence of  
liver graft autophagy by measuring the levels of  estab-
lished markers, Beclin-1 and LCB3. As evidenced in Fig-
ure 9, Beclin-1 and LCB3 levels fell significantly in livers 
washed with PEG-35 rinse solutions compared to those 
washed with either RLS or BS alone.
DISCUSSION
Several rinse solutions have been proposed for the ef-
ficient washout of  liver grafts before transplantation. In 
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Figure 4  Phosphorylated adenosine monophosphate-activated protein 
kinase protein levels (A), e-NOS protein levels (B) and nitrites and nitrates 
(C) in livers flushed with different washout solutions (RLS, BS, BS + 
PEG1, and BS + PEG5) and subjected to 2 h of normothermic reperfusion. 
aP < 0.05 vs RLS; cP < 0.05 vs BS. PEG: Polyethylene glycol; RLS: Ringer’s 
lactate solution; BS: Base solution; BS + PEG1: BS with PEG-35 at 1 g/L; BS + 
PEG5: BS with PEG-35 at 5 g/L.
Figure 5  Heme oxygenase 1 (HO-1) (A) and HSP70 (B) protein levels in 
livers flushed with different washout solutions (RLS, BS, BS + PEG1, and 
BS + PEG5) and subjected to 2 h of normothermic reperfusion. aP < 0.05 
vs RLS; cP < 0.05 vs BS; eP < 0.05 vs BS + PEG1. PEG: Polyethylene glycol; 
RLS: Ringer’s lactate solution; BS: Base solution; BS + PEG1: BS with PEG-35 
at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
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this paper we demonstrate that the washout step is neces-
sary for both the removal of  remaining preservation so-
lution, and also for protecting the liver graft against IRI. 
Following our experience in the use of  PEG-35 for fatty 
liver preservation[17,28,29], we have explored its use as a 
rinse solution. Due to the fact that PEG-35 is the oncotic 
agent at low concentrations in the IGL-1 preservation 
solution, we compared rinse solutions supplemented with 
PEG-35 at 1 g/L and 5 g/L. 
PEG polymers are water-soluble, biocompatible, non-
toxic materials that are commercially available at differ-
ent molecular weights[1,19]. PEG is approved for use in 
humans by the FDA, and its applications range from use 
as an excipient in drug formulations, cosmetics, and food 
preparations to use as a conjugating polymer for thera-
peutic protein delivery[31]. To date, the use of  PEG in 
preservation solution has been associated with several ad-
vantages, but it has not yet been tested in rinse solutions. 
In this study, we demonstrated that the PEG-35 rinse 
solution prevented liver injury after 2 h of  reperfusion 
when compared to the grafts flushed with either RLS or 
BS alone. This effective protection was concomitant with 
a subsequent improvement in hepatic function, reflected 
by bile production as a marker of  biliary epithelial cell 
integrity after ischemia[17], and a significant reduction in 
vascular resistance. These results are consistent with pre-
vious reports evidencing the protective role of  different 
PEG molecules for organ preservation[16,20,28]. 
A growing body of  evidence indicates that mitochon-
drial dysfunction is a critical pathological process in liver 
IRI. Impaired mitochondrial function results in defec-
tive energy use and excessive reactive oxygen species 
generation[32]. Here we demonstrated that the addition 
of  PEG-35 to a rinse solution prevented mitochondrial 
damage and oxidative stress, when compared to either 
RLS or BS solutions. Our results are in line with previ-
ously reported data demonstrating the effective anti-
oxidant role of  PEG, through the suppression of  lipid 
peroxidation, after rewarming cold-stored hepatocytes[33]. 
This prevention was also accompanied by subsequent in-
creases in HSP70 and HO-1 expression. Overexpression 
of  both HSPs, well known markers of  graft survival after 
transplantation[34], was more relevant for PEG-35 at 5 
g/L when compared to 1 g/L suggesting that the higher 
concentration was more suitable for increasing liver graft 
tolerance to IRI. 
In our study, the PEG-35 rinse solution increased 
phosphorylated AMPK levels. AMPK is an enzyme 
involved in cellular energy balance that regulates the 
downstream signaling pathways towards an energy-
conserving state[35]. AMPK activation before or during 
organ preservation helps to limit organ injury and main-
tain graft quality[36,37]. We have previously reported that 
AMPK inducers ameliorated fatty liver graft preservation 
when added to preservation solutions[38]. We have now 
demonstrated that PEG-35 rinse solutions contribute to 
AMPK activation; furthermore, rinsing liver grafts with 
solutions containing PEG-35 resulted in activation of  
constitutive eNOS and subsequent NO generation[36,37]. 
NO is a gaseous vasodilator that protects liver endothelial 
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Figure 6  Effects of washout on liver cytoskeleton changes: changes 
in filamentous actin (F-actin) and globular actin (G-actin) ratio in livers 
flushed with different washout solutions (RLS, BS, BS + PEG1, and BS 
+ PEG5) and subjected to 2 h of normothermic reperfusion. aP < 0.05 vs 
RLS; cP < 0.05 vs BS; eP < 0.05 vs BS + PEG1. PEG: Polyethylene glycol; 
RLS: Ringer’s lactate solution; BS: Base solution; BS + PEG1: BS with PEG-35 
at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
Figure 7  Effects of washout on metalloproteinase MMP2 (A) and MMP9 (B) 
protein activity levels in livers flushed with different washout solutions 
(RLS, BS, BS + PEG1, and BS + PEG5) and subjected to 2 h of normother-
mic reperfusion. aP < 0.05 vs RLS; cP < 0.05 vs BS; eP < 0.05 vs BS + PEG1. 
PEG: Polyethylene glycol; RLS: Ringer’s lactate solution; BS: Base solution; BS 
+ PEG1: BS with PEG-35 at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
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cells against IRI[39]. Its activation is consistent with the 
observed decreases in vascular resistance after washing 
out with PEG-35 rinse solutions, which are associated 
with NO generation and contribute to preventing micro-
circulation alterations after liver graft revascularization.
Changes in cytoskeletal structure and cell morphology 
occur in the liver following IRI that can ultimately lead to 
graft dysfunction[40-42]. Recently, it has been reported that 
PEG contributes to the regulation of  endothelial cell bar-
rier by rearranging the actin cytoskeleton[43]. Subcellular 
F-actin is an important component of  the cytoskeleton, 
and the balance between F-actin and monomeric G-actin 
largely determines the functional outcome. It is impor-
tant to note that F-actin forms microfilaments in liver 
cells, which are involved in intracellular processes, the 
maintenance of  cell morphology, and bile canalicular mo-
tility necessary for bile secretion[42,44,45]. With this in mind, 
we explored the effects of  PEG-35 rinse solutions on the 
liver cytoskeleton by measuring F- and G-actin distribu-
tion and ultrastructural changes by confocal microscopy. 
Livers subjected to washout with RLS and BS showed 
low F-actin content reflecting actin cytoskeletal deran-
gement, probably associated with ischemia. In contrast, 
PEG-35 use reversed the loss of  F-actin by increasing its 
polymerization, as reflected by an increased F-actin ratio. 
This confirms the protective effect of  PEG-35 rinse so-
lution in preventing the loss of  cell integrity during IRI. 
Extracellular matrix turnover, influenced by MMP9 
and MMP2, occurs during tissue remodeling after 
IRI[46,47]. In experimental models of  hepatic IRI, inhibi-
ting MMP2 and MMP9 has also reduced tissue dama-
ge[30,48]. In this study, we demonstrated that the PEG-35 
rinse solutions inhibited MMP9 and MMP2 activity, sug-
gesting cytoskeletal stability compared to either RLS or 
BS. This fact is consistent with the reduction of  morpho-
logical alterations on confocal microscopy. Specifically, 
we observed that liver graft cells rinsed with RLS or BS 
acquired a slightly deformed round shape, while those 
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Figure 8  Confocal microscopy findings of a sinusoidal shape when livers were rinsed in a 5 g/L concentration of the polyethylene glycol 35 (PEG-35) solu-
tion. PEG: Polyethylene glycol; RLS: Ringer’s lactate solution.
Figure 9  Effects of washout solution on liver graft autophagy: Beclin 1 (A) and LCB3 (B) protein levels in liver rinsed with different washout solutions (RLS, 
BS, BS + PEG1, and BS + PEG5). aP < 0.05 vs RLS; cP < 0.05 vs BS; eP < 0.05 vs BS + PEG1. PEG: Polyethylene glycol; RLS: Ringer’s lactate solution; BS: Base 
solution; BS + PEG1: BS with PEG-35 at 1 g/L; BS + PEG5: BS with PEG-35 at 5 g/L.
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washed with PEG-35 rinse solutions demonstrated nor-
mal morphology.
Our results suggest that cytoskeletal integrity is better 
preserved by the presence of  PEG-35 in rinse solutions. 
This is consistent with another study where high-mole-
cular-weight PEG physically bound to cardiac myocyte 
plasma membranes was observed to activate signaling 
pathways that protect against hypoxia-reoxygenation as-
sociated cell death[49]. It has also been reported that PEG 
joins various regulatory elements of  the endothelial cell 
barrier, thus providing beneficial effects on the architec-
ture of  the endothelial cytoskeleton[43]. 
Autophagy is associated with the turnover of  long-
lived proteins, cytosolic components, or damaged or-
ganelles. It is a highly regulated process involving the 
formation and delivery of  autophagosomes to lysosomes 
for degradation. Based on growing evidence linking 
autophagy to IRI[50-52], we evaluated its potential invol-
vement during the liver graft washout process. Indeed, 
autophagy has long been recognized to occur in organs 
under stress conditions such as IRI[52,53], although its pre-
cise role remains unclear and controversial. Although we 
know that the activation of  autophagy during ischemia is 
essential for cell survival and maintaining organ function, 
through AMPK dependent mechanisms, its role during 
reperfusion could be detrimental[52,54,55]. Autophagy in 
reperfusion is accompanied by a robust up-regulation of  
Beclin-1, which in turn is exacerbated by the generation 
of  reactive oxygen species, leading to a massive degrada-
tion of  vital molecules and autophagic cell death[55,56]. 
In this study, we demonstrated that liver graft was-
hout using a rinse solution containing PEG-35 prevented 
liver autophagy. This is demonstrated through diminished 
Beclin-1 and LC3B levels, similarly to that reported for 
post-conditioning in a rat brain model[57]. The data re-
ported here are consistent with studies carried out by 
Gotoh et al[58], who implicated autophagy in the initiation 
of  graft dysfunction after rat liver transplantation. Thus, 
we can speculate that the prevention of  mitochondrial 
damage and ROS production by PEG-35 could explain 
the decreases in Beclin-1 and LC3B after liver graft was-
hout. The overall benefits of  using PEG-35 as a rinse 
solution are summarized in Figure 10.
In conclusion, we have demonstrated that the use 
of  a new rinse solution containing PEG-35 protects rat 
liver grafts against IRI and it could therefore be a useful 
clinical tool for increasing liver graft protection against 
reperfusion injury.
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Background
Ischemia-reperfusion injury (IRI) is a determinant factor of graft function during 
and after liver transplantation. IRI is a complex process accompanied by oxida-
tive stress, loss of cell membrane integrity, and cell death. Liver graft washout 
prior to revascularization is an obligatory step to remove any remaining pre-
servation solution; however, this practice is dependent on individual surgical 
practices. Liver graft washout strategies are not standardized and have not 
been investigated in detail. Here, we propose a new rinse solution containing 
polyethylene glycol (PEG) 35 as suitable for liver graft protection against IRI. In 
addition, the underlying mechanisms of IRI are investigated.
Research frontiers
PEG is a non-toxic, water soluble polymer that has been associated with bene-
ficial effects after various insults, including IRI. PEG is known to decrease reac-
tive oxygen species, to protect liver mitochondria, to protect against cell death, 
and to help preserve cell membrane integrity. The presence of PEG-35 (35000 
k-daltons) in the novel Institut Georges Lopez (IGL) 1 preservation solution (as 
an oncotic agent) has been associated with the prevention of hepatic IRI. The 
benefits are due, in part, to adenosine monophosphate protein kinase (AMPK) 
and endothelial nitric oxide synthase (eNOS) activation. Thus, we added 
PEG-35 to a rinse solution to evaluate the potential benefits in washing-out and 
increased graft protection against IRI. 
Innovations and breakthroughs
The authors provide evidence that washing out the liver grafts prior to reperfu-
sion with a rinse solution that contains PEG-35 is an effective tool for providing 
a more effective protection against IRI. This is confirmed by decreases in hepa-
tic injury and oxidative stress, ameliorated hepatic function, and more efficient 
preservation of liver endothelial integrity.
Applications
Liver graft washout with a PEG-35 rinse solution is a useful strategy for efficient 
graft rinse and provides superior prevention before graft revascularization in 
clinical practice. 
Terminology
Rinse solution is used for removing the remaining preservation solution and any 
toxic agents produced during cold storage of the graft. The use of rinse solution 
favors the most suitable graft revascularization and survival after transplanta-
tion.
Peer review
In this study, the authors studied a new rinse solution containing PEG-35 for 
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Figure 10  Benefits of Polyethylene glycol-35 washout solution. PEG: Poly-
ethylene glycol; AMPK: Adenosine monophosphate-activated protein kinase.
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preventing IRI in the liver graft. Using biochemical determinations, Western 
Blot Analysis, zymography and confocal fluorescence microscopy, they studied 
the function of PEG-35 in the processes of liver injury, liver function, oxidative 
stress, mitochondrial injury, liver cytoskeleton alteration and liver autophagy. 
While the role of PEG-35 in the protection against IRI is not surprising, I believe 
that there are merits in this study because it may give some cues for future 
research and clinical application in LT.
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IRI is an important cause of liver damage occurring during surgical procedures 
including hepatic resection and liver transplantation, and represents the main cause of 
graft dysfunction and primary non function after transplantation [117]. PEGs are water 
soluble non-toxic polymers that are known to play an important role in the 
cytoprotection against ischemic damage. Recent studies have shown that PEG exerts 
anti-inflammatory, anti-apoptotic, immunosuppressive and membrane stabilization 
effects [2-4, 6, 198, 199]. From this perspective, it is reasonable to expect that PEG 
administration may be an effective therapeutic strategy against liver IRI. 
The aim of this thesis was to investigate the beneficial effects of PEG 35 in different 
models of IRI that mimic clinical situation of liver surgery. In the first study, we 
investigated the impact of the administration of intravenous PEG 35 before liver warm 
IRI. In the second one, we investigated whether intravenously administrated PEG 35 
could protect against cold IRI in steatotic rat livers. Finally, we developed a new 
washout solution containing PEG 35 to prevent reperfusion injury after prolonged cold 
preservation. 
We have focused our studies on PEG with molecular weight of 35kDa because it has 
been previously demonstrated that PEG 35 was effective to prevent cold IRI in liver 
when it was added to IGL-1 preservation solutions [23, 194, 200]. Moreover, PEG 35 
has been shown to protect renal cells against cold ischemia [201]. However, PEGs with 
different molecular weights such as PEG8 [187] or PEG20 [202] might also be useful 
for conferring protection against IRI.  However, PEG 35 was more effective than 
PEG20 in protecting porcine proximal tubular epithelial cell line against cold storage at 
the same doses used [201]. Ramified PEGs showing the some molecular weight as 
linear ones could have more interactions with hepatocytes membrane and thus afford an 
additional protection of liver cytoskeleton. 
1. PEG preconditioning in warm IRI 
In order to achieve an efficient hepato-protection, PEG 35 was injected to Sprague 
Dawley rats at 2 and 10 mg/kg before the induction of one hour of partial ischemia 
(70%) and two hours of normothermic reperfusion. Our results showed that PEG 35 
efficiently protects rat liver against IRI and that this effect is dose dependent. Only the 
dose of 10 mg/kg shows a significant decrease in liver injuries. 
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The lessened hepatic injury observed when PEG 35 was administered intravenously 
coincided with increased mitochondrial preservation, as revealed by decreases in GLDH 
levels and intravital microscopy findings. This fact is of great importance since 
mitochondrial protection is essential for graft survival after transplantation [203] 
We next went inside into the mechanisms of protection of PEG 35 and determined 
whether PEG 35 beneficial effect could be related to the activation of protective cell 
signalling pathways. Our results showed that PEG 35 at 10 mg/kg contributes to AMPK 
and AKT activation.  This is in line with previous reports showing that PEG20 protects 
against heart ischemia through AKT activation [6, 197]. Moreover, a crosslink between 
AMPK and Akt activation has been demonstrated in IRI [204]. These observations 
suggest that PEG protective effects are not only related to its known role as an oncotic 
support but also to some pharmacological properties. 
Nitric oxide (NO) is a gaseous vasodilator implicated in the regulation of hepatic 
microcirculation, which is impaired upon IRI [29, 188, 205, 206]. In this sense, we 
found that PEG 35 at 10 mg/kg significantly increased NOx levels and this was not 
correlated with eNOS activation. This observation is concomitant with a previous 
published report showing that PEG induced arteriolar dilatation was independent of 
eNOS induction [188]. The authors suggested that PEG vasodilation effect might be 
related to its hydrophilicity and ability to insert into the endothelial surface layer, which 
preserves shear stress mediated vasodilation during ischemia reperfusion [188].   
Given that apoptotic cell death is involved in IRI, we then investigated the levels of the 
apoptotic markers caspase 3 and 9. As it was expected, ischemia reperfusion  provoked 
an important induction of apoptosis, which was significantly prevented when PEG 35 
was administered at 10 mg/kg. These observations are in line with the results observed 
by Malhotra et al. who demonstrated that PEG15-20 protected cardiac myocytes from 
hypoxia and re-oxygenation induced apoptosis [6]. Moreover, we have previously 
reported that PEG 35 addition to preservation solutions ameliorated liver graft 
preservation by reducing apoptosis after transplantation [68]. 
Structural alterations of the cytoskeleton following ischemia reperfusion have been 
reported to cause disturbances of intracellular transport processes, cell motility and 
microcirculation leading to organ dysfunction [75, 207-209]. In liver cells, F-actin is a 
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relevant component of liver cytoskeleton which forms microfilaments involved in 
intracellular transport processes, such as exocytosis and endocytosis, maintenance of 
cell shape, and canalicular motility responsible for bile flow [209-212]. In this context, 
we have explored whether PEG 35 preconditioning could maintain the cytoskeleton 
structure and preserve the morphological characteristics of hepatocytes. Indeed, our 
present data confirmed that F-actin/G-actin ratio is increased as a consequence of PEG 
administration at 10 mg/kg. Furthermore, confocal microscopy findings confirmed that 
PEG contributes to the regulation of endothelial cell barrier by rearranging the actin 
cytoskeleton. Hepatocytes presented a more normal hexagonal morphology in livers 
pretreated with PEG 35 compared with livers submitted to IRI. All of these observations 
are consistent with a recent study in lung endothelial cells evidencing that PEG15-20 
preserves the architecture of the endothelial cytoskeleton [213]. Moreover, it has been 
demonstrated that PEG induced membrane stabilization through sarcolemmal lipid-raft 
architecture preservation [6]. These published data suggested that PEG interaction with 
cell membrane (adhesion or intercalation) preserved the cytoskeleton. In our study we 
further evidenced that PEG-induced-p38 MAPK activation may also be responsible for 
cytoskeleton preservation. However, the precise mechanisms of how PEG could affect 
cytoskeleton remain to be elucidated. 
Until now, PEG was used only as additive to preservation solution in IRI researches. 
This study gives the first evidences that PEG could be used as a preconditioning agent 
to protect against liver ischemia reperfusion damage. The innovation of this study was 
the route of administration of PEG: intravenously. Next, we used the effective dose 
obtained in this study (10 mg/Kg) to investigate the effects of PEG in a model of cold 
ischemia in steatotic liver grafts.  
 
2. PEG preconditioning in cold IRI 
This is the first report describing the use of PEG to protect steatotic livers against cold 
IRI. In this study, we have shown that the protective effects of PEG 35 that were seen in 
livers subjected to one hour of ischemia are applicable to an ex vivo rat model of cold 
IRI. Intravenous delivery of PEG 35 at 10 mg/kg prior to 24h cold ischemia followed by 
2h resulted in significant recovery of liver graft function, markedly less mitochondrial 
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injury as measured by GLDH release and intravital microscopy findings, and decreased 
vascular resistance. Similar to our previous study, PEG treatment again led to the 
upregulation of prosurvival signaling as measured by the phosphorylation of Akt and 
AMPK. Conversely, PEG regulated MAPKs by reducing p-p38 activation in contrary to 
the first study where we have seen that PEG induced a significant activation of p38 
MAPKs. This fact may be explained by the dual role of p38-MAPKs in IRI. Indeed, it 
has been shown that p38 activation was protective in warm ischemia but its induction 
worsened cold ischemia [76, 94, 214, 215]. 
In our study, we have used the isolated perfused rat liver (IPRL) model, a widely used 
and appreciated method to assess cellular injury and liver function in an isolated setting. 
In comparison to other in vitro models, the IPRL-model does have considerable 
advantages, such as the use of the entire intact organ instead of only single cells or 
several layers of cells (i.e. isolated hepatocytes or the liver slice model) and an intact 
cellular architecture. Furthermore, the use of an a-cellular perfusion solution (Krebs 
solution), prevents allo-reactivity and permit conclusive answer in IRI. Regarding liver 
transplantation, IPRL model presents the advantages of minimizing the use of 
laboratory animals, and the suppression of the immunological reactions and the 
influences of other organs occurring during transplantation. On the other hand, this 
model also has some disadvantages such as the duration of reperfusion, which is limited 
to 90-120 minutes and the fact that it remains an in vitro tool, and merely simulates the 
initial phase after liver transplantation. In this sense IPRL model could be considered as 
a pre-screening model.  
We further explored mitochondrial depolarization after cold preservation and we 
evidenced that PEG 35 prevented fatty liver mitochondria depolarization after 
prolonged cold ischemia. Also, mitochondrial injury was lessened after liver reperfusion 
as indicated by the decrease in GLDH release. These results are in accordance with our 
first study and with previous published data showing that PEG 2 kDa improved 
mitochondrial function in vitro and in vivo after acute spinal cord injury [3]. Moreover, 
PEG of 4 kDa inhibited mitochondrial pore transition (MPT) and cytochrome C release 
in rat liver mitochondria [216]. Also, PEG (1.5 and 2kDa) was able to across the 
cytoplasmic membrane and directly interact with neuronal mitochondria to preserve its 
structure and restore function [2]. Interestingly, PEG with higher molecular weight (4 
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kDa) failed to exert significant improvement in neuronal injured mitochondria 
indicating that PEG-mediated mitochondrial protection is dependent on the size of PEG 
[2]. In this sense, the mechanism by which PEG 35 decreased mitochondrial damage 
needs more profound investigation. 
In fatty livers, the fat accumulation in the cytoplasm of the hepatocytes provokes severe 
disturbances in the sinusoidal flow during reperfusion [217]. PEG 35 protective 
mechanisms were associated with the activation of eNOS responsible of NO generation 
and the subsequent diminution of vascular resistance. This could also explain the 
protective mechanism of PEG toward mitochondria as it has been shown that NO 
protects rat hepatocytes against reperfusion injury through the inhibition of MPT [205]. 
However, in our first study we have shown that PEG 35 increased NO production and 
this effect was not related to eNOS activation. The difference between the two 
experimental models (warm ischemia vs cold ischemia) and the duration of the ischemia 
may explain the contrast between the different findings in our studies.  
In our previous studies we evidenced that PEG could be considered as a preconditioning 
drug protecting against both warm and cold IRI. In the next study, we investigated the 
potential protective role of PEG as a post-conditioning agent by its addition to washout 
solution. 
3. PEG postconditioning 
In this study we demonstrated that PEG 35 addition to a newly developed washout 
solution was necessary to achieve liver graft protection against reperfusion injury. 
Moreover, this protection was dose dependent as the concentration of PEG 35 of 5 g/L 
was more efficient than 1 g/L. The decreased hepatic injury was concomitant with the 
subsequent improvement in hepatic function reflected by bile production and a 
significant reduction in vascular resistance.  
Moreover, the addition of PEG 35 to a rinse solution prevented mitochondrial damage 
and oxidative stress, when compared to either RLS or BS solutions. These results are in 
line with the two first studies demonstrating the preservation of mitochondrial integrity 
and with previous reported data showing the antioxidant role of PEG after rewarming 
cold-stored hepatocytes [187]. The prevention of reperfusion damage was also 
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accompanied by subsequent increases in HSP70 and HO-1 expression, two well-known 
markers of graft survival after transplantation [218]. Also, we observed a significant 
increase in AMPK phosphorylation and activation of eNOS. 
In warm IRI, we demonstrated a protective role of PEG by preserving cytoskeleton 
integrity. With this in mind, we explored the effects of PEG 35 rinse solution on the 
liver cytoskeleton by measuring F and G actin distribution and ultra-structural changes 
by confocal microscopy. Livers subjected to washout with RLS and BS showed low F-
actin content reflecting actin cytoskeletal derangement, probably associated with 
ischemia. In contrast, PEG 35 use reversed the loss of F-actin by increasing its 
polymerization, as reflected by an increased F-actin ratio. This confirms the protective 
effect of PEG 35 rinse solution in preventing the loss of cell integrity during IRI.  
Extracellular matrix turnover, influenced by MMP9 and MMP2, occurs during tissue 
remodelling after IRI [219, 220]. In experimental models of hepatic IRI, inhibiting 
MMP2 and MMP9 has also reduced tissue damage [221, 222]. In this study, we 
demonstrated that the PEG 35 rinse solutions inhibited MMP9 and MMP2 activity, 
suggesting cytoskeletal stability compared to either RLS or BS. This fact is consistent 
with the reduction of morphological alterations on confocal microscopy. Specifically, 
we observed that liver graft cells rinsed with RLS or BS acquired a slightly deformed 
round shape, while those washed with PEG 35 rinse solutions demonstrated normal 
morphology. 
Based on growing evidence linking autophagy to IRI [223-225], we evaluated its 
potential involvement during liver graft washout process. In this study, we demonstrated 
that liver graft washout using a rinse solution containing PEG 35 prevented liver 
autophagy. This is demonstrated through diminished Beclin-1 and LC3B levels, 
similarly to that reported for post-conditioning in a rat brain model [226]. The data 
reported here are consistent with studies carried out by Gotoh et al [227], who 
implicated autophagy in the initiation of graft dysfunction after rat liver transplantation. 
Thus, we can speculate that the prevention of mitochondrial damage and ROS 
production by PEG 35 could explain the decreases in Beclin-1 and LC3B after liver 
graft washout.  
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4. Perspectives 
In this thesis we demonstrated the protective role of PEG 35 against hepatic IRI in three 
different conditions. PEG 35 preconditioning was efficient to protect against both cold 
and warm IRI. Also, PEG addition to washout solution (PEG postconditioning) 
decreased significantly reperfusion injury. 
PEGs are multifunctional molecules that can target several pathological processes 
associated with organ injury following IRI including oxidative stress, mitochondrial 
dysfunction, loose of membrane integrity and cell death. They also present the 
advantages of being safe and could be adopted as a cost-effective strategy in clinical 
situation of ischemic damage. Interestingly, we have shown that the effect of PEG 35 is 
dose dependent which raises the question about the relationship between molecular 
weight, concentration and effectiveness.  
In this thesis, we focused our attention on PEG 35, however, PEG of 4 ,8 and 20 kDa 
have been also shown to protect against various type of organ damage including 
ischemic injuries [5, 186, 197]. Also, it could be possible that PEG 35 is more effective 
in liver ischemic injury and PEG 20 is more effective in heart or kidney [6, 193]. 
Moreover, taking into account the interaction between PEG and cell membrane, it might 
be of great interest to test other types of PEG such as ramified ones, which could have 
more interactions with hepatocytes membrane and thus afford an additional protection 
of liver cytoskeleton. 
In our studies, we have demonstrated the effectiveness of PEG in protecting 
mitochondria. However, the precise mechanism of protection still needs to be 
elucidated. Does PEG 35 cross the membrane under ischemic condition and interacts 
directly with the mitochondria or does this protective effect depend on the preservation 
of cytoskeleton? Does PEG with lower molecular weight is more effective in reducing 
mitochondrial injuries? Probably, in vitro studies with isolated hepatocytes and isolated 
mitochondria could give conclusive response to these questions. 
Due to their large molecular size and hydrophilic properties, PEGs generate an oncotic 
sink to reduce cellular edema and stabilize the cytoskeleton. It will be also very 
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interesting to study the effects of PEG in glycocalyx. Indeed, a growing body of 
evidence suggests a key role of the glycocalyx in IRI [40, 80]. 
Finally, although we clearly demonstrated the protective effect of PEG against cold IRI, 
these results need to be confirmed in a model of liver transplantation. Such model could 
also reveal new mechanisms as it has been suggested that PEG reduces immune 
response and inflammation [228]. 
Taking this into account, we firmly believe that the use of PEG is a promising 
therapeutic approach to decrease IRI in clinical practice. The results observed with 
steatotic livers, the safety and cost-effectiveness of this molecule encourages the future 
clinical investigations of PEG in the field of IRI. 
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The conclusions of the present thesis are the following: 
 
 Intravenous administration of PEG 35 at 10 mg/kg protects the liver in an 
experimental model of warm IRI in rats. The protective mechanisms are 
associated with the activation of the pro survival pathways Akt and AMPK and 
the inhibition of apoptosis. PEG 35 also protects the hepatocyte morphology by 
increasing F-/G-actin ratio and activating p-p38. 
 
 Intravenous administration of PEG 35 at 10 mg/kg protects steatotic livers in an 
experimental model of cold IRI in obese rats. The protective effects of PEG 35 
are mediated by the preservation of mitochondrial status, the stabilisation of the 
cytoskeleton and the regulation of the cytoprotective AMPK and Akt signalling 
pathways. 
 
 Liver graft washout with a PEG 35-containing rinse solution increases the 
protection against IRI in a model of isolated perfused rat liver. Protection was 
due to the inhibition of metalloproteinases, the activation of cytoprotective 
AMPK and eNOS signalling pathways and the preservation of cytoskeleton 
integrity. 
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La lesión por isquemia reperfusión (I/R) es un proceso complejo que tiene lugar cuando 
un órgano se ve privado del aporte sanguíneo (isquemia) de forma temporal y se 
manifiesta de forma predominante después del posterior restablecimiento del flujo 
sanguíneo (reperfusión).  
Existen numerosas situaciones en la práctica clínica en las que el hígado se ve sometido 
a una situación de isquemia y posterior reperfusión, entre ellas, la resección hepática y 
el trasplante hepático. En el trasplante hepático la lesión por I/R es la causa principal  
del fallo del injerto y del re-trasplante tras el rechazo inmunológico. Además, la lesión 
por I/R hepática afecta otros órganos aparte del hígado, como el pulmón, riñón y el 
páncreas. El procedimiento estándar para el trasplante hepático se inicia con la 
extracción del hígado del donante. Antes de su extracción el hígado es perfundido con la 
solución de preservación, a una temperatura de 4ºC. En este momento comienza la fase 
de isquemia fría. A continuación, el hígado es extraído del donante y colocado en una 
solución de preservación a baja temperatura (4ºC), con la finalidad de enlentecer al 
máximo el metabolismo hepático hasta su posterior implante en el receptor. Este 
período de isquemia fría suele durar en la práctica clínica de 6 a 8 h tras el cual, el 
órgano es sometido a un período de isquemia caliente, que se prolonga desde que el 
órgano es situado en la cavidad abdominal del receptor hasta que se restablece el flujo 
sanguíneo en el hígado trasplantado. Este período de isquemia caliente corresponde al 
tiempo empleado en realizar la anastomosis de los vasos sanguíneos hepáticos en la 
intervención quirúrgica. Al restablecerse el flujo sanguíneo en el órgano comienza la 
fase de reperfusión. 
Estos períodos de isquemia fría y caliente, y posterior reperfusión que tienen lugar en el 
trasplante hepático provocan la activación de una serie de mecanismos que dan lugar a 
la denominada lesión por I/R. La fisiopatología de la lesión por I/R es muy compleja y 
no está totalmente definida, ya que numerosos factores y mediadores están 
involucrados. La separación de los eventos celulares que ocurren durante la isquemia y 
la reperfusión no es absoluta, ya que durante la isquemia se inducen diversos procesos 
que son determinantes para la inducción de la lesión durante la reperfusión. 
En la fase de isquemia, la falta de oxígeno detiene la cadena respiratoria mitocondrial y 
se produce la depleción de los niveles de ATP. La disminución del nivel energético 
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conduce hacia el metabolismo anaerobio (vía glucolisis y fermentación láctica), con un 
rendimiento energético inferior que en condiciones aeróbicas, y a la acumulación de sus 
metabolitos tales como el ácido láctico. La acidosis metabólica resultante altera la 
cinética normal de los enzimas. La depleción de ATP provoca la alteración de todos los 
sistemas ATP-dependientes, entre ellos las bombas de sodio/potasio y de calcio, con la 
consecuente pérdida del gradiente a través de las membranas celulares. Una 
consecuencia de estas alteraciones es la acumulación del Ca2+ citosólico, el cual activa 
diferentes sistemas enzimáticos, tales como fosfolipasas y proteasas implicadas en la 
respuesta inflamatoria que posteriormente se desarrollará en la fase de reperfusión. Las 
proteasas tras su activación, catalizan la conversión de la xantina deshidrogenasa (XDH) 
a xantina oxidasa (XOD), enzima implicada en la formación de RLO (radicales libres de 
oxígeno) durante la reperfusión. Todos estos fenómenos inducen alteraciones en la 
permeabilidad e integridad de la membrana citoplasmática y de los orgánulos 
intracelulares, que pueden producir el edema celular, y finalmente la muerte celular. 
Durante la reperfusión se produce el restablecimiento del flujo sanguíneo y con él 
ocurren la mayoría de las lesiones. Aunque produce efectos beneficiosos en el tejido 
isquémico al recuperarse los niveles de ATP, también se ponen de manifiesto los 
efectos de los metabolitos tóxicos formados durante la fase previa, que tienen 
repercusión a nivel local y sistémico. Diversos autores sugieren que en la lesión de 
reperfusión se puede distinguir dos fases [17]:  
- Fase precoz o aguda: comprende las primeras 3 a 6 h después de la reperfusión. El 
principal acontecimiento en esta fase es la activación de las células de Kupffer. Esta 
activación se lleva a cabo por la acción previa de componentes activados del sistema del 
complemento, el reclutamiento y la activación de los linfocitos T CD4+.  
- Fase tardía o subaguda: se caracteriza por una infiltración masiva de neutrófilos, 
alcanza su máximo a las 18–24 h de la reperfusión. Estos neutrófilos activados liberan 
RLO y proteasas, ambos causantes del estrés oxidativo y de la lesión hepatocelular que 
se produce en esta fase de la lesión por reperfusión, que supera en gravedad a la de la 
fase precoz. El reclutamiento de neutrófilos polimorfonucleares (PMN) en el hígado tras 
la I/R es tan acusado que la reducción aguda de su recuento periférico se ha propuesto 
como marcador intraoperatorio precoz de la lesión por reperfusión del injerto hepático 
[229]. Además, durante la reperfusión, el daño mitocondrial,  el estrés oxidativo, el 
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estrés del retículo endoplasmático y las citokinas  juegan un papel importante en la 
progresión del daño, especialmente en el caso del hígado esteatósico.  También, el daño 
hepático por I/R está acompañado de alteraciones en el citosqueleto, lo cual resulta en 
perturbaciones en los procesos intracelulares de trasporte y en la microcirculación. La 
F-actina forma los microfilamentos de actina que contribuyen al mantenimiento de la 
forma celular y, durante la isquemia, la F-actina se reduce y contribuye a la pérdida de 
la integridad celular y finalmente al daño del órgano [21]. 
Los polietilenglicoles (PEGs) son polímeros solubles en agua, no tóxicos, con diferentes  
pesos moleculares, que se utilizan  como coadyuvantes en la administración de drogas, 
para prolongar su farmacocinética y son muy bien tolerados en patologías 
gastrointestinales. Algunos de ellos, con un peso molecular de 20 kDa (PEG20) y de 35 
kDa (PEG 35) forman parte de la composición  de soluciones de preservación de 
órganos (SCOT e IGL-1) utilizadas en diversos ensayos experimentales y clínicos [157, 
193, 230].  Basándonos en investigaciones previas que comparan las soluciones UW vs 
IGL-1,  cuya única diferencia reside en el factor oncótico HES (en UW) vs PEG 35(en 
IGL-1) y la concentración de iones Na+/K+, podemos sugerir que el efecto protector de 
IGL-1 es debido a la presencia de PEG 35.  Además, en varios modelos experimentales 
de I/R in vivo e in vitro se ha reportado que varios PEGs ejercen efectos beneficiosos, 
mediante la reducción de las ROS y de la muerte celular [4, 159, 187, 197].  
Atendiendo a lo anteriormente expuesto, la utilización de PEGs puede constituir  una 
excelente herramienta para  prevenir el daño hepático por isquemia reperfusión asociado 
al trasplante. El objetivo de este estudio es investigar los efectos beneficiosos del PEG 
35 en diferentes modelos de lesión por I/R, que imitan una cirugía hepática. En el 
primer estudio, se investigó el impacto de la administración intravenosa de PEG 35 
previa a la inducción de una lesión por I/R caliente. En el segundo, se investigó si el 
PEG 35 administrado por vía intravenosa podría proteger contra la lesión por I/R fría en 
hígados de rata esteatósicos. Por último, hemos desarrollado una nueva solución de 
lavado que contiene PEG 35 para evitar el daño por reperfusión después de la 
conservación en frío prolongado. 
Hemos centrado nuestros estudios en el PEG con peso molecular de 35 kDa, ya que se 
ha demostrado previamente que el PEG 35 reduce la lesión por  I/R fría en el hígado 
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cuando es añadido a soluciones de preservación IGL-1 [68, 156, 158]. Así también se ha 
demostrado que el PEG 35 puede proteger a las células renales contra la isquemia fría 
[154]. Por otro lado, los PEG con diferentes pesos moleculares, tales como el PEG8 
[144] o PEG20 [6] también  protegen contra la I/R. Sin embargo, el PEG 35 resulta más 
eficaz que el PEG20 en la protección de células epiteliales porcinas del túbulo proximal 
contra el almacenamiento en frío a las mismas dosis usadas [201]. Los PEG ramificados 
que presentan el mismo peso molecular que los lineales podrían tener más interacción 
con la membrana de los hepatocitos y así permitir una protección adicional del 
citoesqueleto del hígado. 
1. El precondicionamiento hepático con PEG en un modelo de 
I/R caliente 
Con el fin de lograr una eficiente hepato-protección, se inyectó PEG 35 a ratas Sprague 
Dawley a 2 y 10 mg/ kg antes de la inducción de una hora de isquemia parcial (70%) y 
dos horas de reperfusión normotérmica. Los resultados muestran que el PEG 35 protege 
el hígado de rata frente a la I/R y que este efecto es dependiente de la dosis. Sólo la 
dosis de 10 mg / kg muestra una disminución significativa en las lesiones hepáticas. 
La disminución de la lesión hepática observada cuando el PEG 35 se administra por vía 
intravenosa coincide con un aumento de la preservación mitocondrial, que se revela por 
la disminución en los niveles de GLDH y por los hallazgos en la microscopía intravital. 
Este hecho es de gran importancia, ya que la protección mitocondrial es esencial para la 
supervivencia del injerto después del trasplante [48, 205] 
A continuación, se determinó si el efecto beneficioso del PEG 35 podría estar 
relacionado con la activación de vías de señalización de protección celular. Nuestros 
resultados mostraron que el PEG 35 a 10 mg / kg contribuye a la activación de AMPK y 
Akt. Esto está en consonancia con estudios anteriores que muestran que el PEG20 
protege frente a la isquemia cardiaca a través de la activación de Akt [6, 197]. Por otra 
parte, una asociación entre AMPK y la activación de Akt se ha demostrado en  la I/R 
[204]. Estas observaciones sugieren que los efectos protectores del PEG no sólo están 
relacionados con su papel conocido como apoyo oncótico sino también con algunas 
propiedades farmacológicas. 
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El óxido nítrico (NO) es un gas vasodilatador implicado en la regulación de la 
microcirculación hepática que se deteriora en la I/R [29, 89]. En este sentido, 
encontramos que el PEG 35 a 10 mg/kg aumentó significativamente los niveles de NOx 
y esto no se correlacionó con la activación de la eNOS. Esta observación es 
concomitante con un estudio que muestra que el PEG induce vasodilatación arteriolar 
independiente de la inducción de la eNOS [188]. Los autores sugirieron que el efecto 
vasodilatador del PEG podría estar relacionado con su hidrofilicidad y su capacidad 
para insertarse en la capa de la superficie endotelial [188].  
Dado que la muerte celular por apoptosis está implicada en I/R,  investigamos entonces 
los niveles de marcadores de apoptosis como las caspasas 3 y 9. Como se esperaba, la 
I/R provocó una inducción importante de la apoptosis, lo que fue impedido 
significativamente cuando se administró PEG 35 a 10 mg/kg. Estas observaciones están 
en línea con los resultados observados por Malhotra et al. quienes demostraron que el 
PEG15-20 protege los miocitos cardíacos de la hipoxia y reoxigenación inducida por 
apoptosis [6]. Por otra parte, hemos informado anteriormente de que la adición de PEG 
35 a soluciones de preservación mejora la preservación del injerto hepático mediante la 
reducción de la apoptosis después del trasplante [68]. 
Se han reportado alteraciones estructurales del citoesqueleto después de la isquemia 
reperfusión que causan perturbaciones de los procesos intracelulares de transporte, la 
motilidad celular y la microcirculación, que conducen a la disfunción de órganos [21, 
207]. En las células del hígado, la F-actina es un componente relevante del citoesqueleto 
que forma microfilamentos que participan en los procesos de transporte intracelulares, 
tales como la exocitosis y endocitosis, el mantenimiento de la forma celular, y la 
motilidad canalicular responsable del flujo de la bilis [72, 231]. En este contexto, hemos 
explorado si el preacondicionamiento del PEG 35 podría mantener la estructura del 
citoesqueleto y preservar las características morfológicas de los hepatocitos. De hecho, 
nuestros datos actuales confirman que la relación F-actina/G-actina  incrementa como 
consecuencia de la administración de PEG a 10 mg/kg. Por otra parte, los resultados de 
microscopía confocal confirman que el PEG contribuye a la regulación de la barrera de 
células endoteliales reordenando el citoesqueleto de actina. Los hepatocitos presentan 
una morfología hexagonal más normal en los hígados tratados previamente con PEG 35 
en comparación con hígados sometidos a la I/R. Todas estas observaciones son 
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consistentes con un estudio reciente evidenciando que el PEG15-20 conserva la 
arquitectura del citoesqueleto endotelial las células endoteliales pulmonares [213]. Por 
otra parte, se ha demostrado que el PEG induce la estabilización de la membrana a 
través de la preservación de la arquitectura del sarcolema [6]. Estos datos publicados 
sugieren que la interacción del PEG con la membrana celular (adhesión o intercalación) 
conserva el citoesqueleto. Además, en nuestro estudio evidenciamos que la activación 
de MAPK p38 inducida por el PEG también puede ser responsable de la preservación 
del citoesqueleto. Sin embargo, los mecanismos precisos de cómo el PEG podría afectar 
el citoesqueleto aún no se han dilucidado. 
Hasta ahora, el PEG se ha utilizado sólo como aditivo a la solución de preservación en 
estudios de I/R. Este estudio da las primeras evidencias que el PEG se podría utilizar 
como un agente de preacondicionamiento para proteger contra el daño por isquemia y 
reperfusión en el hígado. La innovación de este estudio fue la vía de administración de 
PEG: la vía intravenosa. A continuación, se utilizó la dosis efectiva de este estudio (10 
mg / kg) para investigar los efectos del PEG en la isquemia fría en injertos hepáticos 
esteatósicos 
2. El precondicionamiento con PEG en un modelo de I/R fría 
Este es el primer estudio que describe el uso del PEG para proteger el hígado 
esteatósico contra la I/R fría. En este estudio, hemos demostrado que los efectos 
protectores del PEG 35 que se observaron en los hígados sometidos a una hora de 
isquemia son extrapolables a un modelo ex-vivo de I/R fría en rata. La administración 
intravenosa de PEG 35 a 10 mg/kg previa a una isquemia fría de 24horas seguida por 2 
h de reperfusion, dió como resultado una recuperación significativa de la función del 
injerto hepático, así como una disminución marcada de la lesión mitocondrial que se 
midió por la liberación de GLDH, los hallazgos de microscopía intravital, y la 
disminución de la resistencia vascular. Similar a nuestro estudio anterior, el tratamiento 
con PEG llevó de nuevo a la regulación al alza de la señalización de supervivencia del  
infarto medido por la fosforilación de AKT y AMPK. Sin embargo, la regulación de las 
MAPKs a través del PEG se traduce en una reducción de la activación del p-p38 
contrariamente al primer estudio en el que hemos visto que el PEG indujo una 
activación significativa de p38. Este hecho puede explicarse por el doble papel de la p38 
MAPK en la I/R. De hecho, se ha demostrado que la activación de la p38 cumple un 
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papel protector en la isquemia caliente pero su inducción en la isquemia fría es dañina  
[90, 92, 94, 215]. 
En nuestro estudio, hemos utilizado el modelo de hígado de rata aislado y perfundido  
(HRAP), un método ampliamente utilizado y apreciado para evaluar la lesión celular y 
la función hepática en un entorno aislado. En comparación con otros modelos in vitro, 
el modelo HRAP tiene ventajas considerables, tales como el uso de todo el órgano 
intacto en lugar de sólo las células individuales o varias capas de células y una intacta 
arquitectura celular. Además, el uso de una solución de perfusión a-celular, (solución de 
Krebs) evita alo-reactividad y permite una respuesta concluyente en la I/R. En cuanto al 
trasplante de hígado, el modelo HRAP presenta las ventajas de reducir al mínimo el uso 
de animales de laboratorio, suprimir las reacciones inmunológicas y las influencias de 
otro órgano que se producen durante el trasplante. La desventaja del modelo HRAP es 
la duración de la reperfusión, que se limita a 90-120 minutos y el hecho de que sigue 
siendo una herramienta in-vitro, y verdaderamente simula la fase inicial después del 
trasplante hepático. En este sentido el modelo HRAP podría considerarse como un 
modelo pre-screening. 
Siguiente, hemos explorado la despolarización mitocondrial después de la conservación 
del hígado y se evidenció que el PEG 35 impidió la despolarización mitocondrial de 
hígados grasos después de una isquemia fría prolongada. Además, la lesión 
mitocondrial disminuyó después de la reperfusión del hígado tal como indica la 
disminución en la liberación de GLDH. Estos resultados están de acuerdo con nuestro 
primer estudio y con datos anteriores publicados que muestran que el PEG 2 kDa 
mejora la función mitocondrial in vitro e in vivo después de la lesión de la médula 
espinal aguda [186]. Por otra parte, el PEG de 4 kDa inhibe transición del poro 
mitocondrial (MPT) y la liberación de citocromo C en las mitocondrias de hígado de 
rata [216]. También, los PEGs (1,5 y 2 kDa) son capaces de atravesar la membrana 
citoplasmática e interactuar directamente con las mitocondrias neuronales para 
preservar su estructura y  restaurar su función. Curiosamente, el PEG con peso 
molecular más alto (4 kDa) no pudo ejercer una mejora significativa en las mitocondrias 
neuronales lesionadas, lo que indica que la protección mitocondrial mediada por el PEG 
es dependiente del tamaño [3]. En este sentido, el mecanismo por el cual el PEG 35 
disminuyó el daño mitocondrial necesita una investigación más profunda. 
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En hígados grasos, la acumulación de grasa en el citoplasma de los hepatocitos provoca 
graves alteraciones en el flujo sinusoidal durante la reperfusión [232]. Los mecanismos 
de protección del PEG 35 se asociaron con la activación de la eNOS responsable de la 
generación de NO y la posterior disminución de la resistencia vascular. Esto también 
podría explicar el mecanismo de protección del PEG hacia la mitocondria ya que se ha 
demostrado que el NO protege los hepatocitos de rata contra la lesión por reperfusión a 
través de la inhibición de la MPT [205]. Sin embargo, en nuestro primer estudio 
observamos que el PEG 35 aumentó la producción de NO pero que este efecto no estaba 
relacionado con la activación de la eNOS. La diferencia entre los dos modelos 
experimentales (isquemia caliente vs isquemia fría) y la duración de la isquemia podría 
explicar el contraste entre los diferentes resultados de nuestros estudios. 
En nuestro estudio anterior se evidenció que el PEG podría ser considerado como un 
fármaco de preacondicionamiento de la protección contra la  lesión de I/R caliente y 
fría. En el siguiente estudio, se investigó el potencial papel protector del PEG como 
agente de poscondicionamiento al ser añadido a la solución de lavado. 
3. El postcondicionamiento con PEG 
En este trabajo se demuestra que la adición del  PEG 35 a una solución de lavado de 
nuevo desarrollo, es necesario para lograr la protección del injerto de hígado contra el 
daño por reperfusión. Por otra parte, esta protección fue dosis dependiente, siendo la 
concentración de PEG 35 de 5 g/L más eficiente que la de  1 g/L. Esta disminución en 
las lesiones hepáticas es concomitante con la consiguiente mejora en la función hepática 
reflejada en la producción de bilis, y una reducción significativa en la resistencia 
vascular. 
Por otra parte, la adición de PEG 35 a una solución de enjuague previno el daño 
mitocondrial y el estrés oxidativo, en comparación con las soluciones Ringer Lactate 
(SRL) y la solución básica (SB) de lavado. Estos resultados están en línea con los dos 
primeros estudios que demuestran la preservación de la integridad mitocondrial y con 
estudios previos que muestran el papel antioxidante del PEG después del 
recalentamiento de los hepatocitos almacenados en frío [144]. La prevención del daño 
por reperfusión también estuvo acompañada por aumentos posteriores en la expresión 
de HSP70 y HO-1, dos marcadores  bien conocidos de la supervivencia del injerto 
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después del trasplante [99, 106]. Además, se observó un aumento significativo de la 
fosforilación de la AMPK y la activación de la eNOS. 
En la I/R caliente, hemos demostrado que el PEG conserva la integridad del 
citoesqueleto. Con esta intención, hemos explorado los efectos del PEG 35 en 
soluciones de enjuague sobre el citoesqueleto de los hepatocitos mediante la medición 
de la distribución de las actinas F y G y  los cambios ultra-estructurales por microscopía 
confocal. Los hígados sometidos al lavado con la SRL y la SB mostraron un bajo 
contenido de F-actina reflejando alteración del citoesqueleto, probablemente asociada a 
la isquemia. En contraste, el uso del PEG 35 impidió la pérdida de F-actina mediante el 
aumento de su polimerización, como se refleja en una relación de F-actina/g-actina 
aumentada. Este hecho confirma el efecto protector de la solución de enjuague con PEG 
35 s en la prevención de la pérdida de integridad celular durante I/R. 
El recambio de la matriz extracelular, influenciado por MMP9 y MMP2, se produce 
durante la remodelación de tejidos después de la I/R [220]. En modelos experimentales 
de I/R hepática, la inhibición de MMP2 y MMP9 también reduce el daño tisular [221, 
222]. En este estudio, hemos demostrado que las soluciones de enjuague PEG 35 
inhibieron la actividad de MMP2 y MMP9, lo que sugiere la estabilidad del 
citoesqueleto en comparación con cualquier solución SRL o SB. Este hecho es 
consistente con la reducción de las alteraciones morfológicas en la microscopía 
confocal. Específicamente, se observó que las células hepáticas del injerto que se 
enjuagaron con SRL o SB adquieren una forma redonda ligeramente deformada, 
mientras que los que se lavaron con soluciones de enjuague conteniendo PEG 35 
mantuvieron la morfología normal. 
La autofagia está asociada con el catabolismo de proteínas de larga vida, componentes 
citosólicos, u orgánulos dañados. Es un proceso altamente regulado que implica la 
formación y entrega de autofagosomas a los lisosomas para degradación. En base a la 
creciente evidencia que vincula la autofagia a la I/R [223-225], se evaluó su potencial 
participación durante el proceso de lavado del injerto hepático. De hecho, hace tiempo 
se ha reconocido que la autofagia se produce en órganos bajo condiciones de estrés tales 
como la I/R [225, 233], aunque su papel exacto sigue sin estar claro y es controvertido. 
Aunque sabemos que la activación de la autofagia durante la isquemia es esencial para 
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la supervivencia celular y el mantenimiento de la función del órgano, a través de un  
mecanismo dependiente de AMPK, su papel durante la reperfusión podría ser 
perjudicial [82, 225, 234]. La autofagia durante la reperfusión se acompaña de una 
robusta regulación de Beclin-1, que a su vez se ve agravada por la generación de 
especies reactivas del oxígeno, lo que lleva a una degradación masiva de moléculas 
vitales y la muerte celular autofágica [55, 234]. En este estudio, hemos demostrado que 
lavando el injerto hepático con una solución de enjuague que contiene PEG 35 impide 
la autofagia hígado. Esto se demuestra a través de niveles de beclin-1 y LC3B 
reducidas, de manera similar a la reportada para el post-acondicionado en un modelo de 
cerebro de rata [226]. Los datos aquí presentados son consistentes con los estudios 
realizados por Gotoh et al [227], que implicó la autofagia en el inicio de la disfunción 
del injerto después del trasplante de hígado de rata. Por lo tanto, podemos especular que 
la prevención del daño mitocondrial y de la producción de ROS por PEG 35 podría 
explicar la disminución en Beclin-1 y LC3B después de lavado injerto hepático. 
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Las conclusiones de la presente tesis son las siguientes: 
 EL PEG 35 administrado por vía intravenosa protege eficientemente el hígado 
de ratas contra la I/R caliente y fría. Los mecanismos de protección están 
asociados con la activación de la pro supervivencia vías Akt y AMPK y la 
inhibición de la apoptosis. También  el PEG 35 protege la morfología de los 
hepatocitos mediante el aumento de la F/ G-actina y la activación de p-p38. 
 
 La administración intravenosa de PEG 35 a 10 mg / kg protege los hígados 
esteatósicos en un modelo experimental de I/R fría en ratas obesas. Los efectos 
protectores de PEG 35 están mediadas por la preservación del estado 
mitocondrial, la estabilización del citoesqueleto y la regulación de las vías de 
señalización citoprotectores AMPK y AKT. 
 
 La adición de PEG 35  a soluciones de lavado aumenta la protección contra la 
lesión por I/R en un modelo de hígado de rata aislado y perfundido. La 
protección era debida a la inhibición de las metaloproteinasas, la activación de 
vías de señalización citoprotectores AMPK y eNOS y la preservación de la 
integridad del citoesqueleto. 
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Abstract
The urgent need to expand the donor pool in order to 
attend to the growing demand for liver transplantation 
has obliged physicians to consider the use of suboptimal 
liver grafts and also to redefine the preservation 
strategies. This review examines the different methods 
of liver graft preservation, focusing on the latest 
advances in both static cold storage and machine 
perfusion (MP). The new strategies for static cold 
storage are mainly designed to increase the fatty 
liver graft preservation via  the supplementation of 
commercial organ preservation solutions with additives. 
In this paper we stress the importance of carrying out 
effective graft washout after static cold preservation, and 
present a detailed discussion of the future perspectives 
for dynamic graft preservation using MP at different 
temperatures (hypothermia at 4 ℃, normothermia 
at 37 ℃ and subnormothermia at 20 ℃-25 ℃). 
Finally, we highlight some emerging applications of 
regenerative medicine in liver graft preservation. In 
conclusion, this review discusses the “state of the art” 
and future perspectives in static and dynamic liver graft 
preservation in order to improve graft viability. 
Key words: Static cold preservation; Suboptimal liver 
grafts; Preservation solutions; Graft washout solutions; 
Machine perfusion and liver bioengineering
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This review focuses on the latest advances in 
liver graft preservation, in both static cold storage and 
dynamic preservation by machine perfusion (MP). We 
describe some new trends for static cold preservation 
based on our experience; we stress the importance of 
developing washout solutions and the use of MP for 
suboptimal liver grafts. Finally, we discuss emerging 
applications of regenerative medicine in liver graft 
preservation. 
function of  the organ and tissue during storage so 
that the graft will be viable at reperfusion. To date, 
the predominant organ preservation method used by 
most centers is SCS. The principles of  SCS are based 
on the diminution of  metabolism by hypothermia. The 
appropriate preservation solution is infused into the 
organ (the cooling phase) and then stored statically[4]. 
Cooling
SCS is the most widely used method for preserving 
organs for transplantation. Cooling is necessary to reduce 
cellular metabolism and the oxygen requirements in order 
to prevent tissue injury[5]. 
In order to obtain viable organs after long-term 
preservation, various methods have been proposed, 
ranging from organ freezing and vitrification[6,7] to 
“supercooling” (subzero non-freezing at 0 ℃ to -5 ℃)[8-11]. 
In general, long-term survival rates after transplantaion 
using these methods are disappointing. 
However, in a recent study by Berendsen et al[12], 
the combination of  “supercooling” (cold preservation 
at -6 ℃) with other parameters achieved effective 
preservation of  liver grafts for 4 d. This promising new 
technique comprises three steps: first, “supercooling” 
of  the organ at -6 ℃ to reduce the cellular metabolism; 
second, subnormothermic mp at 21 ℃ (see the 
dynamic preservation section below), which reinitiates 
the metabolism and replenishes ATp levels, and third, 
the use of  two preservatives, 3-O-methyl-D-glucose 
(3-OmG) and polyethylene-glycol 35 (pEG35). Each 
of  these conditions is necessary to achieve successful 
liver transplantation[13]. With this in mind, supercooling 
techniques may be a potentially useful tool for suboptimal 
livers which are currently discarded for transplantation 
purposes, and may have great impact on global organ 
sharing.
Preservation solutions
Although cold is a fundamental requirement for tissue 
preservation, it has harmful repercussions due to the 
induction of  cell swelling[14] and cytoskeletal alteration[15]. 
This was in part the reason for the development of commercial 
organ preservation solutions able to prevent many of  the 
cellular alterations associated with hypothermia and to 
mitigate the harmful effects of  cooling. 
Euro-Collins (EC) solution was developed in the 
1970s as a high potassium-sodium solution (intracellular 
composition) which does not contain oncotic agents but 
does contain glucose. Given that glucose is impermeable 
to renal cells, this preservation solution was suitable 
for kidney preservation when relatively short times 
were needed or DCD organs were used. However, the 
permeability of  the liver and pancreatic cells to glucose 
leads to the loss of  the osmotic effect, and also causes the 
subsequent anaerobic metabolization of  glucose, inducing 
intracellular acidosis and thus limiting cell preservation. 
This is why glucose was later substituted by other larger 
sugar molecules such as lactobionate and raffinose in 
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INTRODUCTION
Liver transplantation is the definitive treatment option 
for end-stage liver diseases. Besides the immunological 
mechanisms of  graft rejection, liver transplantation 
outcome is also limited by ischemia-reperfusion injury 
(IRI). IRI is a complex multifactorial process caused, 
principally, by the energy depletion during graft cold 
storage in preservation solutions (cold ischemia) and 
the subsequent production of  oxidative stress and 
inflammatory events after graft revascularization in the 
recipient (reperfusion)[1]. IRI is associated with delayed 
graft function and primary graft failure, which remains 
one of  the major clinical problems following liver 
transplantation.
A common strategy to reduce ischemic injury follo-
wing explantation from the donor is the rapid cooling 
of  the organs with the use of  a preservation solution 
to minimize enzymatic activity and energy substrate 
depletion. In recent decades, major advances have been 
made in the area of  liver preservation, including the 
development of  new preservation solutions. Their emer-
gence has helped to decrease hypoxic injury and has 
reduced graft vulnerability against reperfusion insult. 
Currently, the high increase in demand for organs 
has obliged physicians to use suboptimal grafts in 
order to increase the organ supply for transplantation. 
Suboptimal or extended criteria donor (ECD) livers 
include organs characterized by steatosis, old donor 
age, prolonged cold ischemia or donation after cardiac 
death (DCD)[2,3]. It is well known that suboptimal livers 
present increased vulnerability to IRI, and are associated 
with graft dysfunction and long-term survival problems 
after surgery. For this reason, preservation methods for 
suboptimal livers need to be exhaustively explored in 
order to identify the ones that are the most suitable for 
graft conservation.
machine perfusion (mp) has emerged as an alternative 
preservation strategy to static cold storage (SCS). mp is 
already routinely used for kidney transplantation, but a 
great deal is still to be done before it can be regularly used 
in clinical liver transplantation. In this review, we examine 
the SCS and mp techniques in detail, describing the latest 
advances in the development of  preservation solutions 
for liver grafts and providing some proposals and new 
strategies in order to improve current graft preservation 
methods. 
STATIC COLD STORAGE
The main goal in organ preservation is to maintain 
University of  Wisconsin (UW) solution, which remains in 
the extracellular space and preserves its beneficial effect. 
The use of  the UW preservation solution improved organ 
preservation time from 6 to 16 h[16]. 
The efficacy of  UW solution is based on the pre-
vention of  edema by impermeants (raffinose, lacto-
bionate), and the addition of  an ATp precursor (adeno-
sine) and anti-oxidant components (allopurinol, reduced 
glutathione). Drawbacks include the presence of  
hydroxyethyl starch (HES) as oncotic support, which has 
been associated with high blood viscosity and consequent 
tissue saturation with the preservation solution. As a 
result, washout of  blood from the graft and blood flow 
during reperfusion may be reduced[17,18]. In addition, 
the high K+ concentration is associated with cellular 
depolarization and activation of  voltage-dependent 
channels[19]. The problems caused by HES and K+ led to 
the development of  other preservation solutions without 
oncotic agents such as Celsior and HTK (Custodiol) 
and others with pEG as oncotic agent, such as Institute 
Georges Lopez solution (IGL-1) and Tissue and Organ 
Conservation Solution (SCOT).
Celsior was developed initially in the 1990s as a 
cardiac preservation solution with a low potassium 
and high sodium composition. Due to its extracellular 
composition, Celsior was also adopted for the preser-
vation of  abdominal organs as an alternative to UW. 
Other solutions without oncotic agents such as histidine-
tryptophan-ketoglutarate solution (HTK) were also 
developed. HTK presents low viscosity and for this 
reason provides more rapid cooling and better washout 
of  blood elements during organ procurement than UW. 
Celsior and HTK solutions have been extensively used 
for liver transplantation[20-22]. However, some limitations 
for HTK use have recently been described. Stewart et 
al[23] reported that HTK is associated with reduced graft 
survival in case of  additional risk factors such as DCD, 
cold ischemia time over 8 h, and donors over 70 years 
when compared to UW solution.
In IGL-1 preservation solution, HES was substituted 
by a pEG with a molecular weight of  35 KDa (pEG35), 
and the high K+/low Na+ ratio was reversed. Both 
experimental[24,25] and clinical[26-28] studies of  liver and 
kidney transplantation have shown the beneficial effects 
of  IGL-1 against apoptosis, endoplasmic reticulum stress, 
microcirculation dysfunction and immune response. 
moreover, in previous studies of  cold preservation and ex 
vivo perfusion, we have reported that IGL-1 contributes 
to a more efficient preservation of  both non-steatotic 
and steatotic rat liver grafts compared to UW[29-31], The 
beneficial effects of  IGL-1 include prevention of  hepatic 
damage, oxidative stress and mitochondrial injury, and 
are mediated through nitric oxide (NO) production. So 
IGL-1 is the first solution reported to be advantageous in 
SCS of  suboptimal livers.
moreover, a pEG of  smaller size, pEG20, is the basic 
component of  another solution for organ preservation: 
the SCOT, which furthermore contains low K+/high Na+ 
concentrations. SCOT was reported to show a higher 
renal protection against the immune response, mainly 
due to the “immunocamouflage” process provided 
by pEG20[32]. pEG20 at 15 g/L has been found to 
reduce alloantigen recognition after liver reperfusion 
in comparison to UW solution[33]. Even so, the use of  
pEG35 as oncotic agent has been shown to be more 
effective than pEG20 for liver graft preservation[34].
Modification of static preservation solutions
The extended use of  commercial preservation solutions 
has improved the conditions of  liver graft preservation, 
but with the increasing use of  suboptimal grafts it 
seems necessary to explore new alternatives in order to 
prolong the ischemia times and increase graft quality 
during cold storage. Along these lines, new additives have 
been proposed to improve static liver graft preservation 
when UW and IGL-1 solutions are used (Table 1). 
Although these alternatives are promising and have been 
successfully applied in animal models, they require further 
investigation before they can be implemented in clinical 
transplantation. 
Anti-ischemic drugs: previous work in kidney[35,36], 
liver[37,38] and heart[39-41] models has demonstrated the 
anti-oxidant action of  trimetazidine (TmZ), an anti-
ischemic drug. The addition of  TmZ to UW solution 
was tested in both steatotic and non-steatotic rat livers 
after cold storage and ex vivo perfusion[25]. The enrichment 
of  UW solution with TmZ reduced hepatic injury by 
diminishing microcirculatory dysfunction, oxidative stress, 
and mitochondrial damage. In the same experimental 
conditions, supplementation of  IGL-1 solution with 
TmZ offered better liver graft preservation than IGL-1 
solution alone and induced significant activation of  
hypoxia inducible factor-1α (HIF1α) and increased NO 
production[30]. The benefits of  TmZ have been shown 
clinically in patients undergoing hepatic surgery under 
vascular clamping[42]. This would suggest that TmZ has 
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Table 1  Additives for improving static cold storage in 
University of Wisconsin and Institute Georges Lopez preser-
vation solutions
Additive Preservation solution Ref.
TMZ UW, IGL-1 [25,30]
EGF + IGF-1 UW [45]
IGF-1 IGL-1 [44]
EGF IGL-1 [46]
ML IGL-1 [43]
BZ UW, IGL-1 [51,117]
SV UW [64]
BZ, MG132 UW [50]
ML + TMZ IGL-1 [38]
CAII IGL-1 [54]
TMZ: Trimetazidine; EGF: Endothelial growth factor; IGF: Insulin growth 
factor 1; ML: Melatonin; BZ: Bortezomib; SV: Simvastatin; CAII: Carbonic 
anhydrase Ⅱ; UW: University of Wisconsin; IGL-1: Institute Georges 
Lopez.
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we have observed that fatty livers preserved in IGL-1 
solution supplemented with CAⅡ showed lower injury, 
better function and major reductions in liver apoptosis 
parameters[54]. So CA enrichment of  preservation solu-
tions is an up-and-coming approach for improving the 
preservation of  suboptimal liver grafts. 
Statins: Statins, or the 3-hydroxyl-3-methylglutaryl 
coenzyme A inhibitor family, are a group of  drugs known 
to decrease cholesterol levels and treat dyslipidemias[55]. 
They also have a variety of  anti-inflammatory, antioxidant 
and immunoregulatory effects[56,57] and they maintain the 
endothelial barrier by activation of  eNOS and subsequent 
production of  NO[58-60]. Due to their various effects, 
statins have been proposed as effective pharmacological 
agents against IRI in both normal and steatotic livers[61-63]. 
UW supplementation with simvastatin (a synthetic analog 
of  statin) prevented the deleterious effects of  cold 
storage in endothelial cells, due to the enhancement of  
vasoprotective pathways, thus improving liver viability[64]. 
With this in mind, the supplementation of  IGL-1 with 
simvastatin could promote the NO generation induced by 
IGL-1 solution alone, and may contribute to preventing 
the exacerbated microcirculation complications existing 
in fatty liver grafts after revascularization. In addition, 
increased levels of  NO could contribute to stabilize 
cytoprotective factors such as HIF-α, which are generated 
as an adaptive response to the hypoxic conditions that 
characterize cold preservation[30].
New potential additives: some considerations
Sirtuin activators: Sirtuin1 (SIRT1) is a deacetylase 
that regulates the activity of  various non-histone and 
histone proteins and as a result is involved in various 
cell processes such as apoptosis and oxidative stress[65-68]. 
SIRT1 induces AmpK activation through LKB1 
deacetylation, and favors NO production by e-NOS 
activation[69,70]. Further, in a recent study published by 
our group, we mentioned that SIRT1 is involved in the 
beneficial effects of  ischemic preconditioning, partly via 
AmpK and eNOS activation[68]. Consequently, addition 
of  SIRT1 activators in preservation solutions may be 
a promising strategy for prolonging storage periods; 
SIRT1 activators may activate AmpK and maintain the 
cell energy status, and may also increase NO levels and 
alleviate microcirculation disturbances, especially in fatty 
livers. preliminary data obtained from our laboratory 
showed that SIRT1 is a differential marker in steatotic 
and non-steatotic livers during cold preservation. Since 
SIRT1 activity requires high NAD+ levels, NAD+ 
activators may also contribute to better liver graft 
preservation by activating not only SIRT1, but also other 
members of  sirtuin-family such as Sirtuin3 (SIRT3). 
SIRT3 is located in the mitochondria and affects the 
acetylation status of  various mitochondrial proteins[71]. 
Enhancement of  SIRT3 activity could thus achieve better 
mitochondrial preservation and prevent reactive oxygen 
potential for use as an additive in commercial preservation 
solutions for clinical transplantation purposes. 
Hormones: melatonin (mL), a hormone produced by 
the pineal gland in a circadian manner, has been shown 
to be highly beneficial for enhancing resistance of  both 
steatotic and non-steatotic livers against IRI when added 
to IGL-1. mL decreased hepatic injury by overexpression 
of  endothelial NO synthase (e-NOS) and Heme Oxy-
genase-1, and reduced mitochondrial damage and 
oxidative stress[43]. These protective effects of  mL in 
fatty liver graft preservation were further potentiated by 
addition of  TmZ to IGL-1 + mL solution[38]. protective 
mechanisms were dependent on AmpK activation. 
Furthermore, UW and IGL-1 solutions enriched with 
trophic factors like epidermal growth factor and insulin-
like growth factor-1 enhanced the resistance of  steatotic 
livers to IRI, partly due to Akt and eNOS signaling 
activation, and reduced cytokine release[44-46].
Proteasome inhibitors: The ubiquitin proteasome 
system (UpS) is an energy-dependent system that degra-
des misfolded proteins and regulates various cellular 
processes[47]. It has been established that proteasome 
activation is a pathophysiologically relevant mechanism 
of  cold ischemic myocardial injury. A subset of  26S 
proteasomes appears to be a cell-destructive protease 
that is activated as ATp levels decline[48]. The addition 
to UW solution of  epoxomicin, a proteasome inhibitor, 
reduced cardiac edema and preserved the ultrastructural 
integrity of  the post-ischemic cardiomyocyte[49]. In liver, 
we have recently demonstrated that the addition of  the 
reversible UpS inhibitors bortezomib (BRZ) and mG132 
to UW solution improved steatotic and non-steatotic liver 
preservation, and that the protective effect of  BRZ was 
superior to that of  mG132[50]. Supplementation of  IGL-1 
solution with BRZ also showed protective effects which 
were partially mediated through the activation of  AmpK 
and Akt/mTOR signaling[51]. 
Carbonic anhydrase Ⅱ: Carbonic anhydrase (CA) are 
Zn-metalloenzymes that catalyze the reversible reaction 
between carbon dioxide hydration and bicarbonate 
dehydration. Recently the function of  CAs has aroused 
great interest, as they contribute to the transport of  
CO2 and protons across the biological membranes and 
are involved in pH regulation, CO2 homeostasis and 
biosynthetic reactions such as gluconeogenesis, lipo-
genesis and ureagenesis. In mammals 16 different 
CAs are found, with different amino acid sequences, 
enzymatic properties and sites of  expression[52]. Since 
carbonic anhydrase Ⅱ (CAⅡ) also contributes to 
acid-base homeostasis[53], we suggest that it could be 
modulated in conditions of  liver preservation and that its 
addition to the preservation solution could be an efficient 
strategy for reversing pH alterations provoked by cold 
ischemia. Indeed, in preliminary studies at our laboratory, 
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species (ROS) production during reperfusion. 
Nrf2 activators: moreover, recent studies have demon-
strated the importance of  Nrf2 in IRI models[72-74]. 
Nrf2 is activated under conditions of  oxidative stress 
and induces the transcription of  anti-oxidant enzymes 
in order to eliminate redox stress. Nrf2-deficient livers 
exhibit enhanced liver injury upon IRI[75]. Consequently, 
we propose the use of  Nrf2 activators in preservation 
solutions in order to alleviate oxidative stress during 
reperfusion.
All in all, extensive studies in experimental models 
have proposed modified preservation solutions in order 
to extend cold storage and to maintain graft viability 
as far as possible. Since IRI is a multifactorial process, 
preservation solutions could incorporate various 
pharmacological agents in order to combine diffe-rent 
protective mechanisms and thus improve liver pre-
servation. Nonetheless, the use of  pharmacological 
agents may be limited by their potential toxicity and side 
effects or their unsuitability for suboptimal grafts, and so 
novel strategies of  preservation should be developed. 
Liver graft wash out
After cold storage, the liver grafts preserved in com-
mercial preservation solutions need to be washed out to 
remove the solution before reperfusion and also to obtain 
the most suitable conditions for graft revascularization 
and viability after transplantation. Although research into 
rinse solutions is limited, recent data from our laboratory 
show that washing out the liver grafts preserved in UW 
for 24 h, with a rinse solution containing pEG35, is an 
effective tool for reducing liver graft injury after two 
hours of  ex vivo perfusion[76]. pEG35 in the rinse solution 
was associated with decreased oxidative stress and 
mitochondrial damage, increased activation of  AmpK, 
and enhanced NO generation. In addition, it contributed 
to restoring cytoskeleton integrity following IRI. In 
contrast, when livers were preserved in IGL-1 solution, 
these benefits were not evident, probably due to the 
presence of  pEG35 as oncotic agent (unpublished data).
It is well known that pEG molecules are water-
soluble polymers of  various molecular weights which 
are non-immunogenic and non-toxic[77]. In general, 
pEGs prevent the generation of  ROS[78,79], enhance cell 
survival pathways in hypoxia/reoxygenation conditions 
and repair endothelial cell damage during post-ischemic 
reperfusion[80,81]. pEG exerts its cytoprotective role 
through the restoration of  membrane integrity[15,78,81,82] 
or by entering the cell through the disrupted membranes 
and interacting with cellular organelles[83]. In hypothermic 
hepatocyte preservation, pEG8 (8 kDa) prevented cell 
swelling through a mechanism that was independent of  
its osmotic properties[14]. 
DYNAMIC PRESERVATION: MACHINE 
PERFUSION TECHNIQUES 
For standard liver grafts, SCS with different preservation 
solutions remains highly successful. However, with 
the increasing need for organs in recent years, the use 
of  novel techniques for optimizing suboptimal graft 
preservation is arousing interest. 
MP consists of  creating a controlled recirculating flow 
of  preservation solution through the organ using a pump. 
This continuous perfusion permits better penetration 
of  the preservation solution, a thorough washout of  
blood and equilibration of  the interstitium with the 
perfusate medium, delivery of  oxygen and nutrients 
(if  the perfusate is oxygenated), and removal of  toxic 
metabolites (when the perfusate is renewed or filtered). In 
addition, it allows real-time monitoring of  the functional 
and biochemical performance of  the graft and the 
provision of  metabolic support during preservation[84].
Unlike the kidney, the mp protocol for the liver is 
determined mainly by the temperature of  preservation: 
hypothermic (Hmp) at 4 ℃, normothermic (Nmp) at 
37 ℃ and subnormothermic (SNmp) at 20 ℃-25 ℃. 
Also, several flows and pressures (pulsatile or not), 
single or dual perfusion (hepatic artery and portal vein), 
oxygenation or non-oxygenation, and different mp 
solution compositions have been tested in various liver 
graft experimental models[85].
HMP
Hmp is a dynamic cold preservation method at 4 ℃ 
which ensures homogeneous and continuous supply 
of  metabolic substrates to the graft during the ex vivo 
period[86]. During Hmp, aerobic metabolism decreases but 
does not stop completely and the provision of  metabolic 
substrates allows the reduction of  the cellular insults seen 
during reperfusion. 
Hmp offers several advantages over SCS. Guarrera 
et al[87] were the first to compare HMP to SCS in human 
liver transplantation, and showed that Hmp improves 
graft function and attenuates classical biochemical 
markers of  liver preservation injury. Given the fact that 
ROS accumulation during ischemia can lead to signi-
ficant hepatocyte toxicity, Hmp has been shown to 
protect the rodent liver from ROS by a reduction in 
glutathione depletion and superoxide anion release when 
compared with SCS[88]. And in the case of  suboptimal 
livers, Bessems et al[89] showed that Hmp improved both 
hepatocellular and endothelial function while reducing 
damage in a diet-induced rat fatty liver model. 
In contrast to the kidney, in which successful Hmp 
does not necessarily depend upon oxygenation, oxy-
genated Hmp (HOpE) has been developed as a means 
of  improving the quality of  liver preservation in normal 
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or ECD livers[90]. Oxygenated preservation enables 
grafts to restore tissue homeostasis and to maintain the 
functional integrity of  hepatocytes during ischemia. 
In a recent study, Schlegel et al[91] also described a 
protective effect on the rodent biliary system using 
HOpE in DCD grafts that underwent transplantation. 
As expected, perfusion with the HOpE system decreased 
the parameters of  hepatocellular injury and lowered 
immunogenic upregulation. 
Perfusates for HMP: In general, the composition of  
perfusate solutions used for Hmp is based on a re-
formulation of  UW solution, in which lactobionate is 
replaced by gluconate. This solution, named Belzer-mp 
solution (Belzer-mpS), continues to be the predominant 
perfusion solution.
Bessems et al[92] described a new Hmp solution, 
polysol, which contains amino acids, histidine, glutamine, 
tryptophan, ascorbic acid and α-tocopherol. Their studies 
show that polysol improved liver preservation compared 
to Belzer’s mpS, with lower enzyme release and increased 
bile production. Vasosol has also been proposed as an 
efficient alternative for HMP[87]. Its composition is based 
on Belzer-mpS but it is supplemented with antioxidants 
(N-acetyl-cysteine), metabolic substrates (α-ketoglutarate, 
L-arginine) and vasodilators (prostaglandin E1 and 
nitroglycerin). Recently, the benefits of  Vasosol have been 
improved by the addition of  α-tocopherol to further 
enhance antioxidant properties when Hmp is used[93].
sNMP
Recently it has been suggested that the use of  SNmp 
systems may be suitable for ex vivo preservation and 
recovery of  human liver for transplantation. SNmp is 
an intermediate status for graft conservation, using sub-
thermic conditions (20 ℃-25 ℃), taking advantage of  the 
lower metabolic demand in sub-physiological temperature 
conditions, while still maintaining sufficient metabolism 
for viability testing and improvement of  graft function. 
SNmp has already proven advantageous in reducing 
markers of  biliary injury during preservation and in 
restoring normal biliary physiology[94]. A recent study by 
Bruinsma et al[95] is the first demonstration of  the capacity 
of  SNmp to sustain human livers. This group showed 
that SNmp effectively supports the human liver ex vivo 
with minimal injury, and normalizes physiological post-
ischemia disturbances.
NMP
The principle of  normothermic perfusion is the mainte-
nance of  normal cellular metabolism in a physio-logical 
environment throughout the preservation period by 
maintaining normal temperature (37 ℃) and providing 
oxygen and essential substrates[96]. This ensures large-
scale metabolic activity and the maintenance of  energy 
reserves such as ATp content. Nmp has the advantage of  
allowing viability assessment prior to transplantation. As 
the liver metabolism is maintained during preservation, 
markers including bile production and liver enzymes can 
be measured. 
Nmp is an emerging technology whose potential in 
liver preservation has been described in several animal 
studies, which have shown its superiority over SCS in the 
preservation of  liver grafts[96-98]. Interestingly, porcine and 
murine models of  DCD livers are significantly improved 
by Nmp compared to organs preserved by SCS[99,100]. 
Recently, Ravikumar et al[101] reported the first clinical 
trial of  transplanted livers with Nmp. Their study 
included 10 transplanted patients with relatively low risk 
donors and recipients, and showed that Nmp is safe and 
feasible in human applications. This study opens up new 
avenues for research into liver graft preservation with 
Nmp.
Recently, Nmp has emerged as a novel tool for 
decreasing steatosis in a process named “defatting”. In 
a preliminary study using porcine livers, ex vivo normo-
thermic perfusion for 48 h led to a 50% reduction in 
lipid droplet size in perivenous hepatocytes, reaching the 
size found in control lean livers[102]. moreover, Nmp of  
steatotic livers from Zucker ob rats using a “defatting 
cocktail” decreased the intracellular lipid content by 
50% over 3 h of  perfusion[103]. Decreasing steatosis 
prior to transplantation by short term Nmp would allow 
the transplantation of  severely steatotic livers and thus 
alleviate the donor liver shortage.
Perfusates for NMP: Nmp requires advanced metabolic 
support since the organ is fully metabolically active. 
Therefore, typically diluted blood-based perfusates are 
used. more recently, a solution initially described for lung 
perfusion has also been applied to liver grafts[104]. Steen is 
a buffered extracellular solution containing dextran and 
albumin at an optimized colloid osmotic pressure.
For defatting purposes, the perfusate developed 
contains different compounds to activate nuclear receptors 
such as ppARs, pregnane X receptor, and constitutive 
androstane receptor in order to exert an insulin-mimetic 
effect and to stimulate intracellular cAmp. This liquid 
was added into minimum Essential cell culture medium 
as a perfusate to stimulate the lipid metabolism of  
obese rat liver grafts preserved using Nmp. With this 
cocktail, a significant decrease (50%) in steatosis was 
observed after 3 h of  Nmp[103]. A recent study showed 
that the supplementation of  this cocktail with L-car-
nitine, together with hyperoxic exposure, abolished the 
sensitivity of  macrosteatotic hepatocytes to hypoxia 
reoxygenation (H/R)[105].
BIOENGINEERING IN LIVER GRAFT 
PRESERVATION
In the context of  liver graft preservation, bioengineered 
human livers represent an opportunity to test new 
solutions and liver preservation methods, thus potentially 
bypassing the requirement of  precious and scarce human 
organs. Bioengineering allows quicker and cheaper 
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development and transfer to the clinic[106].
Over the past few years, organ bioengineering has 
come of  age. The seminal study by Ott et al[107] in 2008 on 
heart decellularization and recellularization paved the way 
for whole organ bioengineering. After this initial study of  
the heart, many other organs followed. In 2009, Baptista 
et al[108] described the first methods for liver, pancreas 
and kidney decellularization and recellularization, and 
their paper was followed by an exponential growth of  
publications by many other authors. 
Currently, with several solid organs already successfully 
bioengineered and under further development by 
several groups around the world, this technology has 
huge potential. However, bioengineered organs are still 
not available to the transplant surgeon as alternative 
grafts. There are already several applications that can 
be addressed and extended with the current generation 
of  bioengineered organs and their acellular scaffolds. 
most of  these applications, like drug metabolism[106], 
organ/tissue physiology[106,107,109,110], matrix biology[111], 
developmental biology[111,112], and stem cell biology[113] are 
perfectly complemented by these novel bioengineered 
human tissues which will open up exciting new experi-
mental avenues. 
In the particular context of  normothermic perfusion, 
the enabling bioreactor and culture media technology 
developed in the bioengineering process of  livers may 
constitute a new body of  knowledge that can help 
further the development of  Nmp for liver preservation, 
due to the similarities of  the conditions used[114]. Finally, 
the use of  normothermic perfusion bioreactors in 
liver preservation and bioengineered human livers may 
also provide a better route and environment for ex vivo 
administration of  mesenchymal stem cells. The use of  
these cells has been proposed as a novel way to attenuate 
IRI and to downregulate the alloimmune response 
(adaptive immunity) and promotes engraftment after 
transplantation[115]. This has been demonstrated for rat 
kidneys, thus raising the hope that it may also work in the 
liver and other solid organs[116].
CONCLUSION
Due to its low cost and simple technical and logistical 
requirements, SCS is still preferred to mp as the standard 
method of  preservation in liver transplantation. SCS 
is probably unsuitable for suboptimal liver grafts, 
because they have already suffered severe tissue damage 
secondary to hypoxia during the initial period of  warm 
ischemia. Additional damage to the organ due to 
hypothermic conditions may limit the ability to restore 
cellular function, because metabolic activity is decreased 
at low temperatures. 
The growing need to use suboptimal livers and 
to expand donor pool is accompanied by the drive to 
improve current preservation techniques before trans-
plantation. In this situation, there has been renewed 
interest in liver graft preservation using machine per-
fusion. Both Hmp and Nmp have been found to be 
beneficial in preserving normal and suboptimal livers, 
and their relative merits are currently being debated. 
more basic research and randomized controlled trials are 
needed. As for SNmp preservation, it remains relatively 
unexplored at present. 
Studies on the cost-effectiveness of  mp and SCS will 
continue over the coming years, but considerable support 
for mp is beginning to emerge. Table 2 summarizes its 
advantages and disadvantages for liver preservation. It 
seems clear that mp strategies will play an increasing role 
and that their use should be optimized, including the 
subsequent development of  new perfusion solutions. 
With this in mind, the future of  liver mp preservation 
will also depend on the composition of  perfusion 
solutions. At present, little attention is being paid to the 
potential advantages of  adding cytoprotective, immuno-
modulating, pro-regenerative components to the mp 
solutions. 
It is well known that pEG protects cell membranes; it 
has already been used as a colloid in machine perfusion, 
just as it was previously in SCS. The development of  
different pEG molecules could establish new frontiers 
in the design of  new perfusion solutions for application 
in mp techniques and may increase graft conservation in 
the future. The revitalization of  steatotic livers through 
defatting agents represents another interesting future 
application, given that the worldwide incidence of  
severely steatotic livers is expected to rise together with 
the increase in obesity rates.
Finally, bioengineering is another area with great 
potential for graft preservation in clinical transplantation.
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